



(51) International Patent Classification:

A61K 47/59 (2017.01) C12N 15/00 (2006.01)  
A61K 51/12 (2006.01)

(21) International Application Number:

PCT/US2022/026998

(22) International Filing Date:

29 April 2022 (29.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/182,605 30 April 2021 (30.04.2021) US

(71) Applicant: **THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA** [US/US]; 3600 Civic Center Boulevard, 9th Floor, Philadelphia, PA 19104 (US).

(72) Inventors: **PARHIZ, Hamideh**; 1629 Briar Hill Road, Gladwynce, PA 19035 (US). **WEISSMAN, Drew**; 614 S. Hancock Street, Philadelphia, PA 19147 (US).

(74) Agent: **FONVILLE, Natalie et al.**; Riverside Law, LLP, 175 Strafford Avenue, Suite 100, Wayne, PA 19087 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: LIPID NANOPARTICLE THERAPEUTICS THAT EVADE THE IMMUNE RESPONSE




Fig. 1

(57) Abstract: The present invention relates to compositions and methods for effective delivery of a therapeutic agent to a subject using a delivery vehicle comprising a domain to evade the subject's immune response. In some embodiments, the present invention relates to compositions and methods for targeted delivery of a therapeutic agent to a subject using a delivery vehicle comprising a domain to evade the subject's immune response and a domain for targeting a specific cell type. The invention also relates to methods of use of the compositions of the invention for the treatment of diseases and disorders, including the treatment of diseases and disorders in subjects having an inflammatory or autoimmune disease or disorder.



**Published:**

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))



## SUMMARY OF THE INVENTION

In one embodiment, the invention relates to a composition for delivering a therapeutic agent to a subject in need thereof, the composition comprising a therapeutic agent and a delivery vehicle, wherein the delivery vehicle comprises a moiety to inhibit uptake of the composition by a macrophage.

In one embodiment, the moiety to inhibit uptake of the composition by a macrophage is a CD47 polypeptide, an active CD47 polypeptide fragment, an activator of SIRP $\alpha$  activity, a PD-L1 polypeptide, an active PD-L1 polypeptide fragment, an activator of PD-1 activity, a CD24 polypeptide, an active CD24 polypeptide fragment, an activator of Siglec-10 activity, a poly glutamic acid peptide, a  $\beta$ 2M polypeptide, an active  $\beta$ 2M polypeptide fragment, or an activator of LILRB1 activity.

In one embodiment, the moiety to inhibit uptake of the composition by a macrophage comprises a CD47 polypeptide comprising a sequence of SEQ ID NO:1, SEQ ID NO:2, or a fragment or variant thereof.

In one embodiment, the delivery vehicle further comprises a targeting moiety specific for binding to a target cell.

In one embodiment, the target cell is an endothelial cell, an immune cell or a stem cell.

In one embodiment, the therapeutic agent comprises at least one isolated nucleoside-modified RNA molecule.

In one embodiment, the at least one isolated nucleoside-modified RNA comprises at least one pseudouridine or 1-methyl-pseudouridine.

In one embodiment, the at least one isolated nucleoside-modified RNA is a purified nucleoside-modified RNA.

In one embodiment, the composition further comprises an adjuvant.

In one embodiment, the delivery vehicle comprises a lipid nanoparticle (LNP). In one embodiment, the at least one nucleoside-modified RNA is encapsulated within the LNP.

In one embodiment, the invention relates to a method of treating a disease or disorder in a subject in need thereof, the method comprising administering a

composition for delivering a therapeutic agent to a subject in need thereof, the composition comprising a therapeutic agent and a delivery vehicle, wherein the delivery vehicle comprises a moiety to inhibit uptake of the composition by a macrophage to the subject.

5                   In one embodiment, the moiety to inhibit uptake of the composition by a macrophage is a CD47 polypeptide, an active CD47 polypeptide fragment, an activator of SIRP $\alpha$  activity, a PD-L1 polypeptide, an active PD-L1 polypeptide fragment, an activator of PD-1 activity, a CD24 polypeptide, an active CD24 polypeptide fragment, an activator of Siglec-10 activity, a poly glutamic acid peptide, a  $\beta$ 2M polypeptide, an active  $\beta$ 2M  
10 polypeptide fragment, or an activator of LILRB1 activity.

                  In one embodiment, the moiety to inhibit uptake of the composition by a macrophage comprises a CD47 polypeptide comprising a sequence of SEQ ID NO:1, SEQ ID NO:2, or a fragment or variant thereof.

                  In one embodiment, the subject has an inflammatory or autoimmune  
15 disease or disorder. In one embodiment, the therapeutic agent is an agent for the treatment of an inflammatory or autoimmune disease or disorder.

                  In one embodiment, the composition is administered by a delivery route selected from intradermal, subcutaneous, inhalation, intranasal, and intramuscular.

                  In one embodiment, the invention relates to a method of delivering a  
20 therapeutic agent to a target cell, the method comprising administering a composition for delivering a therapeutic agent to a subject in need thereof, the composition comprising a therapeutic agent and a delivery vehicle, wherein the delivery vehicle comprises a moiety to inhibit uptake of the composition by a macrophage and further comprising a targeting moiety specific for binding to a target cell. to the subject.

25                   In one embodiment, the moiety to inhibit uptake of the composition by a macrophage is a CD47 polypeptide, an active CD47 polypeptide fragment, an activator of SIRP $\alpha$  activity, a PD-L1 polypeptide, an active PD-L1 polypeptide fragment, an activator of PD-1 activity, a CD24 polypeptide, an active CD24 polypeptide fragment, an activator of Siglec-10 activity, a poly glutamic acid peptide, a  $\beta$ 2M polypeptide, an active  $\beta$ 2M  
30 polypeptide fragment, or an activator of LILRB1 activity.

In one embodiment, the moiety to inhibit uptake of the composition by a macrophage comprises a CD47 polypeptide comprising a sequence of SEQ ID NO:1, SEQ ID NO:2, or a fragment or variant thereof.

5 In one embodiment, the target cell is an endothelial cell, an immune cell or a stem cell.

In one embodiment, the therapeutic agent is an agent for the treatment of an inflammatory or autoimmune disease or disorder.

In one embodiment, the composition is administered by a delivery route of intradermal, subcutaneous, inhalation, intranasal, or intramuscular.

10 In one embodiment, the invention relates to a pharmaceutical composition for in vivo delivery of a lipid nanoparticle (LNP) to a non-hepatic cell of a subject while avoiding delivery to hepatic cells, wherein the LNP comprises a pegylated lipid conjugated to an active CD47 polypeptide, and a therapeutic agent.

15 In one embodiment, the LNP further comprises a pegylated lipid conjugated to a binding moiety. In one embodiment, the binding moiety is a whole antibody or an antigen binding fragment thereof.

In one embodiment, the LNP further comprises unconjugated pegylated lipid.

20 In one embodiment, the active CD47 polypeptide comprises SEQ ID NO:1 or SEQ ID NO:2.

In one embodiment, the invention relates to a method of delivering a LNP to a non-hepatic cell of a subject in vivo while avoiding delivery to hepatic cells comprising administering the pharmaceutical composition for in vivo delivery of a lipid nanoparticle (LNP) to a non-hepatic cell of a subject while avoiding delivery to hepatic cells, wherein the LNP comprises a pegylated lipid conjugated to an active CD47 polypeptide, and a therapeutic agent. In one embodiment, the LNP further comprises a pegylated lipid conjugated to a binding moiety. In one embodiment, the binding moiety is a whole antibody or an antigen binding fragment thereof. In one embodiment, the LNP further comprises unconjugated pegylated lipid. In one embodiment, the active CD47 polypeptide comprises SEQ ID NO:1 or SEQ ID NO:2.

25  
30

In one embodiment, administering comprises intravenous administration.

In one embodiment, an inflammatory response is reduced, or not exacerbated, as compared to an LNP lacking an active CD47 polypeptide, PEG shielding, or a combination thereof. In some embodiments, a toxicity is reduced, or not exacerbated, as compared to an LNP lacking an active CD47 polypeptide, PEG shielding, or a  
5 combination thereof.

In one embodiment, a proportion of administered therapeutic agent reaching a targeted cell or tissue is increased as compared to an LNP lacking an active CD47 polypeptide, PEG shielding, or a combination thereof.

In one embodiment, a physiologically effective dosage is reduced as  
10 compared to an LNP lacking an active CD47 polypeptide, PEG shielding, or a combination thereof.

#### BRIEF DESCRIPTION OF THE DRAWINGS

The following detailed description of embodiments of the invention will  
15 be better understood when read in conjunction with the appended drawings. It should be understood that the invention is not limited to the precise arrangements and instrumentalities of the embodiments shown in the drawings.

Figure 1 depicts a diagram of method for preparation of CD47 modified-targeted LNPs. Schematic illustration of the targeted CD47-modified mRNA-loaded  
20 LNPs. Novel double post-insertion technique enabling functionalization of LNPs with minimal “self” peptide provides evasion of uptake by macrophages, along with antibody targeting moieties. The targeted CD47-modified LNP provides an mRNA delivery platform with enhanced tissue/cell targeting feature, minimum off-target uptake, and high safety.

Figure 2A through Figure 2D depicts data demonstrating that CD47  
25 modification on LNP significantly decreases the non-specific uptake/mRNA translation. Figure 2A depicts data demonstrating that RAW 264.7 macrophage cells were incubated with mRNA-LNP and CD47/mRNA-LNP (mRNA-LNP which was decorated with CD47), and microscopy was performed after 48 hours. CD47/mRNA-LNP results in  
30 significantly lower mRNA translation in RAW 264.7 macrophage *in vitro* when compared to mRNA-LNP. Figure 2B depicts data demonstrating that radiolabeled

CD47/mRNA-LNP and mRNA-LNP were injected i.v. to the mice and tissues were harvested at one hour post-injection. CD47/mRNA-LNP results in significantly lower tissue uptake in all organs especially liver while increased in blood. Figure 2C depicts localization ratios showing the radioactivity in each organ normalized to blood levels, again confirming results in Figure 2B. Figure 2D depicts data demonstrating that CD47/mRNA-LNP and mRNA-LNP encapsulating nucleoside modified luciferase mRNA were injected i.v. to the mice at 0.3 mg mRNA/kg and tissues were harvested 4 hours post-injection. CD47/mRNA-LNP results in very close to zero signal in all organs especially liver when compared to mRNA-LNP.

Figure 3 depicts data demonstrating CD47/mRNA-LNP recruits significantly less PBMC when compared to mRNA-LNP. 30 minutes after i.v. injection of CD47/mRNA-LNP and mRNA-LNP, total PBMC count was measured. Significantly less PBMC recruitment was observed upon i.v. injection of CD47-modified LNP when compared to LNP lacking CD47.

Figure 4A through Figure 4C depicts data demonstrating that the targeting efficiency increases when combined with CD47. Figure 4A depicts data demonstrating that radiolabeled CD31-targeted mRNA-LNP and CD47/CD31-targeted mRNA-LNP (CD31-targeted mRNA-LNP which was modified with CD47 as well) were injected i.v. to the mice and lungs were harvested at one hour post-injection. CD47/CD31-targeted mRNA-LNP results in higher lung uptake when compared to CD31-targeted mRNA-LNP. Figure 4B depicts localization ratios showing the radioactivity in the lungs normalized to blood levels, again confirming results in Figure 4A. Figure 4C depicts data demonstrating that CD47/CD31-targeted mRNA-LNP and CD31-targeted mRNA-LNP encapsulating nucleoside modified luciferase mRNA were injected i.v. to the mice at 0.3 mg mRNA/kg and tissues were harvested 4 hours post-injection. CD47/CD31-targeted mRNA-LNP results in very close to zero signal in liver, but significantly higher signal in the lungs when compared to CD31-targeted mRNA-LNP.

Figure 5A through Figure 5C depicts data demonstrating that CD47 modification boosts T cell targeting efficiency. Figure 5A depicts data demonstrating that CD4-targeted mRNA-LNP and CD47/CD4-targeted mRNA-LNP encapsulating nucleoside modified luciferase mRNA were injected i.v. to the mice at 0.3 mg mRNA/kg

and tissues were harvested 4 hours post-injection. CD47/CD4-targeted mRNA-LNP results in significantly lower signal in liver, but also higher signal in the spleens (target organ) when compared to CD4-targeted mRNA-LNP. CD47/CD4-targeted mRNA-LNP and CD4-targeted mRNA-LNP encapsulating nucleoside modified Cre mRNA were  
5 injected i.v. to the Ai6 mice at 0.3 mg mRNA/kg and lymph nodes (Figure 5B) and spleens (Figure 5C) were harvested 24 hours post-injection. Ai6, as a murine reporter model, is engineered with a Cre reporter allele designed to have a loxP-flanked STOP cassette preventing transcription of a CAG promoter-driven green fluorescent reporter gene (ZsGreen1) inserted into the Gt(ROSA)26Sor locus. CD47/CD4-targeted mRNA-LNP  
10 results in higher ZsGreen expression in target cell population (CD3+CD8- cells) in both lymph nodes (Figure 5B) and spleens (Figure 5C) when compared to CD4-targeted mRNA-LNP.

Figure 6A and Figure 6B depict data demonstrating that pro-inflammatory cytokines are elevated after IV treatment of LNP-mRNA in systemic mouse model of  
15 inflammation (IV-LPS). Pro-inflammatory cytokines of (Figure 6A) IL-6 in plasma and Figure 6B) MIP-2 in liver homogenate were significantly elevated following LNP-mRNA administration to i.v. LPS-treated mice. This phenomenon was called inflammation exacerbation.

Figure 7A and Figure 7B depict data demonstrating enhanced LNP uptake  
20 by monocytes/macrophages in LPS-treated mice. Figure 7A depicts data demonstrating the cell type distribution in naive vs. LPS-treated mice. The population of monocyte/macrophages taking up the LNP-mRNA is almost tripled in presence of LPS. Figure 7B depicts data demonstrating the cell type distribution positive for LNP.

Figure 8A and Figure 8B depict data demonstrating that removal of  
25 macrophages using Clodronate reduces systemic pro-inflammatory markers. Removal of macrophages by Clodronate administration significantly lowered the level of pro-inflammatory cytokines (Figure 8A) IL-6 in blood, and (Figure 8B) MIP-2 in liver homogenate in LPS-treated mice which received LNP-mRNAs.

Figure 9 depicts data demonstrating that decreasing macrophage uptake by  
30 CD47-modified LNPs alleviates systemic pro-inflammatory markers in LPS model of systemic inflammation. In the context of inflammation, i.v. treated LPS mice,

CD47/mRNA-LNP showed significantly lower pro-inflammatory cytokine of IL-6, when compared to mRNA-LNP. The data demonstrate that with CD47/mRNA-LNP, we can improve the safety profile and be able to use mRNA-LNP in inflammatory conditions, as there was a reduced pro-inflammatory response using the CD47-optimized LNP as  
5 compared to LNP not comprising CD47.

Figure 10 depicts data demonstrating that optimized D47/mRNA-LNP minimizes hepatic acute phase response by RNA-Seq analysis. Figure 10A provides data demonstrating that there is a significant down-regulation of 30 genes, ranging from -18.40 to -2.11 fold in CD47/mRNA-LNP treated and untreated mice compared to un-  
10 modified control NP0. Among these genes, eight are directly involved in the APR pro-inflammatory protein family. In same RNA-seq dataset, a bioinformatic principle component analysis (PCA) (Figure 10B) was performed on the significantly differentially expressed genes. As predicted, results indicate that plotted RNA-seq data from CD47/mRNA-LNP clusters closer to untreated mice with similar behavior whereas  
15 unmodified mRNA-LNP sparse to the opposite side of the matrix. This data supports the transcriptomic resemblance of untreated control to CD47/mRNA-LNP treated liver tissue.

Figure 11 depicts data demonstrating protein corona analysis of optimized CD47/mRNA-LNP in murine serum. Protein corona formed around CD47-modified LNP  
20 is completely different from the one on non-modified LNP. ApoE, acute phase proteins, proteins involved in inflammatory responses and apoptosis are the ones found in protein corona on non-modified LNP, but not CD47-modified ones.

#### DETAILED DESCRIPTION

25 The present invention relates to compositions for efficient delivery of a therapeutic agent, comprising a delivery vehicle, wherein the delivery vehicle comprises at least one moiety or domain for evasion of the immune response. In one embodiment, the delivery vehicle further comprises a targeting domain or moiety for delivery of the therapeutic agent to a target cell.

30 In one embodiment, the domain for evasion of the immune system comprises a moiety to prevent macrophage uptake. In one embodiment the moiety to

prevent macrophage uptake comprises an inhibitory of phagocytosis. In one embodiment the moiety to prevent macrophage uptake comprises a CD47 moiety, PD-L1, CD24, a poly glutamic acid peptide, or the beta-2-microglobulin subunit of the major histocompatibility class 1 complex.

5                    In one embodiment, the targeting domain specifically binds to a marker of a cell type of interest. For example, in one embodiment, the targeting domain directs the vehicle to an endothelial cell, a T cell, a stem cell, or another specific cell type of interest.

                    In certain embodiments, the delivery vehicle is a lipid nanoparticle comprising at least one lipid conjugated to a domain for evasion of the immune system.

10                   In one embodiment, the delivery vehicle is a lipid nanoparticle comprising at least one lipid conjugated to a domain for evasion of the immune system and further comprising at least one lipid conjugated to a targeting domain.

                    The present invention also relates to methods of use of the compositions described herein for targeted delivery of therapeutics as well as methods of treating  
15                   diseases or disorders in subjects having inflammatory conditions using the compositions described herein which evade the subject's immune response.

### Definitions

                    Unless defined otherwise, all technical and scientific terms used herein  
20                   have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

                    As used herein, each of the following terms has the meaning associated with it in this section.

                    The articles "a" and "an" are used herein to refer to one or to more than  
25                   one (*i.e.*, to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

                    "About" as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of  $\pm 20\%$ ,  $\pm 10\%$ ,  $\pm 5\%$ ,  $\pm 1\%$ , or  $\pm 0.1\%$  from the specified value, as such variations are appropriate  
30                   to perform the disclosed methods.

The term “antibody,” as used herein, refers to an immunoglobulin molecule, which specifically binds with an antigen or epitope. Antibodies can be intact immunoglobulins derived from natural sources or from recombinant sources and can be immunoreactive portions of intact immunoglobulins. Antibodies are typically tetramers  
5 of immunoglobulin molecules. The antibodies in the present invention may exist in a variety of forms including, for example, polyclonal antibodies, monoclonal antibodies, Fv, Fab and F(ab)<sub>2</sub>, as well as single chain antibodies and humanized antibodies (Harlow et al., 1999, In: Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989, In: Antibodies: A Laboratory Manual, Cold Spring  
10 Harbor, New York; Houston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science 242:423-426).

The term “antibody fragment” refers to a portion of an intact antibody and refers to the antigenic-specificity determining variable regions of an intact antibody. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')<sub>2</sub>, and Fv  
15 fragments, linear antibodies, scFv antibodies, and multispecific antibodies formed from antibody fragments.

An “antibody heavy chain,” as used herein, refers to the larger of the two types of polypeptide chains present in all antibody molecules in their naturally occurring conformations.

20 An “antibody light chain,” as used herein, refers to the smaller of the two types of polypeptide chains present in all antibody molecules in their naturally occurring conformations. k and l light chains refer to the two major antibody light chain isotypes.

By the term “synthetic antibody” as used herein, is meant an antibody, which is generated using recombinant DNA technology, such as, for example, an  
25 antibody expressed by a bacteriophage. The term should also be construed to mean an antibody which has been generated by the synthesis of a DNA molecule encoding the antibody and which DNA molecule expresses an antibody protein, or an amino acid sequence specifying the antibody, wherein the DNA or amino acid sequence has been obtained using synthetic DNA or amino acid sequence technology which is available and  
30 well known in the art. The term should also be construed to mean an antibody, which has been generated by the synthesis of an RNA molecule encoding the antibody. The RNA

molecule expresses an antibody protein, or an amino acid sequence specifying the antibody, wherein the RNA has been obtained by transcribing DNA (synthetic or cloned) or other technology, which is available and well known in the art.

5 A “disease” is a state of health of an animal wherein the animal cannot maintain homeostasis, and wherein if the disease is not ameliorated then the animal’s health continues to deteriorate. In contrast, a “disorder” in an animal is a state of health in which the animal is able to maintain homeostasis, but in which the animal’s state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the animal’s state of health.

10 An “effective amount” as used herein, means an amount which provides a therapeutic or prophylactic benefit.

The term “physiologically effective dosage” refers to an amount of an agent that produces a measurable biologic or physiologic effect in the recipient subject that is related to the activity of the agent(s). The physiologically effective dosage will vary depending on the compound, the age, weight, etc., of the subject being administered the agent, and the biologic or physiologic effect being measured.

“Encoding” refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (i.e., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom. Thus, a gene encodes a protein if transcription and translation of mRNA corresponding to that gene produces the protein in a cell or other biological system. Both the coding strand, the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and the non-coding strand, used as the template for transcription of a gene or cDNA, can be referred to as encoding the protein or other product of that gene or cDNA.

“Expression vector” refers to a vector comprising a recombinant polynucleotide comprising expression control sequences operatively linked to a nucleotide sequence to be expressed. An expression vector comprises sufficient cis-acting elements for expression; other elements for expression can be supplied by the host cell or

in an in vitro expression system. Expression vectors include all those known in the art, such as cosmids, plasmids (e.g., naked or contained in liposomes) RNA, and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) that incorporate the recombinant polynucleotide.

5                   “Homologous” refers to the sequence similarity or sequence identity between two polypeptides or between two nucleic acid molecules. When a position in both of the two compared sequences is occupied by the same base or amino acid monomer subunit, e.g., if a position in each of two DNA molecules is occupied by adenine, then the molecules are homologous at that position. The percent of homology  
10 between two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of positions compared X 100. For example, if 6 of 10 of the positions in two sequences are matched or homologous then the two sequences are 60% homologous. By way of example, the DNA sequences ATTGCC and TATGGC share 50% homology. Generally, a comparison is made when two  
15 sequences are aligned to give maximum homology.

                  “Isolated” means altered or removed from the natural state. For example, a nucleic acid or a peptide naturally present in a living animal is not “isolated,” but the same nucleic acid or peptide partially or completely separated from the coexisting materials of its natural state is “isolated.” An isolated nucleic acid or protein can exist in  
20 substantially purified form, or can exist in a non-native environment such as, for example, a host cell.

                  In the context of the present invention, the following abbreviations for the commonly occurring nucleosides (nucleobase bound to ribose or deoxyribose sugar via N-glycosidic linkage) are used. “A” refers to adenosine, “C” refers to cytidine, “G” refers  
25 to guanosine, “T” refers to thymidine, and “U” refers to uridine.

                  Unless otherwise specified, a “nucleotide sequence encoding an amino acid sequence” includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. The phrase nucleotide sequence that encodes a protein or an RNA may also include introns to the extent that the nucleotide  
30 sequence encoding the protein may in some version contain an intron(s).

By the term “modulating,” as used herein, is meant mediating a detectable increase or decrease in the level of a response in a subject compared with the level of a response in the subject in the absence of a treatment or compound, and/or compared with the level of a response in an otherwise identical but untreated subject. The term  
5 encompasses perturbing and/or affecting a native signal or response thereby mediating a beneficial therapeutic response in a subject, preferably, a human.

Unless otherwise specified, a “nucleotide sequence encoding an amino acid sequence” includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. Nucleotide sequences that encode  
10 proteins and RNA may include introns. In addition, the nucleotide sequence may contain modified nucleosides that are capable of being translation by translational machinery in a cell. For example, an mRNA where all of the uridines have been replaced with pseudouridine, 1-methyl psuedouridine, or another modified nucleoside.

The term “operably linked” refers to functional linkage between a  
15 regulatory sequence and a heterologous nucleic acid sequence resulting in expression of the latter. For example, a first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the  
20 coding sequence. Generally, operably linked DNA or RNA sequences are contiguous and, where necessary to join two protein coding regions, in the same reading frame.

The terms “patient,” “subject,” “individual,” and the like are used interchangeably herein, and refer to any animal, or cells thereof whether in vitro or in situ, amenable to the methods described herein. In certain non-limiting embodiments, the  
25 patient, subject or individual is a human.

The term “polynucleotide” as used herein is defined as a chain of nucleotides. Furthermore, nucleic acids are polymers of nucleotides. Thus, nucleic acids and polynucleotides as used herein are interchangeable. One skilled in the art has the general knowledge that nucleic acids are polynucleotides, which can be hydrolyzed into  
30 the monomeric “nucleotides.” The monomeric nucleotides can be hydrolyzed into nucleosides. As used herein polynucleotides include, but are not limited to, all nucleic

acid sequences which are obtained by any means available in the art, including, without limitation, recombinant means, i.e., the cloning of nucleic acid sequences from a recombinant library or a cell genome, using ordinary cloning technology and PCR™, and the like, and by synthetic means.

5                   In certain instances, the polynucleotide or nucleic acid of the invention is a “nucleoside-modified nucleic acid,” which refers to a nucleic acid comprising at least one modified nucleoside. A “modified nucleoside” refers to a nucleoside with a modification. For example, over one hundred different nucleoside modifications have been identified in RNA (Rozenki, et al., 1999, The RNA Modification Database: 1999 update. Nucl Acids  
10 Res 27: 196-197).

                  In certain embodiments, “pseudouridine” refers, in another embodiment, to m<sup>1</sup>acp<sup>3</sup>Y (1-methyl-3-(3-amino-3-carboxypropyl) pseudouridine. In another embodiment, the term refers to m<sup>1</sup>Y (1-methylpseudouridine). In another embodiment, the term refers to Ym (2'-O-methylpseudouridine. In another embodiment, the term refers  
15 to m<sup>5</sup>D (5-methyldihydrouridine). In another embodiment, the term refers to m<sup>3</sup>Y (3-methylpseudouridine). In another embodiment, the term refers to a pseudouridine moiety that is not further modified. In another embodiment, the term refers to a monophosphate, diphosphate, or triphosphate of any of the above pseudouridines. In another embodiment, the term refers to any other pseudouridine known in the art. Each possibility represents a  
20 separate embodiment of the present invention.

                  As used herein, the terms “peptide,” “polypeptide,” and “protein” are used interchangeably, and refer to a compound comprised of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and no limitation is placed on the maximum number of amino acids that can comprise a  
25 protein’s or peptide’s sequence. Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds. As used herein, the term refers to both short chains, which also commonly are referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types. “Polypeptides” include,  
30 for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified

polypeptides, derivatives, analogs, fusion proteins, among others. The polypeptides include natural peptides, recombinant peptides, synthetic peptides, or a combination thereof.

5 The term “promoter” as used herein is defined as a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a polynucleotide sequence. For example, the promoter that is recognized by bacteriophage RNA polymerase and is used to generate the mRNA by in vitro transcription.

10 By the term “specifically binds,” as used herein with respect to an affinity ligand, in particular, an antibody, is meant an antibody which recognizes a specific antigen, but does not substantially recognize or bind other molecules in a sample. For example, an antibody that specifically binds to an antigen from one species may also bind to that antigen from one or more other species. But, such cross-species reactivity does not itself alter the classification of an antibody as specific. In another example, an antibody  
15 that specifically binds to an antigen may also bind to different allelic forms of the antigen. However, such cross reactivity does not itself alter the classification of an antibody as specific. In some instances, the terms “specific binding” or “specifically binding,” can be used in reference to the interaction of an antibody, a protein, or a peptide with a second chemical species, to mean that the interaction is dependent upon the  
20 presence of a particular structure (e.g., an antigenic determinant or epitope) on the chemical species; for example, an antibody recognizes and binds to a specific protein structure rather than to proteins generally. If an antibody is specific for epitope “A”, the presence of a molecule containing epitope A (or free, unlabeled A), in a reaction containing labeled “A” and the antibody, will reduce the amount of labeled A bound to  
25 the antibody.

The term “therapeutic” as used herein means a treatment and/or prophylaxis. A therapeutic effect is obtained by suppression, diminution, remission, or eradication of at least one sign or symptom of a disease or disorder.

30 The term “therapeutically effective amount” refers to the amount of the subject compound that will elicit the biological or medical response of a tissue, system, or subject that is being sought by the researcher, veterinarian, medical doctor or other

clinician. The term “therapeutically effective amount” includes that amount of a compound that, when administered, is sufficient to prevent development of, or alleviate to some extent, one or more of the signs or symptoms of the disorder or disease being treated. The therapeutically effective amount will vary depending on the compound, the disease and its severity and the age, weight, etc., of the subject to be treated.

To “treat” a disease as the term is used herein, means to reduce the frequency or severity of at least one sign or symptom of a disease or disorder experienced by a subject.

The term “transfected” or “transformed” or “transduced” as used herein refers to a process by which exogenous nucleic acid is transferred or introduced into the host cell. A “transfected” or “transformed” or “transduced” cell is one which has been transfected, transformed or transduced with exogenous nucleic acid. The cell includes the primary subject cell and its progeny.

The phrase “under transcriptional control” or “operatively linked” as used herein means that the promoter is in the correct location and orientation in relation to a polynucleotide to control the initiation of transcription by RNA polymerase and expression of the polynucleotide.

A “vector” is a composition of matter which comprises an isolated nucleic acid and which can be used to deliver the isolated nucleic acid to the interior of a cell. Numerous vectors are known in the art including, but not limited to, linear polynucleotides, polynucleotides associated with ionic or amphiphilic compounds, plasmids, and viruses. Thus, the term “vector” includes an autonomously replicating plasmid or a virus. The term should also be construed to include non-plasmid and non-viral compounds which facilitate transfer of nucleic acid into cells, such as, for example, polylysine compounds, liposomes, and the like. Examples of viral vectors include, but are not limited to, adenoviral vectors, adeno-associated virus vectors, retroviral vectors, and the like.

“Alkyl” refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, which is saturated or unsaturated (i.e., contains one or more double and/or triple bonds), having from one to twenty-four carbon atoms (C<sub>1</sub>-C<sub>24</sub> alkyl), one to twelve carbon atoms (C<sub>1</sub>-C<sub>12</sub> alkyl), one to eight carbon

atoms (C<sub>1</sub>-C<sub>8</sub> alkyl) or one to six carbon atoms (C<sub>1</sub>-C<sub>6</sub> alkyl) and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n propyl, 1-methylethyl (iso propyl), n butyl, n pentyl, 1,1 dimethylethyl (t butyl), 3 methylhexyl, 2 methylhexyl, ethenyl, prop 1 enyl, but-1-enyl, pent-1-enyl, penta-1,4-dienyl, ethynyl, propynyl,  
5 butynyl, pentynyl, hexynyl, and the like. Unless specifically stated otherwise, an alkyl group is optionally substituted.

“Alkylene” or “alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, which is saturated or unsaturated (*i.e.*, contains one or more double  
10 (alkenylene) and/or triple bonds (alkynylene)), and having, for example, from one to twenty-four carbon atoms (C<sub>1</sub>-C<sub>24</sub> alkylene), one to fifteen carbon atoms (C<sub>1</sub>-C<sub>15</sub> alkylene), one to twelve carbon atoms (C<sub>1</sub>-C<sub>12</sub> alkylene), one to eight carbon atoms (C<sub>1</sub>-C<sub>8</sub> alkylene), one to six carbon atoms (C<sub>1</sub>-C<sub>6</sub> alkylene), two to four carbon atoms (C<sub>2</sub>-C<sub>4</sub> alkylene), one to two carbon atoms (C<sub>1</sub>-C<sub>2</sub> alkylene), *e.g.*, methylene, ethylene,  
15 propylene, *n*-butylene, ethenylene, propenylene, *n*-butenylene, propynylene, *n*-butynylene, and the like. The alkylene chain is attached to the rest of the molecule through a single or double bond and to the radical group through a single or double bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless  
20 stated otherwise specifically in the specification, an alkylene chain may be optionally substituted.

“Cycloalkyl” or “carbocyclic ring” refers to a stable non aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which may include fused or bridged ring systems, having from three to fifteen  
25 carbon atoms, preferably having from three to ten carbon atoms, and which is saturated or unsaturated and attached to the rest of the molecule by a single bond. Monocyclic radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic radicals include, for example, adamantyl, norbornyl, decalanyl, 7,7 dimethyl bicyclo[2.2.1]heptanyl, and the like. Unless  
30 specifically stated otherwise, a cycloalkyl group is optionally substituted.

“Cycloalkylene” is a divalent cycloalkyl group. Unless otherwise stated specifically in the specification, a cycloalkylene group may be optionally substituted.

“Heterocyclyl” or “heterocyclic ring” refers to a stable 3- to 18-membered non-aromatic ring radical which consists of two to twelve carbon atoms and from one to  
5 six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. Unless stated otherwise specifically in the specification, the heterocyclyl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the  
10 heterocyclyl radical may be partially or fully saturated. Examples of such heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl,  
15 pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholyl, thiamorpholyl, 1-oxo-thiomorpholyl, and 1,1-dioxo-thiomorpholyl. Unless specifically stated otherwise, a heterocyclyl group may be optionally substituted.

The term “substituted” used herein means any of the above groups (e.g.,  
20 alkyl, cycloalkyl or heterocyclyl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, Cl, Br, and I; oxo groups (=O); hydroxyl groups (-OH); alkoxy groups (-OR<sup>a</sup>, where R<sup>a</sup> is C<sub>1</sub>-C<sub>12</sub> alkyl or cycloalkyl); carboxyl groups (-OC(=O)R<sup>a</sup> or -C(=O)OR<sup>a</sup>, where R<sup>a</sup> is H, C<sub>1</sub>-C<sub>12</sub> alkyl or cycloalkyl); amine groups (-NR<sup>a</sup>R<sup>b</sup>, where R<sup>a</sup> and R<sup>b</sup> are each  
25 independently H, C<sub>1</sub>-C<sub>12</sub> alkyl or cycloalkyl); C<sub>1</sub>-C<sub>12</sub> alkyl groups; and cycloalkyl groups. In some embodiments the substituent is a C<sub>1</sub>-C<sub>12</sub> alkyl group. In other embodiments, the substituent is a cycloalkyl group. In other embodiments, the substituent is a halo group, such as fluoro. In other embodiments, the substituent is a oxo group. In other  
embodiments, the substituent is a hydroxyl group. In other embodiments, the substituent  
30 is an alkoxy group. In other embodiments, the substituent is a carboxyl group. In other embodiments, the substituent is an amine group.

“Optional” or “optionally” (e.g., optionally substituted) means that the subsequently described event or circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, “optionally substituted alkyl” means that the alkyl radical  
5 may or may not be substituted and that the description includes both substituted alkyl radicals and alkyl radicals having no substitution.

Ranges: throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible  
10 limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual  
15 numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.

### Description

The present invention relates in part to compositions and methods for  
20 targeted delivery of a delivery vehicle having increased efficacy and a reduction in off-target effects. In one aspect, the present invention relates to composition comprising a delivery vehicle conjugated to a domain for evasion of the host immune system. In one aspect, the present invention relates to composition comprising a delivery vehicle conjugated to a domain for evasion of the host immune system, and further conjugated to  
25 a targeting domain.

In one embodiment, the domain for evasion of the immune system comprises a moiety to reduce or prevent macrophage uptake. In some embodiments, the domain for evasion of the immune system can be a peptide, a protein, or a peptidomimetic. Exemplary moieties that can be incorporated into a delivery vehicle of  
30 the invention to prevent macrophage uptake include, but are not limited to, a CD47 moiety, PD-L1, CD24, a poly glutamic acid peptide, or the beta-2-microglobulin subunit

of the major histocompatibility class 1 complex ( $\beta$ 2M), or a functional fragment thereof, or a combination thereof. In one embodiment, the domain for the evasion of the immune response comprises a CD47 polypeptide comprising a sequence as set forth in SEQ ID NO:1 or SEQ ID NO:2, or a fragment or variant thereof.

5                   In some embodiments, the domain for evasion of the immune system binds the inhibitory receptor SIRP $\alpha$  on macrophages, and activates SIRP $\alpha$  signaling, thus reducing or preventing macrophage uptake of the therapeutic agent. In one embodiment, therefore, the invention relates to compositions comprising a moiety for activating SIRP $\alpha$  signaling. In some embodiments, the moiety for activating SIRP $\alpha$  signaling is a nucleic acid molecule, a small molecule, a protein, a peptide, or a peptidomimetic.

10                   In some embodiments, the domain for evasion of the immune system binds PD-1 on macrophages, and activates PD-1 signaling, thus reducing or preventing macrophage uptake of the therapeutic agent. In one embodiment, therefore, the invention relates to compositions comprising a moiety for activating PD-1 signaling. In some

15                   embodiments, the moiety for activating PD-1 signaling is a nucleic acid molecule, a small molecule, a protein, a peptide, or a peptidomimetic.

                    In some embodiments, the domain for evasion of the immune system binds the Siglec-10 receptor on macrophages, and activates Siglec-10 receptor signaling, thus reducing or preventing macrophage uptake of the therapeutic agent. In one

20                   embodiment, therefore, the invention relates to compositions comprising a moiety for activating Siglec-10 signaling. In some embodiments, the moiety for activating Siglec-10 signaling is a nucleic acid molecule, a small molecule, a protein, a peptide, or a peptidomimetic.

                    In some embodiments, the domain for evasion of the immune system binds the inhibitory receptor LILRB1 on macrophages, and activates LILRB1 receptor signaling, thus reducing or preventing macrophage uptake of the therapeutic agent. In one

25                   embodiment, therefore, the invention relates to compositions comprising a moiety for activating LILRB1 signaling. In some embodiments, the moiety for activating LILRB1 signaling is a nucleic acid molecule, a small molecule, a protein, a peptide, or a

30                   peptidomimetic.

Phagocytosis inhibitors

The present invention relates to the prevention and treatment of a disease or disorder by administration of a therapeutic agent for the treatment of the disease or disorder formulated with a delivery vehicle which expresses a moiety for the evasion of the immune response. In one embodiment, the moiety for the evasion of the immune response comprises an inhibitor of phagocytosis. In one embodiment, the composition comprises a delivery vehicle conjugated to a phagocytosis inhibitor that binds an inhibitory cell surface molecule of a macrophage and providing an inhibitory signal, thereby preventing phagocytosis of the delivery vehicle and associated therapeutic molecule.

In some embodiments, the moiety for the evasion of the immune response comprises a CD47 polypeptide, an active CD47 polypeptide fragment, or an activator of SIRP $\alpha$  activity. In some embodiments, the moiety for the evasion of the immune response comprises a PD-L1 polypeptide, an active PD-L1 polypeptide fragment, or an activator of PD-1 activity. In some embodiments, the moiety for the evasion of the immune response comprises a CD24 polypeptide, an active CD24 polypeptide fragment, or an activator of Siglec-10 activity. In some embodiments, the moiety for the evasion of the immune response comprises a poly glutamic acid peptide. In some embodiments, the moiety for the evasion of the immune response comprises a  $\beta$ 2M polypeptide, an active  $\beta$ 2M polypeptide fragment, or an activator of LILRB1 activity.

In one embodiment, the moiety for the evasion of the immune response comprises a CD47 polypeptide comprising a sequence as set forth in SEQ ID NO:1 or SEQ ID NO:2, or a fragment or variant thereof.

There are two primary mechanisms by which LNP are taken up by the liver. Hepatocytes can take up LNP by receptor-mediated processes, for example, based on the interaction with ApoE. This can be avoided by shielding the LNP surface with pegylated lipid. Lipid conjugates with a targeting moiety and/or an active CD47 polypeptide can contribute to shielding. The Kupffer cells of the liver, which are macrophages, can take up LNP by phagocytosis. This can be avoided by SIRP $\alpha$  signaling activation (e.g., by binding of an active CD47 polypeptide.) Accordingly, LNP comprising sufficient surface shielding in combination with a phagocytosis inhibitor can

substantially reduce, or even completely avoid, uptake by the liver. This affords several advantages. Liver can be the primary destination of systemically administered LNPs. By reducing or avoiding liver uptake more of the administered LNP will be available to be taken up by targeted cells, whether targeting is accomplished by lipid composition or  
5 inclusion of a targeting moiety on the LNP, either increasing efficiency of transfection of the targeted cells or reducing required dosage. This will also reduce lipid exposure to and accumulation in the liver reducing or avoiding toxic and/or proinflammatory effects that the lipid components can exert on the liver. Finally, in some instances, the therapeutic agent can have deleterious or undesirable effects in the liver. By avoiding delivery to the  
10 liver, these effects can be reduced or eliminated.

Thus, in some embodiments the invention relates to compositions and methods of delivering a LNP to a non-hepatic cell of a subject *in vivo* while avoiding delivery to hepatic cells, wherein the LNP comprises a pegylated lipid conjugated to an an activator of SIRP $\alpha$  activity, and a therapeutic agent. In some embodiments, the  
15 activator of SIRP $\alpha$  activity is a CD47 polypeptide, or an active CD47 polypeptide fragment. In some embodiments the LNP further comprises a pegylated lipid conjugated to a targeting moiety. In some embodiments the targeting moiety is an antibody or antigen-binding fragment thereof. In some embodiments, the LNP further comprises unconjugated pegylated lipid.

20 Activation of a protein can be assessed using a wide variety of methods, including those disclosed herein, as well as methods well-known in the art or to be developed in the future. That is, the person of skill in the art would appreciate, based upon the disclosure provided herein, that increasing activity of SIRP $\alpha$ , PD-1, Siglec-10 or LILRB1 activity can be readily assessed using methods that assess the level of  
25 phagocytosis of a composition comprising the activator of the invention.

An activator of the invention can include, but should not be construed as being limited to, a chemical compound, a protein, a peptidomimetic, an antibody, a nucleic acid molecule. One of skill in the art would readily appreciate, based on the disclosure provided herein, that a SIRP $\alpha$ , PD-1, Siglec-10 or LILRB1 activator  
30 encompasses a chemical compound that increases the signaling, activity, or the like of SIRP $\alpha$ , PD-1, Siglec-10 or LILRB1. In some embodiments, the activity is decreasing or

inhibiting phagocytosis. Additionally, a SIRP $\alpha$ , PD-1, Siglec-10 or LILRB1 activator encompasses a chemically modified compound, and derivatives, as is well known to one of skill in the chemical arts.

Further, one of skill in the art would, when equipped with this disclosure  
5 and the methods exemplified herein, appreciate that the invention includes such inhibitors of phagocytosis as discovered in the future, as can be identified by well-known criteria in the art of pharmacology, which have the physiological results of preventing or decreasing the level of phagocytosis. Therefore, the present invention is not limited in any way to any particular activator or inhibitor as exemplified or disclosed herein; rather, the  
10 invention encompasses those activators or inhibitors that would be understood by the person of skill in the art to be useful as are known in the art and as are discovered in the future.

Methods of identifying and producing a CD47, PD-L1, CD24, a poly glutamic acid peptide or  $\beta$ 2M polypeptide or functional fragments thereof are well known  
15 to those of ordinary skill in the art, including, but not limited, obtaining polypeptide from a naturally occurring source. Alternatively, a CD47, PD-L1, CD24, a poly glutamic acid peptide or  $\beta$ 2M polypeptide or a functional fragment thereof can be synthesized chemically. Further, the person of skill in the art would appreciate, based upon the teachings provided herein, that a CD47, PD-L1, CD24, a poly glutamic acid peptide or  
20  $\beta$ 2M polypeptide or a functional fragment thereof can be obtained from a recombinant organism. Compositions and methods for chemically synthesizing polypeptide molecules and for obtaining them from natural sources are well known in the art and are described in the art.

## 25 Targeting Molecule

In various embodiments, the delivery vehicle of the invention comprises a targeting domain that binds to a cell surface molecule of a target cell of interest, including, but not limited to, an endothelial cell, a T cell or a stem cell. In certain  
30 embodiments, the targeting domain binds to a cell surface molecule of a target cell of interest, thereby directing the composition to the target cell. In one embodiment, the composition comprises a delivery vehicle conjugated to a targeting domain that binds a

cell surface molecule of a target cell of interest, thereby directing the composition to the target cell.

For example, in various embodiments, for compositions targeting an endothelial cell, the targeting domain binds to a molecule selected from the group including, but not limited to, (ICAM-1), platelet-endothelial cell adhesion molecule-1 (PECAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin, angiotensin-converting enzyme (ACE), aminopeptidase P (APP), plasmalemma vesicle protein-1 (PV1), P-selectin, VE-cadherin, receptors for cytokines, plasma proteins and microbes.

In some embodiments, the targeted delivery vehicles of the invention comprising a targeting moiety that binds to a surface molecule of an immune cell including, but not limited to, T cells (including killer T cells, helper T cells, regulatory T cells, and gamma delta T cells), natural killer (NK) cells, antigen presenting cells, dendritic cells, B cells, or Langerhans cells. In some embodiments, the targeted delivery vehicle comprises a targeting moiety that binds to a surface molecule of a T cell. Exemplary targeting moieties that can be used to target the compositions of the invention to T cells include, but are not limited to, an anti-CD4, anti-CD-8, anti-CD5, anti-CD3, or anti-CD25 targeting ligand. Exemplary compositions and methods for targeting T cells in vivo are described in WO2022/081694, WO2022/081699, and WO2022/081702 which are hereby incorporated by reference in their entirety.

In some embodiments, the targeted delivery vehicles of the invention comprising a targeting moiety that binds to a surface molecule of a stem cell including, but not limited to, a somatic stem cell, a mesenchymal stem cell, or a hematopoietic stem cell. Exemplary surface molecules of a stem cell include, but are not limited to, CD34, CD117, CD90, CD133, CD105, ABCG2, Bone morphogenetic protein receptor (BMPR), CD44, Sca-1, Thy-1, CD133, alkaline phosphatase, alpha-fetoprotein, CD70, CD90, CD105, CD73, Stro-1, SSEA-4, CD271, CD146, GD2, SSEA-3, SUSD2, Stro-4, MSCA-1, CD56, CD200, PODXL, CD13, CD29, CD44, and CD10. Exemplary compositions and methods for targeting stem cells in vivo are described in International Patent Application No. PCT/US22/26933 and International Patent Application No. PCT/US22/26981 which are hereby incorporated by reference in their entirety.

However, the present invention is not limited to vehicles directed to an endothelial cell, a T cell or a stem cell. Rather, the present invention encompasses a delivery vehicle comprising a targeting domain that directs the vehicle to any specific target cell, as mediated the by binding of the targeting domain to a specific marker. In  
5 some embodiments, the vehicle is targeted to a specific treatment site in need. For example, the targeting domain can be directed specifically to sites of inflammation.

The present invention also relates in part to methods of treating diseases or disorders in subjects in need thereof, the method comprising the administration of a composition including a delivery vehicle conjugated to a domain for evasion of the  
10 immune response. In some embodiments, the method comprises administration of a composition including a delivery vehicle conjugated to a domain for evasion of the immune response and further conjugated to a targeting domain.

In some embodiments, the invention provides a method for treating an inflammatory disease or disorder in subjects in need thereof, the method comprising the  
15 administration of a composition including a delivery vehicle conjugated to a domain for evasion of the immune response. In some embodiments, the method comprises administration of a composition including a delivery vehicle conjugated to a domain for evasion of the immune response and further conjugated to a targeting domain.

In some embodiments, the invention provides a method for treating an  
20 inflammatory or a non-inflammatory disease or disorder in subjects who have an ongoing or prior diagnosis of an inflammatory disease or disorder, the method comprising the administration of a composition including a delivery vehicle conjugated to a domain for evasion of the immune response. In some embodiments, the method comprises administration of a composition including a delivery vehicle conjugated to a domain for  
25 evasion of the immune response and further conjugated to a targeting domain.

### Delivery Vehicle

In some embodiments, the delivery vehicle is a colloidal dispersion  
30 system, such as macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes.

An exemplary colloidal system for use as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle).

The use of lipid formulations is contemplated for the introduction of the at least one agent into a host cell (in vitro, ex vivo or in vivo). In another aspect, the at least one agent may be associated with a lipid. The at least one agent associated with a lipid may be encapsulated in the aqueous interior of a liposome, interspersed within the lipid bilayer of a liposome, attached to a liposome via a linking molecule that is associated with both the liposome and the oligonucleotide, entrapped in a liposome, complexed with a liposome, dispersed in a solution containing a lipid, mixed with a lipid, combined with a lipid, contained as a suspension in a lipid, contained or complexed with a micelle, or otherwise associated with a lipid. Lipid, lipid/nucleic acid or lipid/expression vector associated compositions are not limited to any particular structure in solution. For example, they may be present in a bilayer structure, as micelles, or with a “collapsed” structure. They may also simply be interspersed in a solution, possibly forming aggregates that are not uniform in size or shape. Lipids are fatty substances which may be naturally occurring or synthetic lipids. For example, lipids include the fatty droplets that naturally occur in the cytoplasm as well as the class of compounds which contain long-chain aliphatic hydrocarbons and their derivatives, such as fatty acids, alcohols, amines, amino alcohols, and aldehydes.

Lipids suitable for use can be obtained from commercial sources. For example, dimyristyl phosphatidylcholine (“DMPC”) can be obtained from Sigma, St. Louis, MO; dicetyl phosphate (“DCP”) can be obtained from K & K Laboratories (Plainview, NY); cholesterol (“Chol”) can be obtained from Calbiochem-Behring; dimyristyl phosphatidylglycerol (“DMPG”) and other lipids may be obtained from Avanti Polar Lipids, Inc. (Birmingham, AL). Stock solutions of lipids in chloroform or chloroform/methanol can be stored at about -20°C. Chloroform is used as the only solvent since it is more readily evaporated than methanol. “Liposome” is a generic term encompassing a variety of single and multilamellar lipid vehicles formed by the generation of enclosed lipid bilayers or aggregates. Liposomes can be characterized as having vesicular structures with a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous

medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers (Ghosh et al., 1991 *Glycobiology* 5: 505-10). However, compositions that have different  
5 structures in solution than the normal vesicular structure are also encompassed. For example, the lipids may assume a micellar structure or merely exist as nonuniform aggregates of lipid molecules. Also contemplated are lipofectamine-agent complexes.

In one embodiment, delivery of the at least one agent comprises any suitable delivery method, including exemplary delivery methods described elsewhere  
10 herein. In certain embodiments, delivery of the at least one agent to a subject comprises mixing the at least one agent with a transfection reagent prior to the step of contacting. In another embodiment, a method of the present invention further comprises administering the at least one agent together with the transfection reagent. In another embodiment, the transfection reagent is a cationic lipid reagent.

15 In another embodiment, the transfection reagent is a lipid-based transfection reagent. In another embodiment, the transfection reagent is a protein-based transfection reagent. In another embodiment, the transfection reagent is a polyethyleneimine based transfection reagent. In another embodiment, the transfection reagent is calcium phosphate. In another embodiment, the transfection reagent is  
20 Lipofectin®, Lipofectamine®, or TransIT®. In another embodiment, the transfection reagent is any other transfection reagent known in the art.

In another embodiment, the transfection reagent forms a liposome. Liposomes, in another embodiment, increase intracellular stability, increase uptake efficiency and improve biological activity. In another embodiment, liposomes are hollow  
25 spherical vesicles composed of lipids arranged in a similar fashion as those lipids which make up the cell membrane. In some embodiments, the liposomes comprise an internal aqueous space for entrapping water-soluble compounds. In another embodiment, liposomes can deliver the at least one agent to cells in an active form.

In one embodiment, the composition comprises a lipid nanoparticle (LNP)  
30 and at least one agent.

The term “lipid nanoparticle” refers to a particle having at least one dimension on the order of nanometers (e.g., 1-1,000 nm) which includes one or more lipids. In various embodiments, the particle includes a lipid of Formula (I), (II) or (III). In some embodiments, lipid nanoparticles are included in a formulation comprising at least one agent as described herein. In some embodiments, such lipid nanoparticles comprise a cationic lipid (e.g., a lipid of Formula (I), (II) or (III)) and one or more excipient selected from neutral lipids, charged lipids, steroids and polymer conjugated lipids (e.g., a pegylated lipid such as a pegylated lipid of structure (IV), such as compound IVa). In some embodiments, the at least one agent is encapsulated in the lipid portion of the lipid nanoparticle or an aqueous space enveloped by some or all of the lipid portion of the lipid nanoparticle, thereby protecting it from enzymatic degradation or other undesirable effects induced by the mechanisms of the host organism or cells e.g. an adverse immune response.

In various embodiments, the lipid nanoparticles have a mean diameter of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 110 nm, from about 70 nm to about 100 nm, from about 80 nm to about 100 nm, from about 90 nm to about 100 nm, from about 70 to about 90 nm, from about 80 nm to about 90 nm, from about 70 nm to about 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, or 150 nm. In one embodiment, the lipid nanoparticles have a mean diameter of about 83 nm. In one embodiment, the lipid nanoparticles have a mean diameter of about 102 nm. In one embodiment, the lipid nanoparticles have a mean diameter of about 103 nm. In some embodiments, the lipid nanoparticles are substantially non-toxic. In certain embodiments, the at least one agent, when present in the lipid nanoparticles, is resistant in aqueous solution to degradation by intra- or intercellular enzymes

The LNP may comprise any lipid capable of forming a particle to which the at least one agent is attached, or in which the at least one agent is encapsulated. The term “lipid” refers to a group of organic compounds that are derivatives of fatty acids (e.g., esters) and are generally characterized by being insoluble in water but soluble in

many organic solvents. Lipids are usually divided in at least three classes: (1) “simple lipids” which include fats and oils as well as waxes; (2) “compound lipids” which include phospholipids and glycolipids; and (3) “derived lipids” such as steroids.

In one embodiment, the LNP comprises one or more cationic lipids, and  
5 one or more stabilizing lipids. Stabilizing lipids include neutral lipids and pegylated lipids.


In one embodiment, the LNP comprises a cationic lipid. As used herein, the term “cationic lipid” refers to a lipid that is cationic or becomes cationic (protonated) as the pH is lowered below the pK of the ionizable group of the lipid, but is progressively  
10 more neutral at higher pH values. At pH values below the pK, the lipid is then able to associate with negatively charged nucleic acids. In certain embodiments, the cationic lipid comprises a zwitterionic lipid that assumes a positive charge on pH decrease.

In certain embodiments, the cationic lipid comprises any of a number of lipid species which carry a net positive charge at a selective pH, such as physiological  
15 pH. Such lipids include, but are not limited to, N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC); N-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA); N,N-distearyl-N,N-dimethylammonium bromide (DDAB); N-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP); 3-(N—(N',N'-dimethylaminoethane)-carbonyl)cholesterol (DC-Chol), N-(1-(2,3-dioleoyloxy)propyl)-  
20 N-2-(spermincarboxamido)ethyl)-N,N-dimethylammonium trifluoroacetate (DOSPA), dioctadecylamidoglycyl carboxyspermine (DOGS), 1,2-dioleoyl-3-dimethylammonium propane (DODAP), N,N-dimethyl-2,3-dioleoyloxy)propylamine (DODMA), and N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethyl ammonium bromide (DMRIE). Additionally, a number of commercial preparations of cationic lipids are available which  
25 can be used in the present invention. These include, for example, LIPOFECTIN® (commercially available cationic liposomes comprising DOTMA and 1,2-dioleoyl-sn-3-phosphoethanolamine (DOPE), from GIBCO/BRL, Grand Island, N.Y.); LIPOFECTAMINE® (commercially available cationic liposomes comprising N-(1-(2,3-dioleoyloxy)propyl)-N-(2-(spermincarboxamido)ethyl)-N,N-dimethylammonium  
30 trifluoroacetate (DOSPA) and (DOPE), from GIBCO/BRL); and TRANSFECTAM® (commercially available cationic lipids comprising dioctadecylamidoglycyl

carboxyspermine (DOGS) in ethanol from Promega Corp., Madison, Wis.). The following lipids are cationic and have a positive charge at below physiological pH: DODAP, DODMA, DMDMA, 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA).

5 In one embodiment, the cationic lipid is an amino lipid. Suitable amino lipids useful in the invention include those described in WO 2012/016184, incorporated herein by reference in its entirety. Representative amino lipids include, but are not limited to, 1,2-dilinoleyloxy-3-(dimethylamino)acetoxyp propane (DLin-DAC), 1,2-dilinoleyloxy-3-morpholinopropane (DLin-MA), 1,2-dilinoleoyl-3-dimethylaminopropane (DLinDAP),  
 10 1,2-dilinoleythio-3-dimethylaminopropane (DLin-S-DMA), 1-linoleoyl-2-linoleyloxy-3-dimethylaminopropane (DLin-2-DMAP), 1,2-dilinoleyloxy-3-trimethylaminopropane chloride salt (DLin-TMA.Cl), 1,2-dilinoleoyl-3-trimethylaminopropane chloride salt (DLin-TAP.Cl), 1,2-dilinoleyloxy-3-(N-methylpiperazino)propane (DLin-MPZ), 3-(N,N-dilinoleylamino)-1,2-propanediol (DLinAP), 3-(N,N-dioleylamino)-1,2-propanediol  
 15 (DOAP), 1,2-dilinoleyloxo-3-(2-N,N-dimethylamino)ethoxypropane (DLin-EG-DMA), and 2,2-dilinoley-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA).

Suitable amino lipids include those having the formula:



20 wherein R<sub>1</sub> and R<sub>2</sub> are either the same or different and independently optionally substituted C<sub>10</sub>-C<sub>24</sub> alkyl, optionally substituted C<sub>10</sub>-C<sub>24</sub> alkenyl, optionally substituted C<sub>10</sub>-C<sub>24</sub> alkynyl, or optionally substituted C<sub>10</sub>-C<sub>24</sub> acyl;

R<sub>3</sub> and R<sub>4</sub> are either the same or different and independently optionally substituted C<sub>1</sub>-C<sub>6</sub> alkyl, optionally substituted C<sub>2</sub>-C<sub>6</sub> alkenyl, or optionally substituted C<sub>2</sub>-C<sub>6</sub> alkynyl or R<sub>3</sub> and R<sub>4</sub> may join to form an optionally substituted heterocyclic ring of 4  
 25 to 6 carbon atoms and 1 or 2 heteroatoms chosen from nitrogen and oxygen;

R<sub>5</sub> is either absent or present and when present is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;


m, n, and p are either the same or different and independently either 0 or 1 with the proviso that m, n, and p are not simultaneously 0;

q is 0, 1, 2, 3, or 4; and

Y and Z are either the same or different and independently O, S, or NH.

5 In one embodiment, R<sub>1</sub> and R<sub>2</sub> are each linoleyl, and the amino lipid is a dilinoleyl amino lipid. In one embodiment, the amino lipid is a dilinoleyl amino lipid.

A representative useful dilinoleyl amino lipid has the formula:



DLin-K-DMA

wherein n is 0, 1, 2, 3, or 4.

10 In one embodiment, the cationic lipid is a DLin-K-DMA. In one embodiment, the cationic lipid is DLin-KC2-DMA (DLin-K-DMA above, wherein n is 2).

In one embodiment, the cationic lipid component of the LNPs has the structure of Formula (I):

15

(I)

or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein:

20 L<sup>1</sup> and L<sup>2</sup> are each independently -O(C=O)-, -(C=O)O- or a carbon-carbon double bond;

$R^{1a}$  and  $R^{1b}$  are, at each occurrence, independently either (a) H or C<sub>1</sub>-C<sub>12</sub> alkyl, or (b)  $R^{1a}$  is H or C<sub>1</sub>-C<sub>12</sub> alkyl, and  $R^{1b}$  together with the carbon atom to which it is bound is taken together with an adjacent  $R^{1b}$  and the carbon atom to which it is bound to form a carbon-carbon double bond;

5  $R^{2a}$  and  $R^{2b}$  are, at each occurrence, independently either (a) H or C<sub>1</sub>-C<sub>12</sub> alkyl, or (b)  $R^{2a}$  is H or C<sub>1</sub>-C<sub>12</sub> alkyl, and  $R^{2b}$  together with the carbon atom to which it is bound is taken together with an adjacent  $R^{2b}$  and the carbon atom to which it is bound to form a carbon-carbon double bond;

10  $R^{3a}$  and  $R^{3b}$  are, at each occurrence, independently either (a) H or C<sub>1</sub>-C<sub>12</sub> alkyl, or (b)  $R^{3a}$  is H or C<sub>1</sub>-C<sub>12</sub> alkyl, and  $R^{3b}$  together with the carbon atom to which it is bound is taken together with an adjacent  $R^{3b}$  and the carbon atom to which it is bound to form a carbon-carbon double bond;

15  $R^{4a}$  and  $R^{4b}$  are, at each occurrence, independently either (a) H or C<sub>1</sub>-C<sub>12</sub> alkyl, or (b)  $R^{4a}$  is H or C<sub>1</sub>-C<sub>12</sub> alkyl, and  $R^{4b}$  together with the carbon atom to which it is bound is taken together with an adjacent  $R^{4b}$  and the carbon atom to which it is bound to form a carbon-carbon double bond;

$R^5$  and  $R^6$  are each independently methyl or cycloalkyl;

$R^7$  is, at each occurrence, independently H or C<sub>1</sub>-C<sub>12</sub> alkyl;

20  $R^8$  and  $R^9$  are each independently C<sub>1</sub>-C<sub>12</sub> alkyl; or  $R^8$  and  $R^9$ , together with the nitrogen atom to which they are attached, form a 5, 6 or 7-membered heterocyclic ring comprising one nitrogen atom;

a and d are each independently an integer from 0 to 24;

b and c are each independently an integer from 1 to 24; and

e is 1 or 2.

25 In certain embodiments of Formula (I), at least one of  $R^{1a}$ ,  $R^{2a}$ ,  $R^{3a}$  or  $R^{4a}$  is C<sub>1</sub>-C<sub>12</sub> alkyl, or at least one of L<sup>1</sup> or L<sup>2</sup> is -O(C=O)- or -(C=O)O-. In other embodiments,  $R^{1a}$  and  $R^{1b}$  are not isopropyl when a is 6 or n-butyl when a is 8.

In still further embodiments of Formula (I), at least one of  $R^{1a}$ ,  $R^{2a}$ ,  $R^{3a}$  or  $R^{4a}$  is C<sub>1</sub>-C<sub>12</sub> alkyl, or at least one of L<sup>1</sup> or L<sup>2</sup> is -O(C=O)- or -(C=O)O-; and

30  $R^{1a}$  and  $R^{1b}$  are not isopropyl when a is 6 or n-butyl when a is 8.

In other embodiments of Formula (I),  $R^8$  and  $R^9$  are each independently unsubstituted  $C_1$ - $C_{12}$  alkyl; or  $R^8$  and  $R^9$ , together with the nitrogen atom to which they are attached, form a 5, 6 or 7-membered heterocyclic ring comprising one nitrogen atom;

In certain embodiments of Formula (I), any one of  $L^1$  or  $L^2$  may be  
 5  $-O(C=O)-$  or a carbon-carbon double bond.  $L^1$  and  $L^2$  may each be  $-O(C=O)-$  or may each be a carbon-carbon double bond.


In some embodiments of Formula (I), one of  $L^1$  or  $L^2$  is  $-O(C=O)-$ . In other embodiments, both  $L^1$  and  $L^2$  are  $-O(C=O)-$ .

In some embodiments of Formula (I), one of  $L^1$  or  $L^2$  is  $-(C=O)O-$ . In  
 10 other embodiments, both  $L^1$  and  $L^2$  are  $-(C=O)O-$ .

In some other embodiments of Formula (I), one of  $L^1$  or  $L^2$  is a carbon-carbon double bond. In other embodiments, both  $L^1$  and  $L^2$  are a carbon-carbon double bond.


In still other embodiments of Formula (I), one of  $L^1$  or  $L^2$  is  $-O(C=O)-$   
 15 and the other of  $L^1$  or  $L^2$  is  $-(C=O)O-$ . In more embodiments, one of  $L^1$  or  $L^2$  is  $-O(C=O)-$  and the other of  $L^1$  or  $L^2$  is a carbon-carbon double bond. In yet more embodiments, one of  $L^1$  or  $L^2$  is  $-(C=O)O-$  and the other of  $L^1$  or  $L^2$  is a carbon-carbon double bond.

It is understood that “carbon-carbon” double bond, as used throughout the  
 20 specification, refers to one of the following structures:




wherein  $R^a$  and  $R^b$  are, at each occurrence, independently H or a substituent. For example, in some embodiments  $R^a$  and  $R^b$  are, at each occurrence, independently H,  $C_1$ - $C_{12}$  alkyl or cycloalkyl, for example H or  $C_1$ - $C_{12}$  alkyl.

25 In other embodiments, the lipid compounds of Formula (I) have the following structure (Ia):




(Ia)

In other embodiments, the lipid compounds of Formula (I) have the following structure (Ib):



(Ib)

In yet other embodiments, the lipid compounds of Formula (I) have the following structure (Ic):



(Ic)

10

In certain embodiments of the lipid compound of Formula (I), a, b, c and d are each independently an integer from 2 to 12 or an integer from 4 to 12. In other embodiments, a, b, c and d are each independently an integer from 8 to 12 or 5 to 9. In some certain embodiments, a is 0. In some embodiments, a is 1. In other embodiments, a is 2. In more embodiments, a is 3. In yet other embodiments, a is 4. In some embodiments, a is 5. In other embodiments, a is 6. In more embodiments, a is 7. In yet other embodiments, a is 8. In some embodiments, a is 9. In other embodiments, a is 10. In more embodiments, a is 11. In yet other embodiments, a is 12. In some embodiments, a is

15

13. In other embodiments, a is 14. In more embodiments, a is 15. In yet other embodiments, a is 16.

In some other embodiments of Formula (I), b is 1. In other embodiments, b is 2. In more embodiments, b is 3. In yet other embodiments, b is 4. In some  
5 embodiments, b is 5. In other embodiments, b is 6. In more embodiments, b is 7. In yet other embodiments, b is 8. In some embodiments, b is 9. In other embodiments, b is 10. In more embodiments, b is 11. In yet other embodiments, b is 12. In some embodiments, b is 13. In other embodiments, b is 14. In more embodiments, b is 15. In yet other embodiments, b is 16.

10 In some more embodiments of Formula (I), c is 1. In other embodiments, c is 2. In more embodiments, c is 3. In yet other embodiments, c is 4. In some embodiments, c is 5. In other embodiments, c is 6. In more embodiments, c is 7. In yet other embodiments, c is 8. In some embodiments, c is 9. In other embodiments, c is 10. In more embodiments, c is 11. In yet other embodiments, c is 12. In some embodiments, c is  
15 13. In other embodiments, c is 14. In more embodiments, c is 15. In yet other embodiments, c is 16.

In some certain other embodiments of Formula (I), d is 0. In some embodiments, d is 1. In other embodiments, d is 2. In more embodiments, d is 3. In yet other embodiments, d is 4. In some embodiments, d is 5. In other embodiments, d is 6. In  
20 more embodiments, d is 7. In yet other embodiments, d is 8. In some embodiments, d is 9. In other embodiments, d is 10. In more embodiments, d is 11. In yet other embodiments, d is 12. In some embodiments, d is 13. In other embodiments, d is 14. In more embodiments, d is 15. In yet other embodiments, d is 16.

In some other various embodiments of Formula (I), a and d are the same.  
25 In some other embodiments, b and c are the same. In some other specific embodiments, a and d are the same and b and c are the same.

The sum of a and b and the sum of c and d in Formula (I) are factors which may be varied to obtain a lipid of Formula (I) having the desired properties. In one embodiment, a and b are chosen such that their sum is an integer ranging from 14 to 24.  
30 In other embodiments, c and d are chosen such that their sum is an integer ranging from

14 to 24. In further embodiment, the sum of a and b and the sum of c and d are the same. For example, in some embodiments the sum of a and b and the sum of c and d are both the same integer which may range from 14 to 24. In still more embodiments, a, b, c and d are selected such the sum of a and b and the sum of c and d is 12 or greater.

5 In some embodiments of Formula (I), e is 1. In other embodiments, e is 2.

The substituents at  $R^{1a}$ ,  $R^{2a}$ ,  $R^{3a}$  and  $R^{4a}$  of Formula (I) are not particularly limited. In certain embodiments  $R^{1a}$ ,  $R^{2a}$ ,  $R^{3a}$  and  $R^{4a}$  are H at each occurrence. In certain other embodiments at least one of  $R^{1a}$ ,  $R^{2a}$ ,  $R^{3a}$  and  $R^{4a}$  is C<sub>1</sub>-C<sub>12</sub> alkyl. In certain other  
10 embodiments at least one of  $R^{1a}$ ,  $R^{2a}$ ,  $R^{3a}$  and  $R^{4a}$  is C<sub>1</sub>-C<sub>8</sub> alkyl. In certain other  
embodiments at least one of  $R^{1a}$ ,  $R^{2a}$ ,  $R^{3a}$  and  $R^{4a}$  is C<sub>1</sub>-C<sub>6</sub> alkyl. In some of the foregoing  
embodiments, the C<sub>1</sub>-C<sub>8</sub> alkyl is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl,  
tert-butyl, n-hexyl or n-octyl.

In certain embodiments of Formula (I),  $R^{1a}$ ,  $R^{1b}$ ,  $R^{4a}$  and  $R^{4b}$  are C<sub>1</sub>-C<sub>12</sub> alkyl at each occurrence.

15 In further embodiments of Formula (I), at least one of  $R^{1b}$ ,  $R^{2b}$ ,  $R^{3b}$  and  $R^{4b}$  is H or  $R^{1b}$ ,  $R^{2b}$ ,  $R^{3b}$  and  $R^{4b}$  are H at each occurrence.

In certain embodiments of Formula (I),  $R^{1b}$  together with the carbon atom to which it is bound is taken together with an adjacent  $R^{1b}$  and the carbon atom to which it is bound to form a carbon-carbon double bond. In other embodiments of the foregoing  
20  $R^{4b}$  together with the carbon atom to which it is bound is taken together with an adjacent  
 $R^{4b}$  and the carbon atom to which it is bound to form a carbon-carbon double bond.


The substituents at  $R^5$  and  $R^6$  of Formula (I) are not particularly limited in the foregoing embodiments. In certain embodiments one or both of  $R^5$  or  $R^6$  is methyl. In certain other embodiments one or both of  $R^5$  or  $R^6$  is cycloalkyl for example cyclohexyl.  
25 In these embodiments the cycloalkyl may be substituted or not substituted. In certain other embodiments the cycloalkyl is substituted with C<sub>1</sub>-C<sub>12</sub> alkyl, for example tert-butyl.


The substituents at  $R^7$  are not particularly limited in the foregoing embodiments of Formula (I). In certain embodiments at least one  $R^7$  is H. In some other embodiments,  $R^7$  is H at each occurrence. In certain other embodiments  $R^7$  is C<sub>1</sub>-C<sub>12</sub>  
30 alkyl.


In certain other of the foregoing embodiments of Formula (I), one of R<sup>8</sup> or R<sup>9</sup> is methyl. In other embodiments, both R<sup>8</sup> and R<sup>9</sup> are methyl.


In some different embodiments of Formula (I), R<sup>8</sup> and R<sup>9</sup>, together with the nitrogen atom to which they are attached, form a 5, 6 or 7-membered heterocyclic ring. In some embodiments of the foregoing, R<sup>8</sup> and R<sup>9</sup>, together with the nitrogen atom to which they are attached, form a 5-membered heterocyclic ring, for example a pyrrolidinyl ring.


In various different embodiments, exemplary lipid of Formula (I) can include






















In some embodiments, the LNPs comprise a lipid of Formula (I), at least one agent, and one or more excipients selected from neutral lipids, steroids and pegylated lipids. In some embodiments the lipid of Formula (I) is compound I-5. In some  
5  
embodiments the lipid of Formula (I) is compound I-6.

In some other embodiments, the cationic lipid component of the LNPs has the structure of Formula (II):



(II)

10 or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein:

$L^1$  and  $L^2$  are each independently  $-O(C=O)-$ ,  $-(C=O)O-$ ,  $-C(=O)-$ ,  $-O-$ ,  $-S(O)_x-$ ,  $-S-S-$ ,  $-C(=O)S-$ ,  $-SC(=O)-$ ,  $-NR^aC(=O)-$ ,  $-C(=O)NR^a-$ ,  $-NR^aC(=O)NR^a$ ,

-OC(=O)NR<sup>a</sup>-, -NR<sup>a</sup>C(=O)O-, or a direct bond;

G<sup>1</sup> is C<sub>1</sub>-C<sub>2</sub> alkylene, -(C=O)-, -O(C=O)-, -SC(=O)-, -NR<sup>a</sup>C(=O)- or a direct bond;

5

G<sup>2</sup> is -C(=O)-, -(C=O)O-, -C(=O)S-, -C(=O)NR<sup>a</sup> or a direct bond;

G<sup>3</sup> is C<sub>1</sub>-C<sub>6</sub> alkylene;

R<sup>a</sup> is H or C<sub>1</sub>-C<sub>12</sub> alkyl;

R<sup>1a</sup> and R<sup>1b</sup> are, at each occurrence, independently either: (a) H or C<sub>1</sub>-C<sub>12</sub> alkyl; or (b) R<sup>1a</sup> is H or C<sub>1</sub>-C<sub>12</sub> alkyl, and R<sup>1b</sup> together with the carbon atom to which it is bound is taken together with an adjacent R<sup>1b</sup> and the carbon atom to which it is bound to form a carbon-carbon double bond;

10

R<sup>2a</sup> and R<sup>2b</sup> are, at each occurrence, independently either: (a) H or C<sub>1</sub>-C<sub>12</sub> alkyl; or (b) R<sup>2a</sup> is H or C<sub>1</sub>-C<sub>12</sub> alkyl, and R<sup>2b</sup> together with the carbon atom to which it is bound is taken together with an adjacent R<sup>2b</sup> and the carbon atom to which it is bound to form a carbon-carbon double bond;

15

R<sup>3a</sup> and R<sup>3b</sup> are, at each occurrence, independently either: (a) H or C<sub>1</sub>-C<sub>12</sub> alkyl; or (b) R<sup>3a</sup> is H or C<sub>1</sub>-C<sub>12</sub> alkyl, and R<sup>3b</sup> together with the carbon atom to which it is bound is taken together with an adjacent R<sup>3b</sup> and the carbon atom to which it is bound to form a carbon-carbon double bond;

R<sup>4a</sup> and R<sup>4b</sup> are, at each occurrence, independently either: (a) H or C<sub>1</sub>-C<sub>12</sub> alkyl; or (b) R<sup>4a</sup> is H or C<sub>1</sub>-C<sub>12</sub> alkyl, and R<sup>4b</sup> together with the carbon atom to which it is bound is taken together with an adjacent R<sup>4b</sup> and the carbon atom to which it is bound to form a carbon-carbon double bond;

20

R<sup>5</sup> and R<sup>6</sup> are each independently H or methyl;

R<sup>7</sup> is C<sub>4</sub>-C<sub>20</sub> alkyl;

25

R<sup>8</sup> and R<sup>9</sup> are each independently C<sub>1</sub>-C<sub>12</sub> alkyl; or R<sup>8</sup> and R<sup>9</sup>, together with the nitrogen atom to which they are attached, form a 5, 6 or 7-membered heterocyclic ring;

a, b, c and d are each independently an integer from 1 to 24; and

x is 0, 1 or 2.


30

In some embodiments of Formula (II), L<sup>1</sup> and L<sup>2</sup> are each independently

$-\text{O}(\text{C}=\text{O})-$ ,  $-(\text{C}=\text{O})\text{O}-$  or a direct bond. In other embodiments,  $\text{G}^1$  and  $\text{G}^2$  are each independently  $-(\text{C}=\text{O})-$  or a direct bond. In some different embodiments,  $\text{L}^1$  and  $\text{L}^2$  are each independently  $-\text{O}(\text{C}=\text{O})-$ ,  $-(\text{C}=\text{O})\text{O}-$  or a direct bond; and  $\text{G}^1$  and  $\text{G}^2$  are each independently  $-(\text{C}=\text{O})-$  or a direct bond.

5 In some different embodiments of Formula (II),  $\text{L}^1$  and  $\text{L}^2$  are each independently  $-\text{C}(\text{O})-$ ,  $-\text{O}-$ ,  $-\text{S}(\text{O})_x-$ ,  $-\text{S}-\text{S}-$ ,  $-\text{C}(\text{O})\text{S}-$ ,  $-\text{SC}(\text{O})-$ ,  $-\text{NR}^a-$ ,  $-\text{NR}^a\text{C}(\text{O})-$ ,  $-\text{C}(\text{O})\text{NR}^a-$ ,  $-\text{NR}^a\text{C}(\text{O})\text{NR}^a-$ ,  $-\text{OC}(\text{O})\text{NR}^a-$ ,  $-\text{NR}^a\text{C}(\text{O})\text{O}-$ ,  $-\text{NR}^a\text{S}(\text{O})_x\text{NR}^a-$ ,  $-\text{NR}^a\text{S}(\text{O})_x-$  or  $-\text{S}(\text{O})_x\text{NR}^a-$ .

10 In other of the foregoing embodiments of Formula (II), the lipid compound has one of the following structures (IIA) or (IIB):



In some embodiments of Formula (II), the lipid compound has structure (IIA). In other embodiments, the lipid compound has structure (IIB).

15 In any of the foregoing embodiments of Formula (II), one of  $\text{L}^1$  or  $\text{L}^2$  is  $-\text{O}(\text{C}=\text{O})-$ . For example, in some embodiments each of  $\text{L}^1$  and  $\text{L}^2$  are  $-\text{O}(\text{C}=\text{O})-$ .

In some different embodiments of Formula (II), one of  $\text{L}^1$  or  $\text{L}^2$  is  $-(\text{C}=\text{O})\text{O}-$ . For example, in some embodiments each of  $\text{L}^1$  and  $\text{L}^2$  is  $-(\text{C}=\text{O})\text{O}-$ .

20 In different embodiments of Formula (II), one of  $\text{L}^1$  or  $\text{L}^2$  is a direct bond. As used herein, a “direct bond” means the group (e.g.,  $\text{L}^1$  or  $\text{L}^2$ ) is absent. For example, in some embodiments each of  $\text{L}^1$  and  $\text{L}^2$  is a direct bond.

In other different embodiments of Formula (II), for at least one occurrence of  $\text{R}^{1a}$  and  $\text{R}^{1b}$ ,  $\text{R}^{1a}$  is H or  $\text{C}_1$ - $\text{C}_{12}$  alkyl, and  $\text{R}^{1b}$  together with the carbon atom to which it


is bound is taken together with an adjacent R<sup>1b</sup> and the carbon atom to which it is bound to form a carbon-carbon double bond.

In still other different embodiments of Formula (II), for at least one occurrence of R<sup>4a</sup> and R<sup>4b</sup>, R<sup>4a</sup> is H or C<sub>1</sub>-C<sub>12</sub> alkyl, and R<sup>4b</sup> together with the carbon atom to which it is bound is taken together with an adjacent R<sup>4b</sup> and the carbon atom to which it is bound to form a carbon-carbon double bond.

In more embodiments of Formula (II), for at least one occurrence of R<sup>2a</sup> and R<sup>2b</sup>, R<sup>2a</sup> is H or C<sub>1</sub>-C<sub>12</sub> alkyl, and R<sup>2b</sup> together with the carbon atom to which it is bound is taken together with an adjacent R<sup>2b</sup> and the carbon atom to which it is bound to form a carbon-carbon double bond.

In other different embodiments of Formula (II), for at least one occurrence of R<sup>3a</sup> and R<sup>3b</sup>, R<sup>3a</sup> is H or C<sub>1</sub>-C<sub>12</sub> alkyl, and R<sup>3b</sup> together with the carbon atom to which it is bound is taken together with an adjacent R<sup>3b</sup> and the carbon atom to which it is bound to form a carbon-carbon double bond.

In various other embodiments of Formula (II), the lipid compound has one of the following structures (IIC) or (IID):



wherein e, f, g and h are each independently an integer from 1 to 12.

In some embodiments of Formula (II), the lipid compound has structure (IIC). In other embodiments, the lipid compound has structure (IID).

In various embodiments of structures (IIC) or (IID), e, f, g and h are each  
5 independently an integer from 4 to 10.

In certain embodiments of Formula (II), a, b, c and d are each independently an integer from 2 to 12 or an integer from 4 to 12. In other embodiments, a, b, c and d are each independently an integer from 8 to 12 or 5 to 9. In some certain  
10 embodiments, a is 0. In some embodiments, a is 1. In other embodiments, a is 2. In more embodiments, a is 3. In yet other embodiments, a is 4. In some embodiments, a is 5. In other embodiments, a is 6. In more embodiments, a is 7. In yet other embodiments, a is 8. In some embodiments, a is 9. In other embodiments, a is 10. In more embodiments, a is 11. In yet other embodiments, a is 12. In some embodiments, a is 13. In other  
embodiments, a is 14. In more embodiments, a is 15. In yet other embodiments, a is 16.

In some embodiments of Formula (II), b is 1. In other embodiments, b is 2.  
15 In more embodiments, b is 3. In yet other embodiments, b is 4. In some embodiments, b is 5. In other embodiments, b is 6. In more embodiments, b is 7. In yet other embodiments, b is 8. In some embodiments, b is 9. In other embodiments, b is 10. In more embodiments, b is 11. In yet other embodiments, b is 12. In some embodiments, b  
20 is 13. In other embodiments, b is 14. In more embodiments, b is 15. In yet other embodiments, b is 16.

In some embodiments of Formula (II), c is 1. In other embodiments, c is 2.  
In more embodiments, c is 3. In yet other embodiments, c is 4. In some embodiments, c is  
25 5. In other embodiments, c is 6. In more embodiments, c is 7. In yet other embodiments, c is 8. In some embodiments, c is 9. In other embodiments, c is 10. In more embodiments, c is 11. In yet other embodiments, c is 12. In some embodiments, c is 13. In other  
embodiments, c is 14. In more embodiments, c is 15. In yet other embodiments, c is 16.

In some certain embodiments of Formula (II), d is 0. In some  
embodiments, d is 1. In other embodiments, d is 2. In more embodiments, d is 3. In yet  
30 other embodiments, d is 4. In some embodiments, d is 5. In other embodiments, d is 6. In

more embodiments, d is 7. In yet other embodiments, d is 8. In some embodiments, d is 9. In other embodiments, d is 10. In more embodiments, d is 11. In yet other embodiments, d is 12. In some embodiments, d is 13. In other embodiments, d is 14. In more embodiments, d is 15. In yet other embodiments, d is 16.

5                    In some embodiments of Formula (II), e is 1. In other embodiments, e is 2. In more embodiments, e is 3. In yet other embodiments, e is 4. In some embodiments, e is 5. In other embodiments, e is 6. In more embodiments, e is 7. In yet other embodiments, e is 8. In some embodiments, e is 9. In other embodiments, e is 10. In more embodiments, e is 11. In yet other embodiments, e is 12.

10                   In some embodiments of Formula (II), f is 1. In other embodiments, f is 2. In more embodiments, f is 3. In yet other embodiments, f is 4. In some embodiments, f is 5. In other embodiments, f is 6. In more embodiments, f is 7. In yet other embodiments, f is 8. In some embodiments, f is 9. In other embodiments, f is 10. In more embodiments, f is 11. In yet other embodiments, f is 12.

15                   In some embodiments of Formula (II), g is 1. In other embodiments, g is 2. In more embodiments, g is 3. In yet other embodiments, g is 4. In some embodiments, g is 5. In other embodiments, g is 6. In more embodiments, g is 7. In yet other embodiments, g is 8. In some embodiments, g is 9. In other embodiments, g is 10. In more embodiments, g is 11. In yet other embodiments, g is 12.

20                   In some embodiments of Formula (II), h is 1. In other embodiments, e is 2. In more embodiments, h is 3. In yet other embodiments, h is 4. In some embodiments, e is 5. In other embodiments, h is 6. In more embodiments, h is 7. In yet other embodiments, h is 8. In some embodiments, h is 9. In other embodiments, h is 10. In more embodiments, h is 11. In yet other embodiments, h is 12.

25                   In some other various embodiments of Formula (II), a and d are the same. In some other embodiments, b and c are the same. In some other specific embodiments and a and d are the same and b and c are the same.

                      The sum of a and b and the sum of c and d of Formula (II) are factors which may be varied to obtain a lipid having the desired properties. In one embodiment, a  
30                    and b are chosen such that their sum is an integer ranging from 14 to 24. In other

embodiments, c and d are chosen such that their sum is an integer ranging from 14 to 24. In further embodiment, the sum of a and b and the sum of c and d are the same. For example, in some embodiments the sum of a and b and the sum of c and d are both the same integer which may range from 14 to 24. In still more embodiments, a, b, c and d are  
 5 selected such that the sum of a and b and the sum of c and d is 12 or greater.

The substituents at  $R^{1a}$ ,  $R^{2a}$ ,  $R^{3a}$  and  $R^{4a}$  of Formula (II) are not particularly limited. In some embodiments, at least one of  $R^{1a}$ ,  $R^{2a}$ ,  $R^{3a}$  and  $R^{4a}$  is H. In certain embodiments  $R^{1a}$ ,  $R^{2a}$ ,  $R^{3a}$  and  $R^{4a}$  are H at each occurrence. In certain other  
 10 embodiments at least one of  $R^{1a}$ ,  $R^{2a}$ ,  $R^{3a}$  and  $R^{4a}$  is C<sub>1</sub>-C<sub>12</sub> alkyl. In certain other embodiments at least one of  $R^{1a}$ ,  $R^{2a}$ ,  $R^{3a}$  and  $R^{4a}$  is C<sub>1</sub>-C<sub>8</sub> alkyl. In certain other embodiments at least one of  $R^{1a}$ ,  $R^{2a}$ ,  $R^{3a}$  and  $R^{4a}$  is C<sub>1</sub>-C<sub>6</sub> alkyl. In some of the foregoing embodiments, the C<sub>1</sub>-C<sub>8</sub> alkyl is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, n-hexyl or n-octyl.

In certain embodiments of Formula (II),  $R^{1a}$ ,  $R^{1b}$ ,  $R^{4a}$  and  $R^{4b}$  are C<sub>1</sub>-C<sub>12</sub>  
 15 alkyl at each occurrence.

In further embodiments of Formula (II), at least one of  $R^{1b}$ ,  $R^{2b}$ ,  $R^{3b}$  and  $R^{4b}$  is H or  $R^{1b}$ ,  $R^{2b}$ ,  $R^{3b}$  and  $R^{4b}$  are H at each occurrence.


In certain embodiments of Formula (II),  $R^{1b}$  together with the carbon atom to which it is bound is taken together with an adjacent  $R^{1b}$  and the carbon atom to which  
 20 it is bound to form a carbon-carbon double bond. In other embodiments of the foregoing  $R^{4b}$  together with the carbon atom to which it is bound is taken together with an adjacent  $R^{4b}$  and the carbon atom to which it is bound to form a carbon-carbon double bond.

The substituents at  $R^5$  and  $R^6$  of Formula (II) are not particularly limited in the foregoing embodiments. In certain embodiments one of  $R^5$  or  $R^6$  is methyl. In other  
 25 embodiments each of  $R^5$  or  $R^6$  is methyl.

The substituents at  $R^7$  of Formula (II) are not particularly limited in the foregoing embodiments. In certain embodiments  $R^7$  is C<sub>6</sub>-C<sub>16</sub> alkyl. In some other  
 30 embodiments,  $R^7$  is C<sub>6</sub>-C<sub>9</sub> alkyl. In some of these embodiments,  $R^7$  is substituted with  $-(C=O)OR^b$ ,  $-O(C=O)R^b$ ,  $-C(=O)R^b$ ,  $-OR^b$ ,  $-S(O)_xR^b$ ,  $-S-SR^b$ ,  $-C(=O)SR^b$ ,  $-SC(=O)R^b$ ,  $-NR^aR^b$ ,  $-NR^aC(=O)R^b$ ,  $-C(=O)NR^aR^b$ ,  $-NR^aC(=O)NR^aR^b$ ,

-OC(=O)NR<sup>a</sup>R<sup>b</sup>, -NR<sup>a</sup>C(=O)OR<sup>b</sup>, -NR<sup>a</sup>S(O)<sub>x</sub>NR<sup>a</sup>R<sup>b</sup>, -NR<sup>a</sup>S(O)<sub>x</sub>R<sup>b</sup> or -S(O)<sub>x</sub>NR<sup>a</sup>R<sup>b</sup>,  
 wherein: R<sup>a</sup> is H or C<sub>1</sub>-C<sub>12</sub> alkyl; R<sup>b</sup> is C<sub>1</sub>-C<sub>15</sub> alkyl; and x is 0, 1 or 2. For example, in  
 some embodiments R<sup>7</sup> is substituted with -(C=O)OR<sup>b</sup> or -O(C=O)R<sup>b</sup>.

In various of the foregoing embodiments of Formula (II), R<sup>b</sup> is branched  
 5 C<sub>1</sub>-C<sub>15</sub> alkyl. For example, in some embodiments R<sup>b</sup> has one of the following structures:





In certain other of the foregoing embodiments of Formula (II), one of R<sup>8</sup>  
 10 or R<sup>9</sup> is methyl. In other embodiments, both R<sup>8</sup> and R<sup>9</sup> are methyl.


In some different embodiments of Formula (II), R<sup>8</sup> and R<sup>9</sup>, together with  
 the nitrogen atom to which they are attached, form a 5, 6 or 7-membered heterocyclic  
 ring. In some embodiments of the foregoing, R<sup>8</sup> and R<sup>9</sup>, together with the nitrogen atom  
 to which they are attached, form a 5-membered heterocyclic ring, for example a  
 15 pyrrolidinyl ring. In some different embodiments of the foregoing, R<sup>8</sup> and R<sup>9</sup>, together  
 with the nitrogen atom to which they are attached, form a 6-membered heterocyclic ring,  
 for example a piperazinyl ring.


In still other embodiments of the foregoing lipids of Formula (II), G<sup>3</sup> is  
 C<sub>2</sub>-C<sub>4</sub> alkylene, for example C<sub>3</sub> alkylene.


20 In various different embodiments, the lipid compound has one of the  
 following structures:















In some embodiments, the LNPs comprise a lipid of Formula (II), at least one agent, and one or more excipient selected from neutral lipids, steroids and pegylated lipids. In some embodiments, the lipid of Formula (II) is compound II-9. In some  
 5       embodiments, the lipid of Formula (II) is compound II-10. In some embodiments, the

lipid of Formula (II) is compound II-11. In some embodiments, the lipid of Formula (II) is compound II-12. In some embodiments, the lipid of Formula (II) is compound II-32.

In some other embodiments, the cationic lipid component of the LNPs has the structure of Formula (III):



or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein:

one of  $L^1$  or  $L^2$  is  $-\text{O}(\text{C}=\text{O})-$ ,  $-(\text{C}=\text{O})\text{O}-$ ,  $-\text{C}(\text{=O})-$ ,  $-\text{O}-$ ,  $-\text{S}(\text{O})_x-$ ,  $-\text{S}-\text{S}-$ ,  $-\text{C}(\text{=O})\text{S}-$ ,  $\text{SC}(\text{=O})-$ ,  $-\text{NR}^a\text{C}(\text{=O})-$ ,  $-\text{C}(\text{=O})\text{NR}^a-$ ,  $\text{NR}^a\text{C}(\text{=O})\text{NR}^a-$ ,  $-\text{OC}(\text{=O})\text{NR}^a-$  or  $-\text{NR}^a\text{C}(\text{=O})\text{O}-$ , and the other of  $L^1$  or  $L^2$  is  $-\text{O}(\text{C}=\text{O})-$ ,  $-(\text{C}=\text{O})\text{O}-$ ,  $-\text{C}(\text{=O})-$ ,  $-\text{O}-$ ,  $-\text{S}(\text{O})_x-$ ,  $-\text{S}-\text{S}-$ ,  $-\text{C}(\text{=O})\text{S}-$ ,  $\text{SC}(\text{=O})-$ ,  $-\text{NR}^a\text{C}(\text{=O})-$ ,  $-\text{C}(\text{=O})\text{NR}^a-$ ,  $\text{NR}^a\text{C}(\text{=O})\text{NR}^a-$ ,  $-\text{OC}(\text{=O})\text{NR}^a-$  or  $-\text{NR}^a\text{C}(\text{=O})\text{O}-$  or a direct bond;

$G^1$  and  $G^2$  are each independently unsubstituted  $\text{C}_1$ - $\text{C}_{12}$  alkylene or  $\text{C}_1$ - $\text{C}_{12}$  alkenylene;

$G^3$  is  $\text{C}_1$ - $\text{C}_{24}$  alkylene,  $\text{C}_1$ - $\text{C}_{24}$  alkenylene,  $\text{C}_3$ - $\text{C}_8$  cycloalkylene,  $\text{C}_3$ - $\text{C}_8$  cycloalkenylene;

$R^a$  is H or  $\text{C}_1$ - $\text{C}_{12}$  alkyl;

$R^1$  and  $R^2$  are each independently  $\text{C}_6$ - $\text{C}_{24}$  alkyl or  $\text{C}_6$ - $\text{C}_{24}$  alkenyl;

20  $R^3$  is H,  $\text{OR}^5$ , CN,  $-\text{C}(\text{=O})\text{OR}^4$ ,  $-\text{OC}(\text{=O})\text{R}^4$  or  $-\text{NR}^5\text{C}(\text{=O})\text{R}^4$ ;

$R^4$  is  $\text{C}_1$ - $\text{C}_{12}$  alkyl;

$R^5$  is H or  $\text{C}_1$ - $\text{C}_6$  alkyl; and


x is 0, 1 or 2.

In some of the foregoing embodiments of Formula (III), the lipid has one of the following structures (IIIA) or (IIIB):

25



In some of the foregoing embodiments of Formula (III), the lipid has one of the following structures (III G), (III H), (III I), or (III J):



In some of the foregoing embodiments of Formula (III), n is an integer ranging from 2 to 12, for example from 2 to 8 or from 2 to 4. For example, in some embodiments, n is 3, 4, 5 or 6. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6.

10

In some other of the foregoing embodiments of Formula (III), y and z are each independently an integer ranging from 2 to 10. For example, in some embodiments, y and z are each independently an integer ranging from 4 to 9 or from 4 to 6.


In some of the foregoing embodiments of Formula (III), R<sup>6</sup> is H. In other of the foregoing embodiments, R<sup>6</sup> is C<sub>1</sub>-C<sub>24</sub> alkyl. In other embodiments, R<sup>6</sup> is OH.

15

In some embodiments of Formula (III), G<sup>3</sup> is unsubstituted. In other embodiments, G<sup>3</sup> is substituted. In various different embodiments, G<sup>3</sup> is linear C<sub>1</sub>-C<sub>24</sub> alkylene or linear C<sub>1</sub>-C<sub>24</sub> alkenylene.

In some other foregoing embodiments of Formula (III), R<sup>1</sup> or R<sup>2</sup>, or both, is C<sub>6</sub>-C<sub>24</sub> alkenyl. For example, in some embodiments, R<sup>1</sup> and R<sup>2</sup> each, independently have the following structure:

20




wherein:

$R^{7a}$  and  $R^{7b}$  are, at each occurrence, independently H or C<sub>1</sub>-C<sub>12</sub> alkyl; and  
a is an integer from 2 to 12,

wherein  $R^{7a}$ ,  $R^{7b}$  and a are each selected such that  $R^1$  and  $R^2$  each independently comprise  
5 from 6 to 20 carbon atoms. For example, in some embodiments a is an integer ranging  
from 5 to 9 or from 8 to 12.


In some of the foregoing embodiments of Formula (III), at least one  
occurrence of  $R^{7a}$  is H. For example, in some embodiments,  $R^{7a}$  is H at each occurrence.  
In other different embodiments of the foregoing, at least one occurrence of  $R^{7b}$  is C<sub>1</sub>-C<sub>8</sub>  
10 alkyl. For example, in some embodiments, C<sub>1</sub>-C<sub>8</sub> alkyl is methyl, ethyl, n-propyl, iso-  
propyl, n-butyl, iso-butyl, tert-butyl, n-hexyl or n-octyl.


In different embodiments of Formula (III),  $R^1$  or  $R^2$ , or both, has one of  
the following structures:












In some of the foregoing embodiments of Formula (III),  $R^3$  is OH,  
CN, -C(=O)OR<sup>4</sup>, -OC(=O)R<sup>4</sup> or -NHC(=O)R<sup>4</sup>. In some embodiments, R<sup>4</sup> is methyl or  
ethyl.


20 In various different embodiments, the cationic lipid of Formula (III) has  
one of the following structures:














In some embodiments, the LNPs comprise a lipid of Formula (III), at least one agent, and one or more excipient selected from neutral lipids, steroids and pegylated lipids. In some embodiments, the lipid of Formula (III) is compound III-3. In some  
5 embodiments, the lipid of Formula (III) is compound III-7.

In certain embodiments, the cationic lipid is present in the LNP in an amount from about 30 to about 95 mole percent. In one embodiment, the cationic lipid is present in the LNP in an amount from about 30 to about 70 mole percent. In one  
10 embodiment, the cationic lipid is present in the LNP in an amount from about 40 to about 60 mole percent. In one embodiment, the cationic lipid is present in the LNP in an

amount of about 50 mole percent. In one embodiment, the LNP comprises only cationic lipids.

In certain embodiments, the LNP comprises one or more additional lipids which stabilize the formation of particles during their formation.

5 Suitable stabilizing lipids include neutral lipids and anionic lipids.


The term “neutral lipid” refers to any one of a number of lipid species that exist in either an uncharged or neutral zwitterionic form at physiological pH.

Representative neutral lipids include diacylphosphatidylcholines, diacylphosphatidylethanolamines, ceramides, sphingomyelins, dihydro sphingomyelins, cephalins, and cerebroside.

Exemplary neutral lipids include, for example, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl-phosphatidylethanolamine (DOPE), palmitoyl-oleoylphosphatidylcholine (POPC), palmitoyl-oleoyl-phosphatidylethanolamine (POPE) and dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidylethanolamine (DSPE), 16-O-monomethyl PE, 16-O-dimethyl PE, 18-1-trans PE, 1-stearioyl-2-oleoyl-phosphatidylethanol amine (SOPE), and 1,2-dielaidoyl-sn-glycero-3-phosphoethanolamine (transDOPE). In one embodiment, the neutral lipid is 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).

In some embodiments, the LNPs comprise a neutral lipid selected from DSPC, DPPC, DMPC, DOPC, POPC, DOPE and SM. In various embodiments, the molar ratio of the cationic lipid (e.g., lipid of Formula (I)) to the neutral lipid ranges from about 2:1 to about 8:1.

In various embodiments, the LNPs further comprise a steroid or steroid analogue. A “steroid” is a compound comprising the following carbon skeleton:



In certain embodiments, the steroid or steroid analogue is cholesterol. In some of these embodiments, the molar ratio of the cationic lipid (e.g., lipid of Formula (I)) to cholesterol ranges from about 2:1 to 1:1.

5                   The term “anionic lipid” refers to any lipid that is negatively charged at physiological pH. These lipids include phosphatidylglycerol, cardiolipin, diacylphosphatidylserine, diacylphosphatidic acid, N-dodecanoylphosphatidylethanolamines, N-succinylphosphatidylethanolamines, N-glutarylphosphatidylethanolamines, lysylphosphatidylglycerols,  
10 palmitoyloleoylphosphatidylglycerol (POPG), and other anionic modifying groups joined to neutral lipids.


In certain embodiments, the LNP comprises glycolipids (e.g., monosialoganglioside GM<sub>1</sub>). In certain embodiments, the LNP comprises a sterol, such as cholesterol.

15                   In some embodiments, the LNPs comprise a polymer conjugated lipid. The term “polymer conjugated lipid” refers to a molecule comprising both a lipid portion and a polymer portion. An example of a polymer conjugated lipid is a pegylated lipid. The term “pegylated lipid” refers to a molecule comprising both a lipid portion and a polyethylene glycol portion. Pegylated lipids are known in the art and include  
20 1-(monomethoxy-polyethyleneglycol)-2,3-dimyristoylglycerol (PEG-s-DMG) and the like.

In certain embodiments, the LNP comprises an additional, stabilizing - lipid which is a polyethylene glycol-lipid (pegylated lipid). Suitable polyethylene glycol-lipids include PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic  
25 acid, PEG-modified ceramides (e.g., PEG-CerC14 or PEG-CerC20), PEG-modified dialkylamines, PEG-modified diacylglycerols, PEG-modified dialkylglycerols. Representative polyethylene glycol-lipids include PEG-c-DOMG, PEG-c-DMA, and PEG-s-DMG. In one embodiment, the polyethylene glycol-lipid is N-[(methoxy

poly(ethylene glycol)<sub>2000</sub>carbonyl]-1,2-dimyristoyloxypropyl-3-amine (PEG-c-DMA). In one embodiment, the polyethylene glycol-lipid is PEG-c-DOMG). In other embodiments, the LNPs comprise a pegylated diacylglycerol (PEG-DAG) such as 1-(monomethoxy-polyethyleneglycol)-2,3-dimyristoylglycerol (PEG-DMG), a pegylated phosphatidylethanolamine (PEG-PE), a PEG succinate diacylglycerol (PEG-S-DAG) such as 4-O-(2',3'-di(tetradecanoyloxy)propyl-1-O-( $\omega$ -methoxy(polyethoxy)ethyl)butanedioate (PEG-S-DMG), a pegylated ceramide (PEG-cer), or a PEG dialkoxypopyl carbamate such as  $\omega$ -methoxy(polyethoxy)ethyl-N-(2,3-di(tetradecanoyloxy)propyl)carbamate or 2,3-di(tetradecanoyloxy)propyl-N-( $\omega$ -methoxy(polyethoxy)ethyl)carbamate. In various embodiments, the molar ratio of the cationic lipid to the pegylated lipid ranges from about 100:1 to about 25:1.

In some embodiments, the LNPs comprise a pegylated lipid having the following structure (IV):



15

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:

$R^{10}$  and  $R^{11}$  are each independently a straight or branched, saturated or unsaturated alkyl chain containing from 10 to 30 carbon atoms, wherein the alkyl chain is optionally interrupted by one or more ester bonds; and

20

$z$  has mean value ranging from 30 to 60.





In some of the foregoing embodiments of the pegylated lipid (IV),  $R^{10}$  and  $R^{11}$  are not both n-octadecyl when  $z$  is 42. In some other embodiments,  $R^{10}$  and  $R^{11}$  are each independently a straight or branched, saturated or unsaturated alkyl chain containing from 10 to 18 carbon atoms. In some embodiments,  $R^{10}$  and  $R^{11}$  are each independently a straight or branched, saturated or unsaturated alkyl chain containing from 12 to 16 carbon atoms. In some embodiments,  $R^{10}$  and  $R^{11}$  are each independently a straight or branched, saturated or unsaturated alkyl chain containing 12 carbon atoms. In some embodiments,

25

R<sup>10</sup> and R<sup>11</sup> are each independently a straight or branched, saturated or unsaturated alkyl chain containing 14 carbon atoms. In other embodiments, R<sup>10</sup> and R<sup>11</sup> are each independently a straight or branched, saturated or unsaturated alkyl chain containing 16 carbon atoms. In still more embodiments, R<sup>10</sup> and R<sup>11</sup> are each independently a straight or branched, saturated or unsaturated alkyl chain containing 18 carbon atoms. In still other  
 5 embodiments, R<sup>10</sup> is a straight or branched, saturated or unsaturated alkyl chain containing 12 carbon atoms and R<sup>11</sup> is a straight or branched, saturated or unsaturated alkyl chain containing 14 carbon atoms.

In various embodiments, z spans a range that is selected such that the PEG  
 10 portion of (II) has an average molecular weight of about 400 to about 6000 g/mol. In some embodiments, the average z is about 45.

In other embodiments, the pegylated lipid has one of the following structures:



15 wherein n is an integer selected such that the average molecular weight of the pegylated lipid is about 2500 g/mol.

In certain embodiments, the additional lipid is present in the LNP in an amount from about 1 to about 10 mole percent. In one embodiment, the additional lipid is present in the LNP in an amount from about 1 to about 5 mole percent. In one  
 20 embodiment, the additional lipid is present in the LNP in about 1 mole percent or about 1.5 mole percent.

In some embodiments, the LNPs comprise a lipid of Formula (I), a nucleoside-modified RNA, a neutral lipid, a steroid and a pegylated lipid. In some embodiments the lipid of Formula (I) is compound I-6. In different embodiments, the neutral lipid is DSPC. In other embodiments, the steroid is cholesterol. In still different  
5       embodiments, the pegylated lipid is compound IVa.

In certain embodiments, the LNP comprises one or more immune evasion moieties that reduce or prevents phagocytosis of the LNP by macrophages. For example, in one embodiment, the immune evasion moiety binds to an inhibitory receptor on a macrophage and prevents phagocytosis of the LNP.

10               In certain embodiments, the LNP comprises one or more targeting moieties that targets the LNP to a cell or cell population. For example, in one embodiment, the targeting domain is a ligand which directs the LNP to a receptor found on a cell surface.

In one embodiment, the LNP is coated with polypeptides comprising a  
15       domain for evasion of the immune system. For example, in some embodiments the LNP is contacted with a peptidic micelle comprising polypeptides comprising a domain for evasion of the immune system. Following contact with the micelle, the polypeptides comprising the domain for evasion of the immune system coat the LNP. In some embodiments, the LNP comprises at least one lipid conjugated to a targeting domain and  
20       is further coated with polypeptides comprising a domain for evasion of the immune system.


In one embodiment, the LNP comprises at least one lipid conjugated to a domain for evasion of the immune system and at least one lipid conjugated to a targeting domain. In various embodiments, the LNP comprising a combination of at least one lipid  
25       conjugated to a domain for evasion of the immune system and at least one lipid conjugated to a targeting domain may comprise them in any ratio. For example, in some embodiments at least one lipid conjugated to a domain for evasion of the immune system and at least one lipid conjugated to a targeting domain are present in a LNP of the invention in a ratio of 1:1. However, the combination is not limited to any particular ratio.  
30       Rather any ratio that is shown to be effective is encompassed.

In certain embodiments, the LNP is capable of binding a biomolecule in vivo, where the LNP-bound biomolecule can then be recognized by a cell-surface receptor to a) prevent phagocytosis by a macrophage, b) induce internalization by a target cell or a combination thereof.

5 Exemplary LNPs and their manufacture are described in the art, for example in U.S. Patent Application Publication No. US20120276209, Semple et al., 2010, Nat Biotechnol., 28(2):172-176; Akinc et al., 2010, Mol Ther., 18(7): 1357-1364; Basha et al., 2011, Mol Ther, 19(12): 2186-2200; Leung et al., 2012, J Phys Chem C Nanomater Interfaces, 116(34): 18440-18450; Lee et al., 2012, Int J Cancer., 131(5):  
 10 E781-90; Belliveau et al., 2012, Mol Ther nucleic Acids, 1: e37; Jayaraman et al., 2012, Angew Chem Int Ed Engl., 51(34): 8529-8533; Mui et al., 2013, Mol Ther Nucleic Acids, 2, e139; Maier et al., 2013, Mol Ther., 21(8): 1570-1578; and Tam et al., 2013, Nanomedicine, 9(5): 665-74, each of which are incorporated by reference in their entirety.

15 The following Reaction Schemes illustrate methods to make lipids of Formula (I), (II) or (III).


#### GENERAL REACTION SCHEME 1



Embodiments of the lipid of Formula (I) (e.g., compound A-5) can be prepared according to General Reaction Scheme 1 (“Method A”), wherein R is a saturated or unsaturated C<sub>1</sub>-C<sub>24</sub> alkyl or saturated or unsaturated cycloalkyl, m is 0 or 1 and n is an integer from 1 to 24. Referring to General Reaction Scheme 1, compounds of structure A-1 can be purchased from commercial sources or prepared according to methods familiar to one of ordinary skill in the art. A mixture of A-1, A-2 and DMAP is treated with DCC to give the bromide A-3. A mixture of the bromide A-3, a base (e.g., N,N-diisopropylethylamine) and the N,N-dimethyldiamine A-4 is heated at a temperature and time sufficient to produce A-5 after any necessarily workup and or purification step.

20  
 25


## GENERAL REACTION SCHEME 2



Other embodiments of the compound of Formula (I) (e.g., compound B-5) can be prepared according to General Reaction Scheme 2 (“Method B”), wherein R is a saturated or unsaturated C<sub>1</sub>-C<sub>24</sub> alkyl or saturated or unsaturated cycloalkyl, m is 0 or 1 and n is an integer from 1 to 24. As shown in General Reaction Scheme 2, compounds of structure B-1 can be purchased from commercial sources or prepared according to methods familiar to one of ordinary skill in the art. A solution of B-1 (1 equivalent) is treated with acid chloride B-2 (1 equivalent) and a base (e.g., triethylamine). The crude product is treated with an oxidizing agent (e.g., pyridinium chlorochromate) and intermediate product B-3 is recovered. A solution of crude B-3, an acid (e.g., acetic acid), and N,N-dimethylaminoamine B-4 is then treated with a reducing agent (e.g., sodium triacetoxyborohydride) to obtain B-5 after any necessary work up and/or purification.


It should be noted that although starting materials A-1 and B-1 are depicted above as including only saturated methylene carbons, starting materials which include carbon-carbon double bonds may also be employed for preparation of compounds which include carbon-carbon double bonds.

## GENERAL REACTION SCHEME 3



Different embodiments of the lipid of Formula (I) (e.g., compound C-7 or C-9) can be prepared according to General Reaction Scheme 3 (“Method C”), wherein R is a saturated or unsaturated C<sub>1</sub>-C<sub>24</sub> alkyl or saturated or unsaturated cycloalkyl, m is 0 or 1 and n is an integer from 1 to 24. Referring to General Reaction Scheme 3, compounds of structure C-1 can be purchased from commercial sources or prepared according to methods familiar to one of ordinary skill in the art.

## GENERAL REACTION SCHEME 4




Embodiments of the compound of Formula (II) (e.g., compounds D-5 and D-7) can be prepared according to General Reaction Scheme 4 (“Method D”), wherein

5 R<sup>1a</sup>, R<sup>1b</sup>, R<sup>2a</sup>, R<sup>2b</sup>, R<sup>3a</sup>, R<sup>3b</sup>, R<sup>4a</sup>, R<sup>4b</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>8</sup>, R<sup>9</sup>, L<sup>1</sup>, L<sup>2</sup>, G<sup>1</sup>, G<sup>2</sup>, G<sup>3</sup>, a, b, c and d are as defined herein, and R<sup>7'</sup> represents R<sup>7</sup> or a C<sub>3</sub>-C<sub>19</sub> alkyl. Referring to General Reaction Scheme 1, compounds of structure D-1 and D-2 can be purchased from commercial sources or prepared according to methods familiar to one of ordinary skill in the art. A solution of D-1 and D-2 is treated with a reducing agent (e.g., sodium

10 triacetoxyborohydride) to obtain D-3 after any necessary work up. A solution of D-3 and a base (e.g. trimethylamine, DMAP) is treated with acyl chloride D-4 (or carboxylic acid and DCC) to obtain D-5 after any necessary work up and/or purification. D-5 can be reduced with LiAlH<sub>4</sub> D-6 to give D-7 after any necessary work up and/or purification.


## GENERAL REACTION SCHEME 5



Embodiments of the lipid of Formula (II) (e.g., compound E-5) can be prepared according to General Reaction Scheme 5 (“Method E”), wherein R<sup>1a</sup>, R<sup>1b</sup>, R<sup>2a</sup>, R<sup>2b</sup>, R<sup>3a</sup>, R<sup>3b</sup>, R<sup>4a</sup>, R<sup>4b</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, L<sup>1</sup>, L<sup>2</sup>, G<sup>3</sup>, a, b, c and d are as defined herein.

Referring to General Reaction Scheme 2, compounds of structure E-1 and E-2 can be purchased from commercial sources or prepared according to methods familiar to one of ordinary skill in the art. A mixture of E-1 (in excess), E-2 and a base (e.g., potassium carbonate) is heated to obtain E-3 after any necessary work up. A solution of E-3 and a base (e.g. trimethylamine, DMAP) is treated with acyl chloride E-4 (or carboxylic acid and DCC) to obtain E-5 after any necessary work up and/or purification.

## GENERAL REACTION SCHEME 6



General Reaction Scheme 6 provides an exemplary method (Method F) for preparation of Lipids of Formula (III).  $G^1$ ,  $G^3$ ,  $R^1$  and  $R^3$  in General Reaction Scheme 6 are as defined herein for Formula (III), and  $G^{1'}$  refers to a one-carbon shorter homologue of  $G^1$ . Compounds of structure F-1 are purchased or prepared according to methods known in the art. Reaction of F-1 with diol F-2 under appropriate condensation conditions (e.g., DCC) yields ester/alcohol F-3, which can then be oxidized (e.g., PCC) to aldehyde F-4. Reaction of F-4 with amine F-5 under reductive amination conditions yields a lipid of Formula (III).

It should be noted that various alternative strategies for preparation of lipids of Formula (III) are available to those of ordinary skill in the art. For example, other lipids of Formula (III) wherein  $L^1$  and  $L^2$  are other than ester can be prepared according to analogous methods using the appropriate starting material. Further, General Reaction Scheme 6 depicts preparation of a lipids of Formula (III), wherein  $G^1$  and  $G^2$  are the same; however, this is not a required aspect of the invention and modifications to the above reaction scheme are possible to yield compounds wherein  $G^1$  and  $G^2$  are different.

It will be appreciated by those skilled in the art that in the process described herein the functional groups of intermediate compounds may need to be protected by suitable protecting groups. Such functional groups include hydroxy, amino, mercapto and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl or diarylalkylsilyl (for example, *t*-butyldimethylsilyl, *t*-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like. Suitable protecting groups for amino, amidino and guanidino include *t*-butoxycarbonyl, benzyloxycarbonyl, and the

like. Suitable protecting groups for mercapto include -C(O)-R" (where R" is alkyl, aryl or arylalkyl), *p*-methoxybenzyl, trityl and the like. Suitable protecting groups for carboxylic acid include alkyl, aryl or arylalkyl esters. Protecting groups may be added or removed in accordance with standard techniques, which are known to one skilled in the art and as described herein. The use of protecting groups is described in detail in Green, T.W. and P.G.M. Wutz, *Protective Groups in Organic Synthesis* (1999), 3rd Ed., Wiley. As one of skill in the art would appreciate, the protecting group may also be a polymer resin such as a Wang resin, Rink resin or a 2-chlorotrityl-chloride resin.

#### 10 PEG Shielding

In one embodiment, the LNP comprises one or more pegylated lipid that serves to protect the LNP from hepatic uptake by ApoE (herein referred to as "PEG shielding." In one embodiment, the pegylated lipid is conjugated to a targeting domain, or a therapeutic agent. In some embodiments the LNP further comprises a pegylated lipid conjugated to a targeting moiety. In some embodiments the targeting moiety is an antibody or antigen-binding fragment thereof. In one embodiment, the pegylated lipid is conjugated to a phagocytosis inhibitor. In one embodiment, the pegylated lipid is conjugated to an active CD47 polypeptide fragment. In one embodiment, the pegylated lipid is conjugated to SEQ ID NO:1 or SEQ ID NO:2. In some embodiments, the LNP further comprises one or more unconjugated pegylated lipid.

#### Agents

In one embodiment, the delivery vehicle comprises at least one agent. In some embodiments, the agent is a therapeutic agent, an imaging agent, diagnostic agent, a contrast agent, a labeling agent, a detection agent, or a disinfectant. The agent may also include substances with biological activities which are not typically considered to be active ingredients, such as fragrances, sweeteners, flavorings and flavor enhancer agents, pH adjusting agents, effervescent agents, emollients, bulking agents, soluble organic salts, permeabilizing agents, anti-oxidants, colorants or coloring agents, and the like.

30 In one embodiment, the delivery vehicle comprises at least one therapeutic agent. The present invention is not limited to any particular therapeutic agent, but rather

encompasses any suitable therapeutic agent that can be included within the delivery vehicle. Exemplary therapeutic agents include, but are not limited to, anti-viral agents, anti-bacterial agents, anti-oxidant agents, thrombolytic agents, chemotherapeutic agents, anti-inflammatory agents, immunogenic agents, antiseptics, anesthetics, analgesics, pharmaceutical agents, small molecules, peptides, nucleic acids, and the like.

In some embodiments, the LNP or the nanoparticle compositions of the invention further comprises a nucleic acid. In various embodiments the nucleic acid is mRNA, self-replicating RNA, siRNA, miRNA, antisense oligonucleotides, DNA, DNA-RNA hybrids, a gene editing component (for example, a guide RNA a tracr RNA, sgRNA, an mRNA encoding an RNA-guided nuclease, a gene or base editing protein, a zinc-finger nuclease, a Talen, a CRISPR nuclease, such as Cas9, a DNA molecule to be inserted or serve as a template for repair), and the like, or a combination thereof. In some embodiments, the mRNA encodes a gene-editing or base-editing protein. In some embodiments, the nucleic acid is a guide RNA. In still further embodiments, the mRNA encodes a biological response modifier, a chemokine, a cytokine, a  $\gamma$ -chain receptor cytokine such as IL-2, IL-7, IL-15, and IL-21, or an immune checkpoint agonist or antagonist. In some embodiments, the LNP or tLNP comprises both a gene- or base-editing protein-encoding mRNA and one or more guide RNAs. CRISPR nucleases may have altered activity, for example, modifying the nuclease so that it is a nickase instead of making double-strand cuts or so that it binds the sequence specified by the guide RNA but has no enzymatic activity. Base-editing proteins are often fusion proteins comprising a deaminase domain and a sequence-specific DNA binding domain (such as an inactive CRISPR nuclease). In alternative embodiments, rather than comprising an mRNA encoding an RNA-guided nuclease and a guide RNA, the LNP or nanoparticle comprises a ribonucleoprotein, that is a complex comprising a guide RNA bound to a RNA-guided nuclease. In other embodiments, the nanoparticle comprises an RNA and reverse transcriptase. In still other embodiments, the LNP or nanoparticle comprises a virion, virus-like particle, or nucleocapsid.

Imaging Agents

In one embodiment, the delivery vehicle comprises an imaging agent. Imaging agents are materials that allow the delivery vehicle to be visualized after exposure to a cell or tissue. Visualization includes imaging for the naked eye, as well as imaging that requires detecting with instruments or detecting information not normally  
5 visible to the eye, and includes imaging that requires detecting of photons, sound or other energy quanta. Examples include stains, vital dyes, fluorescent markers, radioactive markers, enzymes or plasmid constructs encoding markers or enzymes. Many materials and methods for imaging and targeting that may be used in the delivery vehicle are provided in the Handbook of Targeted delivery of Imaging Agents, Torchilin, ed. (1995)  
10 CRC Press, Boca Raton, Fla.

Visualization based on molecular imaging typically involves detecting biological processes or biological molecules at a tissue, cell, or molecular level. Molecular imaging can be used to assess specific targets for gene therapies, cell-based therapies, and to visualize pathological conditions as a diagnostic or research tool.  
15 Imaging agents that are able to be delivered intracellularly are particularly useful because such agents can be used to assess intracellular activities or conditions. Imaging agents must reach their targets to be effective; thus, in some embodiments, an efficient uptake by cells is desirable. A rapid uptake may also be desirable to avoid the RES, see review in Allport and Weissleder, *Experimental Hematology* 1237-1246 (2001).

20 Further, imaging agents preferably should provide high signal to noise ratios so that they may be detected in small quantities, whether directly, or by effective amplification techniques that increase the signal associated with a particular target. Amplification strategies are reviewed in Allport and Weissleder, *Experimental Hematology* 1237-1246 (2001), and include, for example, avidin-biotin binding systems,  
25 trapping of converted ligands, probes that change physical behavior after being bound by a target, and taking advantage of relaxation rates. Examples of imaging technologies include magnetic resonance imaging, radionuclide imaging, computed tomography, ultrasound, and optical imaging.

Delivery vehicles as set forth herein may advantageously be used in  
30 various imaging technologies or strategies, for example by incorporating imaging agents into delivery vehicles. Many imaging techniques and strategies are known, e.g., see

review in Allport and Weissleder, *Experimental Hematology* 1237-1246 (2001); such strategies may be adapted to use with delivery vehicles. Suitable imaging agents include, for example, fluorescent molecules, labeled antibodies, labeled avidin:biotin binding agents, colloidal metals (e.g., gold, silver), reporter enzymes (e.g., horseradish  
5 peroxidase), superparamagnetic transferrin, second reporter systems (e.g., tyrosinase), and paramagnetic chelates.

In some embodiments, the imaging agent is a magnetic resonance imaging contrast agent. Examples of magnetic resonance imaging contrast agents include, but are not limited to, 1,4,7,10-tetraazacyclododecane-N,N',N''N'''-tetracetic acid (DOTA),  
10 diethylenetriaminepentaacetic (DTPA), 1,4,7,10-tetraazacyclododecane-N,N', N'',N'''-tetraethylphosphorus (DOTEP), 1,4,7,10-tetraazacyclododecane-N,N',N''-triacetic acid (DOTA) and derivatives thereof (see U.S. Pat. Nos. 5,188,816, 5,219,553, and 5,358,704). In some embodiments, the imaging agent is an X-Ray contrast agent. X-ray contrast agents already known in the art include a number of halogenated derivatives,  
15 especially iodinated derivatives, of 5-amino-isophthalic acid.

#### Small molecule therapeutic agents

In various embodiments, the agent is a therapeutic agent. In various embodiments, the therapeutic agent is a small molecule. When the therapeutic agent is a  
20 small molecule, a small molecule may be obtained using standard methods known to the skilled artisan. Such methods include chemical organic synthesis or biological means. Biological means include purification from a biological source, recombinant synthesis and in vitro translation systems, using methods well known in the art. In one embodiment, a small molecule therapeutic agents comprises an organic molecule,  
25 inorganic molecule, biomolecule, synthetic molecule, and the like.

Combinatorial libraries of molecularly diverse chemical compounds potentially useful in treating a variety of diseases and conditions are well known in the art, as are method of making the libraries. The method may use a variety of techniques well-known to the skilled artisan including solid phase synthesis, solution methods,  
30 parallel synthesis of single compounds, synthesis of chemical mixtures, rigid core structures, flexible linear sequences, deconvolution strategies, tagging techniques, and

generating unbiased molecular landscapes for lead discovery vs. biased structures for lead development. In some embodiments of the invention, the therapeutic agent is synthesized and/or identified using combinatorial techniques.

In a general method for small library synthesis, an activated core molecule  
5 is condensed with a number of building blocks, resulting in a combinatorial library of covalently linked, core-building block ensembles. The shape and rigidity of the core determines the orientation of the building blocks in shape space. The libraries can be biased by changing the core, linkage, or building blocks to target a characterized biological structure (“focused libraries”) or synthesized with less structural bias using  
10 flexible cores. In some embodiments of the invention, the therapeutic agent is synthesized via small library synthesis.

The small molecule and small molecule compounds described herein may be present as salts even if salts are not depicted, and it is understood that the invention embraces all salts and solvates of the therapeutic agents depicted here, as well as the non-  
15 salt and non-solvate form of the therapeutic agents, as is well understood by the skilled artisan. In some embodiments, the salts of the therapeutic agents of the invention are pharmaceutically acceptable salts.

Where tautomeric forms may be present for any of the therapeutic agents described herein, each and every tautomeric form is intended to be included in the present  
20 invention, even though only one or some of the tautomeric forms may be explicitly depicted. For example, when a 2-hydroxypyridyl moiety is depicted, the corresponding 2-pyridone tautomer is also intended.

The invention also includes any or all of the stereochemical forms, including any enantiomeric or diastereomeric forms of the therapeutic agents described.  
25 The recitation of the structure or name herein is intended to embrace all possible stereoisomers of therapeutic agents depicted. All forms of the therapeutic agents are also embraced by the invention, such as crystalline or non-crystalline forms of the therapeutic agent. Compositions comprising a therapeutic agents of the invention are also intended, such as a composition of substantially pure therapeutic agent, including a specific  
30 stereochemical form thereof, or a composition comprising mixtures of therapeutic agents

of the invention in any ratio, including two or more stereochemical forms, such as in a racemic or non-racemic mixture.

The invention also includes any or all active analog or derivative, such as a prodrug, of any therapeutic agent described herein. In one embodiment, the therapeutic agent is a prodrug. In one embodiment, the small molecules described herein are candidates for derivatization. As such, in certain instances, the analogs of the small molecules described herein that have modulated potency, selectivity, and solubility are included herein and provide useful leads for drug discovery and drug development. Thus, in certain instances, during optimization new analogs are designed considering issues of drug delivery, metabolism, novelty, and safety.

In some instances, small molecule therapeutic agents described herein are derivatives or analogs of known therapeutic agents, as is well known in the art of combinatorial and medicinal chemistry. The analogs or derivatives can be prepared by adding and/or substituting functional groups at various locations. As such, the small molecules described herein can be converted into derivatives/analogues using well known chemical synthesis procedures. For example, all of the hydrogen atoms or substituents can be selectively modified to generate new analogs. Also, the linking atoms or groups can be modified into longer or shorter linkers with carbon backbones or hetero atoms. Also, the ring groups can be changed so as to have a different number of atoms in the ring and/or to include hetero atoms. Moreover, aromatics can be converted to cyclic rings, and vice versa. For example, the rings may be from 5-7 atoms, and may be carbocyclic or heterocyclic.

As used herein, the term “analog,” “analogue,” or “derivative” is meant to refer to a chemical compound or molecule made from a parent compound or molecule by one or more chemical reactions. As such, an analog can be a structure having a structure similar to that of the small molecule therapeutic agents described herein or can be based on a scaffold of a small molecule therapeutic agents described herein, but differing from it in respect to certain components or structural makeup, which may have a similar or opposite action metabolically. An analog or derivative of any of a small molecule inhibitor in accordance with the present invention can be used to treat a disease or disorder.

In one embodiment, the small molecule therapeutic agents described herein can independently be derivatized, or analogs prepared therefrom, by modifying hydrogen groups independently from each other into other substituents. That is, each atom on each molecule can be independently modified with respect to the other atoms on the same molecule. Any traditional modification for producing a derivative/analog can be used. For example, the atoms and substituents can be independently comprised of hydrogen, an alkyl, aliphatic, straight chain aliphatic, aliphatic having a chain hetero atom, branched aliphatic, substituted aliphatic, cyclic aliphatic, heterocyclic aliphatic having one or more hetero atoms, aromatic, heteroaromatic, polyaromatic, polyamino acids, peptides, polypeptides, combinations thereof, halogens, halo-substituted aliphatics, and the like. Additionally, any ring group on a compound can be derivatized to increase and/or decrease ring size as well as change the backbone atoms to carbon atoms or hetero atoms.

#### 15                    Nucleic acid therapeutic agents

In other related aspects, the therapeutic agent is an isolated nucleic acid. In certain embodiments, the isolated nucleic acid molecule is one of a DNA molecule or an RNA molecule. In certain embodiments, the isolated nucleic acid molecule is a cDNA, mRNA, siRNA, shRNA or miRNA molecule. In some embodiments, the therapeutic agent is an siRNA, miRNA, shRNA, or an antisense molecule, which inhibits a targeted nucleic acid including those encoding proteins that are involved in aggravation of the pathological processes.

In one embodiment, the nucleic acid comprises a promoter/regulatory sequence such that the nucleic acid is capable of directing expression of the nucleic acid. Thus, the invention encompasses expression vectors and methods for the introduction of exogenous nucleic acid into cells with concomitant expression of the exogenous nucleic acid in the cells such as those described, for example, in Sambrook et al. (2012, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York), and in Ausubel et al. (1997, Current Protocols in Molecular Biology, John Wiley & Sons, New York) and as described elsewhere herein.

In one aspect of the invention, a targeted gene or protein, can be inhibited by way of inactivating and/or sequestering the targeted gene or protein. As such, inhibiting the activity of the targeted gene or protein can be accomplished by using a nucleic acid molecule encoding a transdominant negative mutant.

5 In one embodiment, siRNA is used to decrease the level of a targeted protein. RNA interference (RNAi) is a phenomenon in which the introduction of double-stranded RNA (dsRNA) into a diverse range of organisms and cell types causes degradation of the complementary mRNA. In the cell, long dsRNAs are cleaved into short 21-25 nucleotide small interfering RNAs, or siRNAs, by a ribonuclease known as  
10 Dicer. The siRNAs subsequently assemble with protein components into an RNA-induced silencing complex (RISC), unwinding in the process. Activated RISC then binds to complementary transcript by base pairing interactions between the siRNA antisense strand and the mRNA. The bound mRNA is cleaved and sequence specific degradation of mRNA results in gene silencing. See, for example, U.S. Patent No. 6,506,559; Fire et al.,  
15 1998, Nature 391(19):306-311; Timmons et al., 1998, Nature 395:854; Montgomery et al., 1998, TIG 14 (7):255-258; David R. Engelke, Ed., RNA Interference (RNAi) Nuts & Bolts of RNAi Technology, DNA Press, Eagleville, PA (2003); and Gregory J. Hannon, Ed., RNAi A Guide to Gene Silencing, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2003). Soutschek et al. (2004, Nature 432:173-178) describe a  
20 chemical modification to siRNAs that aids in intravenous systemic delivery. Optimizing siRNAs involves consideration of overall G/C content, C/T content at the termini, T<sub>m</sub> and the nucleotide content of the 3' overhang. See, for instance, Schwartz et al., 2003, Cell, 115:199-208 and Khvorova et al., 2003, Cell 115:209-216. Therefore, the present invention also includes methods of decreasing levels of PTPN22 using RNAi technology.

25 In one aspect, the invention includes a vector comprising an siRNA or an antisense polynucleotide. Preferably, the siRNA or antisense polynucleotide is capable of inhibiting the expression of a target polypeptide. The incorporation of a desired polynucleotide into a vector and the choice of vectors are well-known in the art as described in, for example, Sambrook et al. (2012), and in Ausubel et al. (1997), and  
30 elsewhere herein.

In certain embodiments, the expression vectors described herein encode a short hairpin RNA (shRNA) therapeutic agents. shRNA molecules are well known in the art and are directed against the mRNA of a target, thereby decreasing the expression of the target. In certain embodiments, the encoded shRNA is expressed by a cell, and is then  
5 processed into siRNA. For example, in certain instances, the cell possesses native enzymes (e.g., dicer) that cleave the shRNA to form siRNA.

In order to assess the expression of the siRNA, shRNA, or antisense polynucleotide, the expression vector to be introduced into a cell can also contain either a selectable marker gene or a reporter gene or both to facilitate identification of expressing  
10 cells from the population of cells sought to be transfected or infected using the delivery vehicle of the invention. In other embodiments, the selectable marker may be carried on a separate piece of DNA and also be contained within the delivery vehicle. Both selectable markers and reporter genes may be flanked with appropriate regulatory sequences to enable expression in the host cells. Useful selectable markers are known in the art and  
15 include, for example, antibiotic-resistance genes, such as neomycin resistance and the like.

Therefore, in one aspect, the delivery vehicle may contain a vector, comprising the nucleotide sequence or the construct to be delivered. The choice of the vector will depend on the host cell in which it is to be subsequently introduced. In a  
20 particular embodiment, the vector of the invention is an expression vector. Suitable host cells include a wide variety of prokaryotic and eukaryotic host cells. In specific embodiments, the expression vector is selected from the group consisting of a viral vector, a bacterial vector and a mammalian cell vector. Prokaryote- and/or eukaryote-  
vector based systems can be employed for use with the present invention to produce  
25 polynucleotides, or their cognate polypeptides. Many such systems are commercially and widely available.

By way of illustration, the vector in which the nucleic acid sequence is introduced can be a plasmid, which is or is not integrated in the genome of a host cell when it is introduced in the cell. Illustrative, non-limiting examples of vectors in which  
30 the nucleotide sequence of the invention or the gene construct of the invention can be inserted include a tet-on inducible vector for expression in eukaryote cells.

The vector may be obtained by conventional methods known by persons skilled in the art (Sambrook et al., 2012). In a particular embodiment, the vector is a vector useful for transforming animal cells.

In one embodiment, the recombinant expression vectors may also contain  
5 nucleic acid molecules, which encode a peptide or peptidomimetic.

A promoter may be one naturally associated with a gene or polynucleotide sequence, as may be obtained by isolating the 5' non-coding sequences located upstream of the coding segment and/or exon. Such a promoter can be referred to as "endogenous." Similarly, an enhancer may be one naturally associated with a polynucleotide sequence,  
10 located either downstream or upstream of that sequence. Alternatively, certain advantages will be gained by positioning the coding polynucleotide segment under the control of a recombinant or heterologous promoter, which refers to a promoter that is not normally associated with a polynucleotide sequence in its natural environment. A recombinant or heterologous enhancer refers also to an enhancer not normally associated with a  
15 polynucleotide sequence in its natural environment. Such promoters or enhancers may include promoters or enhancers of other genes, and promoters or enhancers isolated from any other prokaryotic, viral, or eukaryotic cell, and promoters or enhancers not "naturally occurring," i.e., containing different elements of different transcriptional regulatory regions, and/or mutations that alter expression. In addition to producing nucleic acid  
20 sequences of promoters and enhancers synthetically, sequences may be produced using recombinant cloning and/or nucleic acid amplification technology, including PCR™, in connection with the compositions disclosed herein (U.S. Patent 4,683,202, U.S. Patent 5,928,906). Furthermore, it is contemplated the control sequences that direct transcription and/or expression of sequences within non-nuclear organelles such as mitochondria,  
25 chloroplasts, and the like, can be employed as well.

Naturally, it will be important to employ a promoter and/or enhancer that effectively directs the expression of the DNA segment in the cell type, organelle, and organism chosen for expression. Those of skill in the art of molecular biology generally know how to use promoters, enhancers, and cell type combinations for protein  
30 expression, for example, see Sambrook et al. (2012). The promoters employed may be constitutive, tissue-specific, inducible, and/or useful under the appropriate conditions to

direct high level expression of the introduced DNA segment, such as is advantageous in the large-scale production of recombinant proteins and/or peptides. The promoter may be heterologous or endogenous.

The recombinant expression vectors may also contain a selectable marker gene, which facilitates the selection of host cells. Suitable selectable marker genes are genes encoding proteins such as G418 and hygromycin, which confer resistance to certain drugs,  $\beta$ -galactosidase, chloramphenicol acetyltransferase, firefly luciferase, or an immunoglobulin or portion thereof such as the Fc portion of an immunoglobulin preferably IgG. The selectable markers may be introduced on a separate vector from the nucleic acid of interest.

Following the generation of the siRNA polynucleotide, a skilled artisan will understand that the siRNA polynucleotide will have certain characteristics that can be modified to improve the siRNA as a therapeutic compound. Therefore, the siRNA polynucleotide may be further designed to resist degradation by modifying it to include phosphorothioate, or other linkages, methylphosphonate, sulfone, sulfate, ketyl, phosphorodithioate, phosphoramidate, phosphate esters, and the like (see, e.g., Agrawal et al., 1987, Tetrahedron Lett. 28:3539-3542; Stec et al., 1985 Tetrahedron Lett. 26:2191-2194; Moody et al., 1989 Nucleic Acids Res. 12:4769-4782; Eckstein, 1989 Trends Biol. Sci. 14:97-100; Stein, In: Oligodeoxynucleotides. Antisense Inhibitors of Gene Expression, Cohen, ed., Macmillan Press, London, pp. 97-117 (1989)).

Any polynucleotide may be further modified to increase its stability in vivo. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends; the use of phosphorothioate or 2' O-methyl rather than phosphodiester linkages in the backbone; and/or the inclusion of nontraditional bases such as inosine, queuosine, and wybutosine and the like, as well as acetyl-, methyl-, thio- and other modified forms of adenine, cytidine, guanine, thymine, and uridine.

In one embodiment of the invention, an antisense nucleic acid sequence, which is expressed by a plasmid vector is used as a therapeutic agent to inhibit the expression of a target protein. The antisense expressing vector is used to transfect a mammalian cell or the mammal itself, thereby causing reduced endogenous expression of the target protein.

Antisense molecules and their use for inhibiting gene expression are well known in the art (see, e.g., Cohen, 1989, In: Oligodeoxyribonucleotides, Antisense Inhibitors of Gene Expression, CRC Press). Antisense nucleic acids are DNA or RNA molecules that are complementary, as that term is defined elsewhere herein, to at least a portion of a specific mRNA molecule (Weintraub, 1990, Scientific American 262:40). In the cell, antisense nucleic acids hybridize to the corresponding mRNA, forming a double-stranded molecule thereby inhibiting the translation of genes.

The use of antisense methods to inhibit the translation of genes is known in the art, and is described, for example, in Marcus-Sakura (1988, Anal. Biochem. 172:289). Such antisense molecules may be provided to the cell via genetic expression using DNA encoding the antisense molecule as taught by Inoue, 1993, U.S. Patent No. 5,190,931.

Alternatively, antisense molecules of the invention may be made synthetically and then provided to the cell. Antisense oligomers of between about 10 to about 30, and more preferably about 15 nucleotides, are preferred, since they are easily synthesized and introduced into a target cell. Synthetic antisense molecules contemplated by the invention include oligonucleotide derivatives known in the art which have improved biological activity compared to unmodified oligonucleotides (see U.S. Patent No. 5,023,243).

In one embodiment of the invention, a ribozyme is used as a therapeutic agent to inhibit expression of a target protein. Ribozymes useful for inhibiting the expression of a target molecule may be designed by incorporating target sequences into the basic ribozyme structure, which are complementary, for example, to the mRNA sequence encoding the target molecule. Ribozymes targeting the target molecule, may be synthesized using commercially available reagents (Applied Biosystems, Inc., Foster City, CA) or they may be genetically expressed from DNA encoding them.

In one embodiment, the therapeutic agent may comprise one or more components of a CRISPR-Cas system, where a guide RNA (gRNA) targeted to a gene encoding a target molecule, and a CRISPR-associated (Cas) peptide form a complex to induce mutations within the targeted gene. In one embodiment, the therapeutic agent comprises a gRNA or a nucleic acid molecule encoding a gRNA. In one embodiment, the

therapeutic agent comprises a Cas peptide or a nucleic acid molecule encoding a Cas peptide.

In one embodiment, the agent comprises a miRNA or a mimic of a miRNA. In one embodiment, the agent comprises a nucleic acid molecule that encodes a miRNA or mimic of a miRNA.

MiRNAs are small non-coding RNA molecules that are capable of causing post-transcriptional silencing of specific genes in cells by the inhibition of translation or through degradation of the targeted mRNA. A miRNA can be completely complementary or can have a region of noncomplementarity with a target nucleic acid, consequently resulting in a "bulge" at the region of non-complementarity. A miRNA can inhibit gene expression by repressing translation, such as when the miRNA is not completely complementary to the target nucleic acid, or by causing target RNA degradation, which is believed to occur only when the miRNA binds its target with perfect complementarity. The disclosure also can include double-stranded precursors of miRNA. A miRNA or pri-miRNA can be 18- 100 nucleotides in length, or from 18-80 nucleotides in length. Mature miRNAs can have a length of 19-30 nucleotides, or 21-25 nucleotides, particularly 21, 22, 23, 24, or 25 nucleotides. MiRNA precursors typically have a length of about 70-100 nucleotides and have a hairpin conformation. miRNAs are generated in vivo from pre-miRNAs by the enzymes Dicer and Drosha, which specifically process long pre-miRNA into functional miRNA. The hairpin or mature microRNAs, or pri-microRNA agents featured in the disclosure can be synthesized in vivo by a cell-based system or in vitro by chemical synthesis.

In various embodiments, the agent comprises an oligonucleotide that comprises the nucleotide sequence of a disease-associated miRNA. In certain embodiments, the oligonucleotide comprises the nucleotide sequence of a disease-associated miRNA in a pre -microRNA, mature or hairpin form. In other embodiments, a combination of oligonucleotides comprising a sequence of one or more disease-associated miRNAs, any pre -miRNA, any fragment, or any combination thereof is envisioned.

MiRNAs can be synthesized to include a modification that imparts a desired characteristic. For example, the modification can improve stability, hybridization

thermodynamics with a target nucleic acid, targeting to a particular tissue or cell -type, or cell permeability, e.g., by an endocytosis-dependent or -independent mechanism.

Modifications can also increase sequence specificity, and consequently decrease off-site targeting. Methods of synthesis and chemical modifications are  
5 described in greater detail below. If desired, miRNA molecules may be modified to stabilize the miRNAs against degradation, to enhance half-life, or to otherwise improve efficacy. Desirable modifications are described, for example, in U.S. Patent Publication Nos. 20070213292, 20060287260, 20060035254, 20060008822, and 2005028824, each of which is hereby incorporated by reference in its entirety. For increased nuclease  
10 resistance and/or binding affinity to the target, the single- stranded oligonucleotide agents featured in the disclosure can include 2'-O-methyl, 2'-fluorine, 2'-O-methoxyethyl, 2'-O-aminopropyl, 2'-amino, and/or phosphorothioate linkages. Inclusion of locked nucleic acids (LNA), ethylene nucleic acids (ENA), e.g., 2'-4'-ethylene- bridged nucleic acids, and certain nucleotide modifications can also increase binding affinity to the target. The  
15 inclusion of pyranose sugars in the oligonucleotide backbone can also decrease endonucleolytic cleavage. An oligonucleotide can be further modified by including a 3' cationic group, or by inverting the nucleoside at the 3'-terminus with a 3'-3' linkage. In another alternative, the 3'-terminus can be blocked with an aminoalkyl group. Other 3' conjugates can inhibit 3'-5' exonucleolytic cleavage. While not being bound by theory, a  
20 3' may inhibit exonucleolytic cleavage by sterically blocking the exonuclease from binding to the 3' end of the oligonucleotide. Even small alkyl chains, aryl groups, or heterocyclic conjugates or modified sugars (D-ribose, deoxyribose, glucose etc.) can block 3'-5'-exonucleases.

In one embodiment, the miRNA includes a 2'-modified oligonucleotide  
25 containing oligodeoxynucleotide gaps with some or all internucleotide linkages modified to phosphorothioates for nuclease resistance. The presence of methylphosphonate modifications increases the affinity of the oligonucleotide for its target RNA and thus reduces the IC<sub>50</sub>. This modification also increases the nuclease resistance of the modified oligonucleotide. It is understood that the methods and reagents of the present  
30 disclosure may be used in conjunction with any technologies that may be developed to enhance the stability or efficacy of an inhibitory nucleic acid molecule.

miRNA molecules include nucleotide oligomers containing modified backbones or non-natural internucleoside linkages. Oligomers having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this disclosure, 5 modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone are also considered to be nucleotide oligomers. Nucleotide oligomers that have modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl-phosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral 10 phosphonates, phosphinates, phosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates. Various salts, mixed salts and free acid forms are also included.

A miRNA described herein, which may be in the mature or hairpin form, may be provided as a naked oligonucleotide. In some cases, it may be desirable to utilize 15 a formulation that aids in the delivery of a miRNA or other nucleotide oligomer to cells (see, e.g., U.S. Pat. Nos. 5,656,611, 5,753,613, 5,785,992, 6,120,798, 6,221,959, 6,346,613, and 6,353,055, each of which is hereby incorporated by reference).

In some examples, the miRNA composition is at least partially crystalline, uniformly crystalline, and/or anhydrous (e.g., less than 80, 50, 30, 20, or 10% water). In 20 another example, the miRNA composition is in an aqueous phase, e.g., in a solution that includes water. The aqueous phase or the crystalline compositions can be incorporated into a delivery vehicle, e.g., a liposome (particularly for the aqueous phase), or a particle (e.g., a microparticle as can be appropriate for a crystalline composition). Generally, the miRNA composition is formulated in a manner that is compatible with the intended 25 method of administration. A miRNA composition can be formulated in combination with another agent, e.g., another therapeutic agent or an agent that stabilizes an oligonucleotide agent, e.g., a protein that complexes with the oligonucleotide agent. Still other agents include chelators, e.g., EDTA (e.g., to remove divalent cations such as Mg), salts, and RNase inhibitors (e.g., a broad specificity RNase inhibitor). In one 30 embodiment, the miRNA composition includes another miRNA, e.g., a second miRNA composition (e.g., a microRNA that is distinct from the first). Still other preparations can

include at least three, five, ten, twenty, fifty, or a hundred or more different oligonucleotide species.

In certain embodiments, the composition comprises an oligonucleotide composition that mimics the activity of a miRNA. In certain embodiments, the composition comprises oligonucleotides having nucleobase identity to the nucleobase sequence of a miRNA, and are thus designed to mimic the activity of the miRNA. In certain embodiments, the oligonucleotide composition that mimics miRNA activity comprises a double-stranded RNA molecule which mimics the mature miRNA hairpins or processed miRNA duplexes.

In one embodiment, the oligonucleotide shares identity with endogenous miRNA or miRNA precursor nucleobase sequences. An oligonucleotide selected for inclusion in a composition of the present invention may be one of a number of lengths. Such an oligonucleotide can be from 7 to 100 linked nucleosides in length. For example, an oligonucleotide sharing nucleobase identity with a miRNA may be from 7 to 30 linked nucleosides in length. An oligonucleotide sharing identity with a miRNA precursor may be up to 100 linked nucleosides in length. In certain embodiments, an oligonucleotide comprises 7 to 30 linked nucleosides. In certain embodiments, an oligonucleotide comprises 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, or 30 linked nucleotides. In certain embodiments, an oligonucleotide comprises 19 to 23 linked nucleosides. In certain embodiments, an oligonucleotide is from 40 up to 50, 60, 70, 80, 90, or 100 linked nucleosides in length.

In certain embodiments, an oligonucleotide has a sequence that has a certain identity to a miRNA or a precursor thereof. Nucleobase sequences of mature miRNAs and their corresponding stem-loop sequences described herein are the sequences found in miRBase, an online searchable database of miRNA sequences and annotation. Entries in the miRBase Sequence database represent a predicted hairpin portion of a miRNA transcript (the stem-loop), with information on the location and sequence of the mature miRNA sequence. The miRNA stem-loop sequences in the database are not strictly precursor miRNAs (pre-miRNAs), and may in some instances include the pre-miRNA and some flanking sequence from the presumed primary transcript. The miRNA nucleobase sequences described herein encompass any version of the miRNA, including

the sequences described in Release 10.0 of the miRBase sequence database and sequences described in any earlier Release of the miRBase sequence database. A sequence database release may result in the re-naming of certain miRNAs. A sequence database release may result in a variation of a mature miRNA sequence. The  
5 compositions of the present invention encompass oligomeric compound comprising oligonucleotides having a certain identity to any nucleobase sequence version of a miRNAs described herein.

In certain embodiments, an oligonucleotide has a nucleobase sequence at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identical to the  
10 miRNA over a region of 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases. Accordingly, in certain embodiments the nucleobase sequence of an oligonucleotide may have one or more non-identical nucleobases with respect to the miRNA.

In certain embodiments, the composition comprises a nucleic acid  
15 molecule encoding a miRNA, precursor, mimic, or fragment thereof. For example, the composition may comprise a viral vector, plasmid, cosmid, or other expression vector suitable for expressing the miRNA, precursor, mimic, or fragment thereof in a desired mammalian cell or tissue.

#### 20 In vitro transcribed RNA

In one embodiment, the composition of the invention comprises in vitro transcribed (IVT) RNA. In one embodiment, the composition of the invention comprises in vitro transcribed (IVT) RNA encoding a therapeutic protein. In one embodiment, the composition of the invention comprises IVT RNA encoding a plurality of therapeutic  
25 proteins.

In one embodiment, an IVT RNA can be introduced to a cell as a form of transient transfection. The RNA is produced by in vitro transcription using a plasmid DNA template generated synthetically. DNA of interest from any source can be directly converted by PCR into a template for in vitro mRNA synthesis using appropriate primers  
30 and RNA polymerase. The source of the DNA can be, for example, genomic DNA, plasmid DNA, phage DNA, cDNA, synthetic DNA sequence or any other appropriate

source of DNA. In one embodiment, the desired template for in vitro transcription is a therapeutic protein, as described elsewhere herein.

In one embodiment, the DNA to be used for PCR contains an open reading frame. The DNA can be from a naturally occurring DNA sequence from the genome of an organism. In one embodiment, the DNA is a full-length gene or a portion of a gene. The gene can include some or all of the 5' and/or 3' untranslated regions (UTRs). The gene can include exons and introns. In one embodiment, the DNA to be used for PCR is a human gene. In another embodiment, the DNA to be used for PCR is a human gene including the 5' and 3' UTRs. In another embodiment, the DNA to be used for PCR is a gene from a pathogenic or commensal organism, including bacteria, viruses, parasites, and fungi. In another embodiment, the DNA to be used for PCR is from a pathogenic or commensal organism, including bacteria, viruses, parasites, and fungi, including the 5' and 3' UTRs. The DNA can alternatively be an artificial DNA sequence that is not normally expressed in a naturally occurring organism. An exemplary artificial DNA sequence is one that contains portions of genes that are ligated together to form an open reading frame that encodes a fusion protein. The portions of DNA that are ligated together can be from a single organism or from more than one organism.

Genes that can be used as sources of DNA for PCR include genes that encode polypeptides that induce or enhance an adaptive immune response in an organism. Preferred genes are genes which are useful for a short-term treatment, or where there are safety concerns regarding dosage or the expressed gene.

In various embodiments, a plasmid is used to generate a template for in vitro transcription of RNA which is used for transfection.

Chemical structures with the ability to promote stability and/or translation efficiency may also be used. The RNA preferably has 5' and 3' UTRs. In one embodiment, the 5' UTR is between zero and 3000 nucleotides in length. The length of 5' and 3' UTR sequences to be added to the coding region can be altered by different methods, including, but not limited to, designing primers for PCR that anneal to different regions of the UTRs. Using this approach, one of ordinary skill in the art can modify the 5' and 3' UTR lengths required to achieve optimal translation efficiency following transfection of the transcribed RNA.

The 5' and 3' UTRs can be the naturally occurring, endogenous 5' and 3' UTRs for the gene of interest. Alternatively, UTR sequences that are not endogenous to the gene of interest can be added by incorporating the UTR sequences into the forward and reverse primers or by any other modifications of the template. The use of UTR sequences that are not endogenous to the gene of interest can be useful for modifying the stability and/or translation efficiency of the RNA. For example, it is known that AU-rich elements in 3' UTR sequences can decrease the stability of RNA. Therefore, 3' UTRs can be selected or designed to increase the stability of the transcribed RNA based on properties of UTRs that are well known in the art.

In one embodiment, the 5' UTR can contain the Kozak sequence of the endogenous gene. Alternatively, when a 5' UTR that is not endogenous to the gene of interest is being added by PCR as described above, a consensus Kozak sequence can be redesigned by adding the 5' UTR sequence. Kozak sequences can increase the efficiency of translation of some RNA transcripts, but does not appear to be required for all RNAs to enable efficient translation. The requirement for Kozak sequences for many RNAs is known in the art. In other embodiments the 5' UTR can be derived from an RNA virus whose RNA genome is stable in cells. In other embodiments various nucleotide analogues can be used in the 3' or 5' UTR to impede exonuclease degradation of the RNA.

To enable synthesis of RNA from a DNA template without the need for gene cloning, a promoter of transcription should be attached to the DNA template upstream of the sequence to be transcribed. When a sequence that functions as a promoter for an RNA polymerase is added to the 5' end of the forward primer, the RNA polymerase promoter becomes incorporated into the PCR product upstream of the open reading frame that is to be transcribed. In one preferred embodiment, the promoter is a T7 RNA polymerase promoter, as described elsewhere herein. Other useful promoters include, but are not limited to, T3 and SP6 RNA polymerase promoters. Consensus nucleotide sequences for T7, T3 and SP6 promoters are known in the art.

In a preferred embodiment, the RNA has both a cap on the 5' end and a 3' poly(A) tail which determine ribosome binding, initiation of translation and stability mRNA in the cell. On a circular DNA template, for instance, plasmid DNA, RNA

polymerase produces a long concatameric product which is not suitable for expression in eukaryotic cells. The transcription of plasmid DNA linearized at the end of the 3' UTR results in normal sized RNA which is effective in eukaryotic transfection when it is polyadenylated after transcription.

5                    On a linear DNA template, phage T7 RNA polymerase can extend the 3' end of the transcript beyond the last base of the template (Schenborn and Mierendorf, *Nuc Acids Res.*, 13:6223-36 (1985); Nacheva and Berzal-Herranz, *Eur. J. Biochem.*, 270:1485-65 (2003).

10                    The conventional method of integration of polyA/T stretches into a DNA template is molecular cloning. However polyA/T sequence integrated into plasmid DNA can cause plasmid instability, which can be ameliorated through the use of recombination incompetent bacterial cells for plasmid propagation.

15                    Poly(A) tails of RNAs can be further extended following in vitro transcription with the use of a poly(A) polymerase, such as *E. coli* polyA polymerase (E-PAP) or yeast polyA polymerase. In one embodiment, increasing the length of a poly(A) tail from 100 nucleotides to between 300 and 400 nucleotides results in about a two-fold increase in the translation efficiency of the RNA. Additionally, the attachment of different chemical groups to the 3' end can increase RNA stability. Such attachment can contain modified/artificial nucleotides, aptamers and other compounds. For example, 20                    ATP analogs can be incorporated into the poly(A) tail using poly(A) polymerase. ATP analogs can further increase the stability of the RNA.

25                    5' caps on also provide stability to RNA molecules. In a preferred embodiment, RNAs produced by the methods to include a 5' cap1 structure. Such cap1 structure can be generated using Vaccinia capping enzyme and 2'-O-methyltransferase enzymes (CellScript, Madison, WI). Alternatively, 5' cap is provided using techniques known in the art and described herein (Cougot, et al., *Trends in Biochem. Sci.*, 29:436-444 (2001); Stepinski, et al., *RNA*, 7:1468-95 (2001); Elango, et al., *Biochim. Biophys. Res. Commun.*, 330:958-966 (2005)).

30                    Nucleoside-modified RNA

In one embodiment, the composition of the present invention comprises a nucleoside-modified nucleic acid. In one embodiment, the composition of the invention comprises a nucleoside-modified RNA encoding a therapeutic protein.

For example, in one embodiment, the composition comprises a  
5 nucleoside-modified RNA. In one embodiment, the composition comprises a nucleoside-modified mRNA. Nucleoside-modified mRNA have particular advantages over non-modified mRNA, including for example, increased stability, low or absent innate immunogenicity, and enhanced translation. Nucleoside-modified mRNA useful in the present invention is further described in U.S. Patent No. 8,278,036, which is incorporated  
10 by reference herein in its entirety.

In certain embodiments, nucleoside-modified mRNA does not activate any pathophysiologic pathways, translates very efficiently and almost immediately following delivery, and serve as templates for continuous protein production in vivo lasting for several days (Kariko et al., 2008, Mol Ther 16:1833-1840; Kariko et al., 2012, Mol Ther  
15 20:948-953). The amount of mRNA required to exert a physiological effect is small and that makes it applicable for human therapy.

In certain instances, expressing a protein by delivering the encoding mRNA has many benefits over methods that use protein, plasmid DNA or viral vectors. During mRNA transfection, the coding sequence of the desired protein is the only  
20 substance delivered to cells, thus avoiding all the side effects associated with plasmid backbones, viral genes, and viral proteins. More importantly, unlike DNA- and viral-based vectors, the mRNA does not carry the risk of being incorporated into the genome and protein production starts immediately after mRNA delivery. For example, high levels of circulating proteins have been measured within 15 to 30 minutes of in vivo injection of  
25 the encoding mRNA. In certain embodiments, using mRNA rather than the protein also has many advantages. Half-lives of proteins in the circulation are often short, thus protein treatment would need frequent dosing, while mRNA provides a template for continuous protein production for several days. Purification of proteins is problematic and they can contain aggregates and other impurities that cause adverse effects (Kromminga and  
30 Schellekens, 2005, Ann NY Acad Sci 1050:257-265).

In certain embodiments, the nucleoside-modified RNA comprises the naturally occurring modified-nucleoside pseudouridine. In certain embodiments, inclusion of pseudouridine makes the mRNA more stable, non-immunogenic, and highly translatable (Kariko et al., 2008, *Mol Ther* 16:1833-1840; Anderson et al., 2010, *Nucleic Acids Res* 38:5884-5892; Anderson et al., 2011, *Nucleic Acids Research* 39:9329-9338; 5 Kariko et al., 2011, *Nucleic Acids Research* 39:e142; Kariko et al., 2012, *Mol Ther* 20:948-953; Kariko et al., 2005, *Immunity* 23:165-175).

It has been demonstrated that the presence of modified nucleosides, including pseudouridines in RNA suppress their innate immunogenicity (Kariko et al., 10 2005, *Immunity* 23:165-175). Further, protein-encoding, in vitro-transcribed RNA containing pseudouridine can be translated more efficiently than RNA containing no or other modified nucleosides (Kariko et al., 2008, *Mol Ther* 16:1833-1840). Subsequently, it is shown that the presence of pseudouridine improves the stability of RNA (Anderson et al., 2011, *Nucleic Acids Research* 39:9329-9338) and abates both activation of PKR 15 and inhibition of translation (Anderson et al., 2010, *Nucleic Acids Res* 38:5884-5892). A preparative HPLC purification procedure has been established that was critical to obtain pseudouridine-containing RNA that has superior translational potential and no innate immunogenicity (Kariko et al., 2011, *Nucleic Acids Research* 39:e142). Administering HPLC-purified, pseudourine-containing RNA coding for erythropoietin into mice and 20 macaques resulted in a significant increase of serum EPO levels (Kariko et al., 2012, *Mol Ther* 20:948-953), thus confirming that pseudouridine-containing mRNA is suitable for in vivo protein therapy.

The present invention encompasses RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside. In 25 certain embodiments, the composition comprises an isolated nucleic acid, wherein the nucleic acid comprises a pseudouridine or a modified nucleoside. In certain embodiments, the composition comprises a vector, comprising an isolated nucleic acid, wherein the nucleic acid comprises a pseudouridine or a modified nucleoside.

In one embodiment, the nucleoside-modified RNA of the invention is IVT 30 RNA, as described elsewhere herein. For example, in certain embodiments, the nucleoside-modified RNA is synthesized by T7 phage RNA polymerase. In another

embodiment, the nucleoside-modified mRNA is synthesized by SP6 phage RNA polymerase. In another embodiment, the nucleoside-modified RNA is synthesized by T3 phage RNA polymerase.

In one embodiment, the modified nucleoside is  $m^1\text{acp}^3\Psi$  (1-methyl-3-(3-amino-3-carboxypropyl) pseudouridine). In another embodiment, the modified nucleoside is  $m^1\Psi$  (1-methylpseudouridine). In another embodiment, the modified nucleoside is  $\Psi m$  (2'-O-methylpseudouridine). In another embodiment, the modified nucleoside is  $m^5D$  (5-methylidihydrouridine). In another embodiment, the modified nucleoside is  $m^3\Psi$  (3-methylpseudouridine). In another embodiment, the modified nucleoside is a pseudouridine moiety that is not further modified. In another embodiment, the modified nucleoside is a monophosphate, diphosphate, or triphosphate of any of the above pseudouridines. In another embodiment, the modified nucleoside is any other pseudouridine-like nucleoside known in the art.

In another embodiment, the nucleoside that is modified in the nucleoside-modified RNA the present invention is uridine (U). In another embodiment, the modified nucleoside is cytidine (C). In another embodiment, the modified nucleoside is adenosine (A). In another embodiment, the modified nucleoside is guanosine (G).

In another embodiment, the modified nucleoside of the present invention is  $m^5C$  (5-methylcytidine). In another embodiment, the modified nucleoside is  $m^5U$  (5-methyluridine). In another embodiment, the modified nucleoside is  $m^6A$  ( $N^6$ -methyladenosine). In another embodiment, the modified nucleoside is  $s^2U$  (2-thiouridine). In another embodiment, the modified nucleoside is  $\Psi$  (pseudouridine). In another embodiment, the modified nucleoside is  $Um$  (2'-O-methyluridine).

In other embodiments, the modified nucleoside is  $m^1A$  (1-methyladenosine);  $m^2A$  (2-methyladenosine);  $Am$  (2'-O-methyladenosine);  $ms^2m^6A$  (2-methylthio- $N^6$ -methyladenosine);  $i^6A$  ( $N^6$ -isopentenyladenosine);  $ms^2i^6A$  (2-methylthio- $N^6$ isopentenyladenosine);  $io^6A$  ( $N^6$ -(cis-hydroxyisopentenyl)adenosine);  $ms^2io^6A$  (2-methylthio- $N^6$ -(cis-hydroxyisopentenyl) adenosine);  $g^6A$  ( $N^6$ -glycinylocarbamoyladenosine);  $t^6A$  ( $N^6$ -threonylocarbamoyladenosine);  $ms^2t^6A$  (2-methylthio- $N^6$ -threonyl carbamoyladenosine);  $m^6t^6A$  ( $N^6$ -methyl- $N^6$ -threonylocarbamoyladenosine);  $hn^6A$  ( $N^6$ -hydroxynorvalylcarbamoyladenosine);  $ms^2hn^6A$

(2-methylthio-N<sup>6</sup>-hydroxynorvalyl carbamoyladeniosine); Ar(p) (2'-O-ribosyladeniosine (phosphate)); I (inosine); m<sup>1</sup>I (1-methylinosine); m<sup>1</sup>Im (1,2'-O-dimethylinosine); m<sup>3</sup>C (3-methylcytidine); Cm (2'-O-methylcytidine); s<sup>2</sup>C (2-thiocytidine); ac<sup>4</sup>C (N<sup>4</sup>-acetylcytidine); f<sup>5</sup>C (5-formylcytidine); m<sup>5</sup>Cm (5,2'-O-dimethylcytidine); ac<sup>4</sup>Cm (N<sup>4</sup>-acetyl-2'-O-methylcytidine); k<sup>2</sup>C (lysidine); m<sup>1</sup>G (1-methylguanosine); m<sup>2</sup>G (N<sup>2</sup>-methylguanosine); m<sup>7</sup>G (7-methylguanosine); Gm (2'-O-methylguanosine); m<sup>2</sup><sub>2</sub>G (N<sup>2</sup>,N<sup>2</sup>-dimethylguanosine); m<sup>2</sup>Gm (N<sup>2</sup>,2'-O-dimethylguanosine); m<sup>2</sup><sub>2</sub>Gm (N<sup>2</sup>,N<sup>2</sup>,2'-O-trimethylguanosine); Gr(p) (2'-O-ribosylguanosine (phosphate)); yW (wybutosine); o<sub>2</sub>yW (peroxywybutosine); OHyW (hydroxywybutosine); OHyW\* (undermodified hydroxywybutosine); imG (wyosine); mimG (methylwyosine); Q (queuosine); oQ (epoxyqueuosine); galQ (galactosyl-queuosine); manQ (mannosyl-queuosine); preQ<sub>0</sub> (7-cyano-7-deazaguanosine); preQ<sub>1</sub> (7-aminomethyl-7-deazaguanosine); G<sup>+</sup> (archaeosine); D (dihydrouridine); m<sup>5</sup>Um (5,2'-O-dimethyluridine); s<sup>4</sup>U (4-thiouridine); m<sup>5</sup>s<sup>2</sup>U (5-methyl-2-thiouridine); s<sup>2</sup>Um (2-thio-2'-O-methyluridine); acp<sup>3</sup>U (3-(3-amino-3-carboxypropyl)uridine); ho<sup>5</sup>U (5-hydroxyuridine); mo<sup>5</sup>U (5-methoxyuridine); cmo<sup>5</sup>U (uridine 5-oxyacetic acid); mcmo<sup>5</sup>U (uridine 5-oxyacetic acid methyl ester); chm<sup>5</sup>U (5-(carboxyhydroxymethyl)uridine); mchm<sup>5</sup>U (5-(carboxyhydroxymethyl)uridine methyl ester); mcm<sup>5</sup>U (5-methoxycarbonylmethyluridine); mcm<sup>5</sup>Um (5-methoxycarbonylmethyl-2'-O-methyluridine); mcm<sup>5</sup>s<sup>2</sup>U (5-methoxycarbonylmethyl-2-thiouridine); nm<sup>5</sup>s<sup>2</sup>U (5-aminomethyl-2-thiouridine); mnm<sup>5</sup>U (5-methylaminomethyluridine); mnm<sup>5</sup>s<sup>2</sup>U (5-methylaminomethyl-2-thiouridine); mnm<sup>5</sup>se<sup>2</sup>U (5-methylaminomethyl-2-selenouridine); ncm<sup>5</sup>U (5-carbamoylmethyluridine); ncm<sup>5</sup>Um (5-carbamoylmethyl-2'-O-methyluridine); cmnm<sup>5</sup>U (5-carboxymethylaminomethyluridine); cmnm<sup>5</sup>Um (5-carboxymethylaminomethyl-2'-O-methyluridine); cmnm<sup>5</sup>s<sup>2</sup>U (5-carboxymethylaminomethyl-2-thiouridine); m<sup>6</sup><sub>2</sub>A (N<sup>6</sup>,N<sup>6</sup>-dimethyladenosine); Im (2'-O-methylinosine); m<sup>4</sup>C (N<sup>4</sup>-methylcytidine); m<sup>4</sup>Cm (N<sup>4</sup>,2'-O-dimethylcytidine); hm<sup>5</sup>C (5-hydroxymethylcytidine); m<sup>3</sup>U (3-methyluridine); cm<sup>5</sup>U (5-carboxymethyluridine); m<sup>6</sup>Am (N<sup>6</sup>,2'-O-dimethyladenosine); m<sup>6</sup><sub>2</sub>Am (N<sup>6</sup>,N<sup>6</sup>,O-2'-trimethyladenosine); m<sup>2,7</sup>G (N<sup>2</sup>,7-dimethylguanosine); m<sup>2,2,7</sup>G (N<sup>2</sup>,N<sup>2</sup>,7-trimethylguanosine); m<sup>3</sup>Um (3,2'-O-dimethyluridine); m<sup>5</sup>D (5-methyldihydrouridine); f<sup>5</sup>Cm (5-formyl-2'-O-methylcytidine); m<sup>1</sup>Gm (1,2'-O-dimethylguanosine); m<sup>1</sup>Am (1,2'-

O-dimethyladenosine);  $\tau\text{m}^5\text{U}$  (5-taurinomethyluridine);  $\tau\text{m}^5\text{s}^2\text{U}$  (5-taurinomethyl-2-thiouridine)); imG-14 (4-demethylwyosine); imG2 (isowyosine); or ac<sup>6</sup>A (N<sup>6</sup>-acetyladenosine).

In another embodiment, a nucleoside-modified RNA of the present  
5 invention comprises a combination of 2 or more of the above modifications. In another embodiment, the nucleoside-modified RNA comprises a combination of 3 or more of the above modifications. In another embodiment, the nucleoside-modified RNA comprises a combination of more than 3 of the above modifications.

In another embodiment, between 0.1% and 100% of the residues in the  
10 nucleoside-modified of the present invention are modified (e.g. either by the presence of pseudouridine or a modified nucleoside base). In another embodiment, 0.1% of the residues are modified. In another embodiment, the fraction of modified residues is 0.2%. In another embodiment, the fraction is 0.3%. In another embodiment, the fraction is 0.4%. In another embodiment, the fraction is 0.5%. In another embodiment, the fraction  
15 is 0.6%. In another embodiment, the fraction is 0.8%. In another embodiment, the fraction is 1%. In another embodiment, the fraction is 1.5%. In another embodiment, the fraction is 2%. In another embodiment, the fraction is 2.5%. In another embodiment, the fraction is 3%. In another embodiment, the fraction is 4%. In another embodiment, the fraction is 5%. In another embodiment, the fraction is 6%. In another embodiment, the  
20 fraction is 8%. In another embodiment, the fraction is 10%. In another embodiment, the fraction is 12%. In another embodiment, the fraction is 14%. In another embodiment, the fraction is 16%. In another embodiment, the fraction is 18%. In another embodiment, the fraction is 20%. In another embodiment, the fraction is 25%. In another embodiment, the fraction is 30%. In another embodiment, the fraction is 35%. In another embodiment, the  
25 fraction is 40%. In another embodiment, the fraction is 45%. In another embodiment, the fraction is 50%. In another embodiment, the fraction is 60%. In another embodiment, the fraction is 70%. In another embodiment, the fraction is 80%. In another embodiment, the fraction is 90%. In another embodiment, the fraction is 100%.

In another embodiment, the fraction is less than 5%. In another  
30 embodiment, the fraction is less than 3%. In another embodiment, the fraction is less than 1%. In another embodiment, the fraction is less than 2%. In another embodiment, the

fraction is less than 4%. In another embodiment, the fraction is less than 6%. In another embodiment, the fraction is less than 8%. In another embodiment, the fraction is less than 10%. In another embodiment, the fraction is less than 12%. In another embodiment, the fraction is less than 15%. In another embodiment, the fraction is less than 20%. In  
5 another embodiment, the fraction is less than 30%. In another embodiment, the fraction is less than 40%. In another embodiment, the fraction is less than 50%. In another embodiment, the fraction is less than 60%. In another embodiment, the fraction is less than 70%.

In another embodiment, 0.1% of the residues of a given nucleoside (i.e.,  
10 uridine, cytidine, guanosine, or adenosine) are modified. In another embodiment, the fraction of the given nucleotide that is modified is 0.2%. In another embodiment, the fraction is 0.3%. In another embodiment, the fraction is 0.4%. In another embodiment, the fraction is 0.5%. In another embodiment, the fraction is 0.6%. In another  
15 embodiment, the fraction is 0.8%. In another embodiment, the fraction is 1%. In another embodiment, the fraction is 1.5%. In another embodiment, the fraction is 2%. In another embodiment, the fraction is 2.5%. In another embodiment, the fraction is 3%. In another embodiment, the fraction is 4%. In another embodiment, the fraction is 5%. In another  
20 embodiment, the fraction is 6%. In another embodiment, the fraction is 8%. In another embodiment, the fraction is 10%. In another embodiment, the fraction is 12%. In another embodiment, the fraction is 14%. In another embodiment, the fraction is 16%. In another  
25 embodiment, the fraction is 18%. In another embodiment, the fraction is 20%. In another embodiment, the fraction is 25%. In another embodiment, the fraction is 30%. In another embodiment, the fraction is 35%. In another embodiment, the fraction is 40%. In another embodiment, the fraction is 45%. In another embodiment, the fraction is 50%. In another  
embodiment, the fraction is 60%. In another embodiment, the fraction is 70%. In another embodiment, the fraction is 80%. In another embodiment, the fraction is 90%. In another embodiment, the fraction is 100%.

In another embodiment, the fraction of the given nucleotide that is  
modified is less than 8%. In another embodiment, the fraction is less than 10%. In  
30 another embodiment, the fraction is less than 5%. In another embodiment, the fraction is less than 3%. In another embodiment, the fraction is less than 1%. In another

embodiment, the fraction is less than 2%. In another embodiment, the fraction is less than 4%. In another embodiment, the fraction is less than 6%. In another embodiment, the fraction is less than 12%. In another embodiment, the fraction is less than 15%. In another embodiment, the fraction is less than 20%. In another embodiment, the fraction is less than 30%. In another embodiment, the fraction is less than 40%. In another embodiment, the fraction is less than 50%. In another embodiment, the fraction is less than 60%. In another embodiment, the fraction is less than 70%.

In another embodiment, a nucleoside-modified RNA of the present invention is translated in the cell more efficiently than an unmodified RNA molecule with the same sequence. In another embodiment, the nucleoside-modified RNA exhibits enhanced ability to be translated by a target cell. In another embodiment, translation is enhanced by a factor of 2-fold relative to its unmodified counterpart. In another embodiment, translation is enhanced by a 3-fold factor. In another embodiment, translation is enhanced by a 5-fold factor. In another embodiment, translation is enhanced by a 7-fold factor. In another embodiment, translation is enhanced by a 10-fold factor. In another embodiment, translation is enhanced by a 15-fold factor. In another embodiment, translation is enhanced by a 20-fold factor. In another embodiment, translation is enhanced by a 50-fold factor. In another embodiment, translation is enhanced by a 100-fold factor. In another embodiment, translation is enhanced by a 200-fold factor. In another embodiment, translation is enhanced by a 500-fold factor. In another embodiment, translation is enhanced by a 1000-fold factor. In another embodiment, translation is enhanced by a 2000-fold factor. In another embodiment, the factor is 10-1000-fold. In another embodiment, the factor is 10-100-fold. In another embodiment, the factor is 10-200-fold. In another embodiment, the factor is 10-300-fold. In another embodiment, the factor is 10-500-fold. In another embodiment, the factor is 20-1000-fold. In another embodiment, the factor is 30-1000-fold. In another embodiment, the factor is 50-1000-fold. In another embodiment, the factor is 100-1000-fold. In another embodiment, the factor is 200-1000-fold. In another embodiment, translation is enhanced by any other significant amount or range of amounts.

30

Polypeptide therapeutic agents

In other related aspects, the therapeutic agent includes an isolated peptide that modulates a target. For example, in one embodiment, the peptide of the invention inhibits or activates a target directly by binding to the target thereby modulating the normal functional activity of the target. In one embodiment, the peptide of the invention modulates the target by competing with endogenous proteins. In one embodiment, the peptide of the invention modulates the activity of the target by acting as a transdominant negative mutant.

The variants of the polypeptide therapeutic agents may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, (ii) one in which there are one or more modified amino acid residues, e.g., residues that are modified by the attachment of substituent groups, (iii) one in which the polypeptide is an alternative splice variant of the polypeptide of the present invention, (iv) fragments of the polypeptides and/or (v) one in which the polypeptide is fused with another polypeptide, such as a leader or secretory sequence or a sequence which is employed for purification (for example, His-tag) or for detection (for example, Sv5 epitope tag). The fragments include polypeptides generated via proteolytic cleavage (including multi-site proteolysis) of an original sequence. Variants may be post-translationally, or chemically modified. Such variants are deemed to be within the scope of those skilled in the art from the teaching herein.

#### Antibody therapeutic agents

The invention also contemplates a delivery vehicle comprising an antibody, or antibody fragment, specific for a target. That is, the antibody can bind to a target to direct the delivery vehicle to a cell expressing the target. In some embodiments, the antibody can inhibit a target to provide a beneficial effect.

As used herein, the term “antibody” refers to a protein comprising an immunoglobulin domain having hypervariable regions determining the specificity with which the antibody binds antigen; so-called complementarity determining regions (CDRs). The term antibody can thus refer to intact or whole antibodies as well as

antibody fragments and constructs comprising an antigen binding portion of a whole antibody. While the canonical natural antibody has a pair of heavy and light chains, camelids (camels, alpacas, llamas, etc.) produce antibodies with both the canonical structure and antibodies comprising only heavy chains. The variable region of the camelid heavy chain only antibody has a distinct structure with a lengthened CDR3 referred to as VHH or, when produced as a fragment, a nanobody. Antigen binding fragments and constructs of antibodies include F(ab)<sub>2</sub>, F(ab), minibodies, F<sub>v</sub>, single-chain F<sub>v</sub> (scF<sub>v</sub>), diabodies, and VH. Such elements may be combined to produce bi- and multi-specific reagents, such as bispecific T cell engagers. The term “monoclonal antibody” arose out of hybridoma technology but is now used to refer to any singular molecular species of antibody regardless of how it was originated or produced. Antibodies can be obtained through immunization, selection from a naïve or immunized library (for example, by phage display), alteration of an isolated antibody-encoding sequence, or any combination thereof.

Antibody variable regions can be those arising from the germ line of a particular species, or they can be chimeric, containing segments of multiple species possibly further altered to optimize characteristics such as binding affinity or low immunogenicity. For treating humans, it is desirable that the antibody have a human sequence. If a human antibody of the desired specificity is not available, but such an antibody from a non-human species is, the non-human antibody can be humanized, for example, through CDR grafting, in which the CDRs from the non-human antibody are placed into the respective positions in a framework of a compatible human antibody by engineering the encoding DNA. Similar considerations and procedures can be applied mutandis mutatis to antibodies for treating other species

The antibodies may be intact monoclonal or polyclonal antibodies, and immunologically active fragments (e.g., an scF<sub>v</sub>, a Fab or (Fab)<sub>2</sub> fragment), an antibody heavy chain, an antibody light chain, humanized antibodies, a genetically engineered single chain F<sub>v</sub> molecule (Ladner et al, U.S. Pat. No. 4,946,778), or a chimeric antibody, for example, an antibody which contains the binding specificity of a murine antibody, but in which the remaining portions are of human origin. Antibodies including monoclonal

and polyclonal antibodies, fragments and chimeras, may be prepared using methods known to those skilled in the art.

Antibodies can be prepared using intact polypeptides or fragments containing an immunizing antigen of interest. The polypeptide or oligopeptide used to immunize an animal may be obtained from the translation of RNA or synthesized chemically and can be conjugated to a carrier protein, if desired. Suitable carriers that may be chemically coupled to peptides include bovine serum albumin and thyroglobulin, keyhole limpet hemocyanin. The coupled polypeptide may then be used to immunize the animal (e.g., a mouse, a rat, or a rabbit).

10

### Combinations

In one embodiment, the composition of the present invention comprises a combination of agents described herein. In certain embodiments, a composition comprising a combination of agents described herein has an additive effect, wherein the overall effect of the combination is approximately equal to the sum of the effects of each individual agent. In other embodiments, a composition comprising a combination of agents described herein has a synergistic effect, wherein the overall effect of the combination is greater than the sum of the effects of each individual agent.

15

A composition comprising a combination of agents comprises individual agents in any suitable ratio. For example, in one embodiment, the composition comprises a 1:1 ratio of two individual agents. However, the combination is not limited to any particular ratio. Rather any ratio that is shown to be effective is encompassed.

20

### Conjugation

In various embodiments of the invention, the delivery vehicle is conjugated to at least one of the domain for evasion of the immune response and the targeting domain. Exemplary methods of conjugation can include, but are not limited to, covalent bonds, electrostatic interactions, and hydrophobic (“van der Waals”) interactions. In one embodiment, the conjugation is a reversible conjugation, such that the delivery vehicle can be disassociated from at least one of the domain for evasion of the immune response and the targeting domain upon exposure to certain conditions or

25

30

chemical agents. In another embodiment, the conjugation is an irreversible conjugation, such that under normal conditions the delivery vehicle does not dissociate from at least one of the domain for evasion of the immune response and the targeting domain.

In some embodiments, the conjugation comprises a covalent bond between  
5 an activated polymer conjugated lipid and at least one of the domain for evasion of the immune response and the targeting domain. The term “activated polymer conjugated lipid” refers to a molecule comprising a lipid portion and a polymer portion that has been activated via functionalization of a polymer conjugated lipid with a first coupling group. In one embodiment, the activated polymer conjugated lipid comprises a first coupling  
10 group capable of reacting with a second coupling group. In one embodiment, the activated polymer conjugated lipid is an activated pegylated lipid. In one embodiment, the first coupling group is bound to the lipid portion of the pegylated lipid. In another embodiment, the first coupling group is bound to the polyethylene glycol portion of the pegylated lipid. In one embodiment, the second functional group is covalently attached to  
15 at least one of the domain for evasion of the immune response and the targeting domain.

The first coupling group and second coupling group can be any functional groups known to those of skill in the art to together form a covalent bond, for example under mild reaction conditions or physiological conditions. In some embodiments, the first coupling group or second coupling group are selected from the group consisting of  
20 maleimides, N-hydroxysuccinimide (NHS) esters, carbodiimides, hydrazide, pentafluorophenyl (PFP) esters, phosphines, hydroxymethyl phosphines, psoralen, imidoesters, pyridyl disulfide, isocyanates, vinyl sulfones, alpha-haloacetyls, aryl azides, acyl azides, alkyl azides, diazirines, benzophenone, epoxides, carbonates, anhydrides, sulfonyl chlorides, cyclooctyne, aldehydes, and sulfhydryl groups. In some  
25 embodiments, the first coupling group or second coupling group is selected from the group consisting of free amines ( $-NH_2$ ), free sulfhydryl groups ( $-SH$ ), free hydroxide groups ( $-OH$ ), carboxylates, hydrazides, and alkoxyamines. In some embodiments, the first coupling group is a functional group that is reactive toward sulfhydryl groups, such as maleimide, pyridyl disulfide, or a haloacetyl. In one embodiment, the first coupling  
30 group is a maleimide.

In one embodiment, the second coupling group is a sulfhydryl group. The sulfhydryl group can be installed on the domain for evasion of the immune response and/or the targeting domain using any method known to those of skill in the art. In one embodiment, the sulfhydryl group is present on a free cysteine residue. In one  
5 embodiment, the sulfhydryl group is revealed via reduction of a disulfide on the domain for evasion of the immune response and/or the targeting domain, such as through reaction with 2-mercaptoethylamine. In one embodiment, the sulfhydryl group is installed via a chemical reaction, such as the reaction between a free amine and 2-iminothilane or N-succinimidyl S-acetylthioacetate (SATA).

10 In some embodiments, the polymer conjugated lipid and the domain for evasion of the immune response, and in some embodiments the targeting domain, are functionalized with groups used in “click” chemistry. Bioorthogonal “click” chemistry comprises the reaction between a functional group with a 1,3-dipole, such as an azide, a nitrile oxide, a nitron, an isocyanide, and the link, with an alkene or an alkyne  
15 dipolarophiles. Exemplary dipolarophiles include any strained cycloalkenes and cycloalkynes known to those of skill in the art, including, but not limited to, cyclooctynes, dibenzocyclooctynes, monofluorinated cyclooctynes, difluorinated cyclooctynes, and biarylazacyclooctynone

## 20 Targeting Domain

In one embodiment, the composition comprises a targeting domain that directs the delivery vehicle to a site. In one embodiment, the site is a site in need of the agent comprised within the delivery vehicle. The targeting domain may comprise a  
25 nucleic acid, peptide, antibody, small molecule, organic molecule, inorganic molecule, glycan, sugar, hormone, and the like that targets the particle to a site in particular need of the therapeutic agent. In certain embodiments, the particle comprises multivalent targeting, wherein the particle comprises multiple targeting mechanisms described herein. In certain embodiments, the targeting domain of the delivery vehicle specifically binds to a target associated with a site in need of an agent comprised within the delivery vehicle.  
30 For example, the targeting domain may be chosen to recognize a ligand that acts as a cell surface marker on target cells associated with a particular disease state. Such a target can

be a protein, protein fragment, antigen, or other biomolecule that is associated with the targeted site. In some embodiments, the targeting domain is an affinity ligand which specifically binds to a target. In certain embodiments, the target (e.g. antigen) associated with a site in need of a treatment with an agent. In some embodiments, the targeting domain may be co-polymerized with the composition comprising the delivery vehicle. In some embodiments, the targeting domain may be covalently attached to the composition comprising the delivery vehicle, such as through a chemical reaction between the targeting domain and the composition comprising the delivery vehicle. In some embodiments, the targeting domain is an additive in the delivery vehicle. Targeting domains of the instant invention include, but are not limited to, antibodies, antibody fragments, proteins, peptides, and nucleic acids.

### Peptides

In one embodiment, the targeting domain of the invention comprises a peptide. In certain embodiments, the peptide targeting domain specifically binds to a target of interest.

The peptide of the present invention may be made using chemical methods. For example, peptides can be synthesized by solid phase techniques (Roberge J Y et al (1995) Science 269: 202-204), cleaved from the resin, and purified by preparative high performance liquid chromatography. Automated synthesis may be achieved, for example, using the ABI 431 A Peptide Synthesizer (Perkin Elmer) in accordance with the instructions provided by the manufacturer.

The peptide may alternatively be made by recombinant means or by cleavage from a longer polypeptide. The composition of a peptide may be confirmed by amino acid analysis or sequencing.

The variants of the peptides according to the present invention may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, (ii) one in which there are one or more modified amino acid residues, e.g., residues that are modified by the attachment of substituent groups, (iii) one in which the peptide is an

alternative splice variant of the peptide of the present invention, (iv) fragments of the peptides and/or (v) one in which the peptide is fused with another peptide, such as a leader or secretory sequence or a sequence which is employed for purification (for example, His-tag) or for detection (for example, Sv5 epitope tag). The fragments include  
5 peptides generated via proteolytic cleavage (including multi-site proteolysis) of an original sequence. Variants may be post-translationally, or chemically modified. Such variants are deemed to be within the scope of those skilled in the art from the teaching herein.

As known in the art the “similarity” between two peptides is determined  
10 by comparing the amino acid sequence and its conserved amino acid substitutes of one peptide to a sequence of a second peptide. Variants are defined to include peptide sequences different from the original sequence, preferably different from the original sequence in less than 40% of residues per segment of interest, more preferably different from the original sequence in less than 25% of residues per segment of interest, more  
15 preferably different by less than 10% of residues per segment of interest, most preferably different from the original protein sequence in just a few residues per segment of interest and at the same time sufficiently homologous to the original sequence to preserve the functionality of the original sequence. The present invention includes amino acid sequences that are at least 60%, 65%, 70%, 72%, 74%, 76%, 78%, 80%, 90%, or 95%  
20 similar or identical to the original amino acid sequence. The degree of identity between two peptides is determined using computer algorithms and methods that are widely known for the persons skilled in the art. The identity between two amino acid sequences is preferably determined by using the BLASTP algorithm [BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, Md. 20894, Altschul, S., et al., J. Mol. Biol. 215: 403-  
25 410 (1990)].

The peptides of the invention can be post-translationally modified. For example, post-translational modifications that fall within the scope of the present invention include signal peptide cleavage, glycosylation, acetylation, isoprenylation, proteolysis, myristoylation, protein folding and proteolytic processing, etc. Some  
30 modifications or processing events require introduction of additional biological machinery. For example, processing events, such as signal peptide cleavage and core

glycosylation, are examined by adding canine microsomal membranes or *Xenopus* egg extracts (U.S. Pat. No. 6,103,489) to a standard translation reaction.

The peptides of the invention may include unnatural amino acids formed by post-translational modification or by introducing unnatural amino acids during  
5 translation.

### Nucleic acids

In one embodiment, the targeting domain of the invention comprises an isolated nucleic acid, including for example a DNA oligonucleotide and a RNA  
10 oligonucleotide. In certain embodiments, the nucleic acid targeting domain specifically binds to a target of interest. For example, in one embodiment, the nucleic acid comprises a nucleotide sequence that specifically binds to a target of interest.

The nucleotide sequences of a nucleic acid targeting domain can alternatively comprise sequence variations with respect to the original nucleotide  
15 sequences, for example, substitutions, insertions and/or deletions of one or more nucleotides, with the condition that the resulting nucleic acid functions as the original and specifically binds to the target of interest.

In the sense used in this description, a nucleotide sequence is “substantially homologous” to any of the nucleotide sequences describe herein when its  
20 nucleotide sequence has a degree of identity with respect to the nucleotide sequence of at least 60%, advantageously of at least 70%, preferably of at least 85%, and more preferably of at least 95%. Other examples of possible modifications include the insertion of one or more nucleotides in the sequence, the addition of one or more nucleotides in any of the ends of the sequence, or the deletion of one or more nucleotides in any end or  
25 inside the sequence. The degree of identity between two polynucleotides is determined using computer algorithms and methods that are widely known for the persons skilled in the art. The identity between two amino acid sequences is preferably determined by using the BLASTN algorithm [BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, Md. 20894, Altschul, S., et al., J. Mol. Biol. 215: 403-410 (1990)].

30

### Antibodies

In one embodiment, the targeting domain of the invention comprises an antibody, or antibody fragment. In certain embodiments, the antibody targeting domain specifically binds to a target of interest. Such antibodies include polyclonal antibodies, monoclonal antibodies, Fab and single chain Fv (scFv) fragments thereof, bispecific  
5 antibodies, heteroconjugates, human and humanized antibodies.

The antibodies may be intact monoclonal or polyclonal antibodies, and immunologically active fragments (e.g., a Fab or (Fab)<sub>2</sub> fragment), an antibody heavy chain, an antibody light chain, humanized antibodies, a genetically engineered single chain Fv molecule (Ladner et al, U.S. Pat. No. 4,946,778), or a chimeric antibody, for  
10 example, an antibody which contains the binding specificity of a murine antibody, but in which the remaining portions are of human origin. Antibodies including monoclonal and polyclonal antibodies, fragments and chimeras, may be prepared using methods known to those skilled in the art.

Such antibodies may be produced in a variety of ways, including  
15 hybridoma cultures, recombinant expression in bacteria or mammalian cell cultures, and recombinant expression in transgenic animals. The choice of manufacturing methodology depends on several factors including the antibody structure desired, the importance of carbohydrate moieties on the antibodies, ease of culturing and purification, and cost. Many different antibody structures may be generated using standard expression  
20 technology, including full-length antibodies, antibody fragments, such as Fab and Fv fragments, as well as chimeric antibodies comprising components from different species. Antibody fragments of small size, such as Fab and Fv fragments, having no effector functions and limited pharmacokinetic activity may be generated in a bacterial expression system. Single chain Fv fragments show low immunogenicity.

25

#### Therapeutic Methods

In some embodiments, the invention provides methods of treatment of a disease or disorder in a subject comprising delivering a therapeutic agent for the treatment of the disease or disorder, wherein the delivery vehicle comprises a moiety for  
30 evasion of the immune response.

In some embodiments, the invention provides methods for targeted delivery of a therapeutic agent for the treatment of a disease or disorder in a subject comprising delivering a therapeutic agent for the treatment of the disease or disorder, wherein the delivery vehicle comprises a moiety for evasion of the immune response and  
5 further comprises a moiety for targeting a cell type of interest.

The present invention also provides methods of delivering at least one agent to a subject in need thereof. In certain embodiments, the method is used to treat or prevent a disease or disorder in a subject, wherein the subject has an inflammatory condition or an autoimmune disease or disorder. In some embodiments, the agent is a  
10 therapeutic agent for the treatment of at least one inflammatory condition or an autoimmune disease or disorder. In some embodiments, the agent is a therapeutic agent for the treatment of a disease or disorder that is not associated with an inflammatory condition or an autoimmune disease or disorder in a subject diagnosed as having with an inflammatory condition or an autoimmune disease or disorder. For example, in some  
15 embodiments the compositions of the invention allow for delivery of therapeutic agents which evade a subject's increased or hyperactive immune response.

Exemplary inflammatory conditions and autoimmune diseases include, but are not limited to, rheumatoid arthritis, systemic lupus erythematosus, alopecia areata, anklosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease,  
20 autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome (alps), autoimmune thrombocytopenic purpura (ATP), Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue syndrome immune deficiency, syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, cicatricial pemphigoid, cold agglutinin  
25 disease, Crest syndrome, Crohn's disease, Deigo's disease, dermatomyositis, dermatomyositis - juvenile, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia - fibromyositis, grave's disease, guillain-barre, hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), Iga nephropathy, insulin dependent diabetes (Type I), juvenile arthritis, Meniere's disease,  
30 mixed connective tissue disease, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychondritis, polyglanular

syndromes, polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, sarcoidosis, scleroderma, Sjogren's syndrome, stiff-man syndrome, Takayasu arteritis, temporal arteritis/giant cell arteritis, ulcerative colitis, 5 uveitis, vasculitis, vitiligo, and Wegener's granulomatosis, and other organ-specific inflammatory disorders.

Therefore, in some embodiments, the invention provides methods of treatment of a non-inflammatory disease or disorder in a subject pre-diagnosed with an inflammatory disease or disorder comprising delivering a therapeutic agent for the 10 treatment of the non-inflammatory disease or disorder, wherein the delivery vehicle comprises a moiety for evasion of the immune response.

It will be appreciated by one of skill in the art, when armed with the present disclosure including the methods detailed herein, that the invention is not limited to treatment of diseases or disorders that are already established. Particularly, the disease 15 or disorder need not have manifested to the point of detriment to the subject; indeed, the disease or disorder need not be detected in a subject before treatment is administered. That is, significant signs or symptoms of diseases or disorders do not have to occur before the present invention may provide benefit. Therefore, the present invention includes a method for preventing diseases or disorders, in that a composition, as 20 discussed previously elsewhere herein, can be administered to a subject prior to the onset of diseases or disorders, thereby preventing diseases or disorders.

One of skill in the art, when armed with the disclosure herein, would appreciate that the prevention of a disease or disorder, encompasses administering to a subject a composition as a preventative measure against the development of, or 25 progression of, a disease or disorder.

The invention encompasses delivery of a delivery vehicle, comprising at least one agent, conjugated to at least one domain for evasion of the immune response. In one embodiment, the delivery vehicle further comprises at least one targeting domain. To practice the methods of the invention; the skilled artisan would understand, based on the 30 disclosure provided herein, how to formulate and administer the appropriate composition

to a subject. The present invention is not limited to any particular method of administration or treatment regimen.

One of skill in the art will appreciate that the compositions of the invention can be administered singly or in any combination. Further, the compositions of the invention can be administered singly or in any combination in a temporal sense, in  
5 that they may be administered concurrently, or before, and/or after each other. One of ordinary skill in the art will appreciate, based on the disclosure provided herein, that the compositions of the invention can be used to prevent or to treat a disease or disorder, and that a composition can be used alone or in any combination with another composition to  
10 affect a therapeutic result. In various embodiments, any of the compositions of the invention described herein can be administered alone or in combination with other modulators of other molecules associated with diseases or disorders.

In one embodiment, the invention includes a method comprising administering a combination of compositions described herein. In certain embodiments,  
15 the method has an additive effect, wherein the overall effect of the administering a combination of compositions is approximately equal to the sum of the effects of administering each individual inhibitor. In other embodiments, the method has a synergistic effect, wherein the overall effect of administering a combination of compositions is greater than the sum of the effects of administering each individual  
20 composition.

The method comprises administering a combination of composition in any suitable ratio. For example, in one embodiment, the method comprises administering two individual compositions at a 1:1 ratio. However, the method is not limited to any particular ratio. Rather any ratio that is shown to be effective is encompassed.  
25

In some embodiments, the present invention includes methods of preparing a therapeutic composition for delivery of at least one agent to endothelial cells lining vascular lumen.

#### Compositions and Methods for non-hepatic delivery

30 One aspect is a pharmaceutical composition for *in vivo* delivery of a lipid nanoparticle (LNP) to a non-hepatic cell of a subject, while avoiding delivery to hepatic

cells, wherein the LNP comprises a pegylated lipid conjugated to an active CD47 polypeptide, and a therapeutic or diagnostic agent. In some embodiments the LNP further comprises a pegylated lipid conjugated to a targeting moiety. In some embodiments the targeting moiety is an antibody or antigen-binding fragment thereof. In some  
5 embodiments, the LNP further comprises unconjugated pegylated lipid.

In some embodiments, an active CD47 polypeptide denotes the whole CD47 protein or a fragment of the CD47 protein that binds to and activates SIRP $\alpha$  signaling to inhibit uptake (phagocytosis) by macrophages. In some embodiments, the CD47 fragment comprises SEQ ID NO:1 or SEQ ID NO:2. In some embodiments, the  
10 CD47 polypeptide comprising SEQ ID NO:1 or SEQ ID NO:2 constitutes means for activating SIRP $\alpha$  signaling or means for reducing or preventing macrophage uptake.

In some embodiments of this method, a deleterious or undesirable effect of the LNP's therapeutic agent is substantially reduced or effectively eliminated. By substantially reduced it is meant that the reduction is more than merely detectable but  
15 leads to a clinically meaningful physiologic improvement. By effectively eliminated it is meant that while there may be some detectable presence of the therapeutic agent in the liver, there is no meaningful physiologic effect. In some embodiments, an inflammatory response is reduced, or not exacerbated as compared to an LNP lacking an active CD47 polypeptide and or PEG shielding. In some embodiments, a toxicity is reduced, or not  
20 exacerbated as compared to an LNP lacking an active CD47 polypeptide and/or PEG shielding. In some embodiments, the physiologically effective dosage is reduced as compared to an LNP lacking an active CD47 polypeptide and/or PEG shielding. In some embodiments, the proportion of administered therapeutic agent reaching the targeted cell or tissue is increased as compared to an LNP lacking an active CD47 polypeptide and/or  
25 PEG shielding.

#### Pharmaceutical Compositions

The formulations of the pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of  
30 pharmacology. In general, such preparatory methods include the step of bringing the active ingredient into association with a carrier or one or more other accessory

ingredients, and then, if necessary or desirable, shaping or packaging the product into a desired single- or multi-dose unit.

Although the description of pharmaceutical compositions provided herein are principally directed to pharmaceutical compositions which are suitable for ethical administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and perform such modification with merely ordinary, if any, experimentation. Subjects to which administration of the pharmaceutical compositions of the invention is contemplated include, but are not limited to, humans and other primates, mammals including commercially relevant mammals such as non-human primates, cattle, pigs, horses, sheep, cats, and dogs.

Pharmaceutical compositions that are useful in the methods of the invention may be prepared, packaged, or sold in formulations suitable for ophthalmic, oral, rectal, vaginal, parenteral, topical, pulmonary, intranasal, buccal, intravenous, intracerebroventricular, intradermal, intramuscular, or another route of administration. Other contemplated formulations include projected nanoparticles, liposomal preparations, resealed erythrocytes containing the active ingredient, and immunogenic-based formulations.

A pharmaceutical composition of the invention may be prepared, packaged, or sold in bulk, as a single unit dose, or as a plurality of single unit doses. As used herein, a "unit dose" is discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.

The relative amounts of the active ingredient, the pharmaceutically acceptable carrier, and any additional ingredients in a pharmaceutical composition of the invention will vary, depending upon the identity, size, and condition of the subject treated

and further depending upon the route by which the composition is to be administered. By way of example, the composition may comprise between 0.1% and 100% (w/w) active ingredient.

In addition to the active ingredient, a pharmaceutical composition of the invention may further comprise one or more additional pharmaceutically active agents.

Controlled- or sustained-release formulations of a pharmaceutical composition of the invention may be made using conventional technology.

As used herein, "parenteral administration" of a pharmaceutical composition includes any route of administration characterized by physical breaching of a tissue of a subject and administration of the pharmaceutical composition through the breach in the tissue. Parenteral administration thus includes, but is not limited to, administration of a pharmaceutical composition by injection of the composition, by application of the composition through a surgical incision, by application of the composition through a tissue-penetrating non-surgical wound, and the like. In particular, parenteral administration is contemplated to include, but is not limited to, intraocular, intravitreal, subcutaneous, intraperitoneal, intramuscular, intradermal, intrasternal injection, intratumoral, intravenous, intracerebroventricular and kidney dialytic infusion techniques.

Formulations of a pharmaceutical composition suitable for parenteral administration comprise the active ingredient combined with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline. Such formulations may be prepared, packaged, or sold in a form suitable for bolus administration or for continuous administration. Injectable formulations may be prepared, packaged, or sold in unit dosage form, such as in ampules or in multi-dose containers containing a preservative. Formulations for parenteral administration include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations. Such formulations may further comprise one or more additional ingredients including, but not limited to, suspending, stabilizing, or dispersing agents. In one embodiment of a formulation for parenteral administration, the active ingredient is provided in dry (i.e., powder or granular) form for reconstitution

with a suitable vehicle (e.g., sterile pyrogen-free water) prior to parenteral administration of the reconstituted composition.

The pharmaceutical compositions may be prepared, packaged, or sold in the form of a sterile injectable aqueous or oily suspension or solution. This suspension or  
5 solution may be formulated according to the known art, and may comprise, in addition to the active ingredient, additional ingredients such as the dispersing agents, wetting agents, or suspending agents described herein. Such sterile injectable formulations may be prepared using a non-toxic parenterally-acceptable diluent or solvent, such as water or 1,3-butane diol, for example. Other acceptable diluents and solvents include, but are not  
10 limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic mono- or di-glycerides. Other parentally-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form, in a liposomal preparation, or as a component of a biodegradable polymer systems. Compositions for sustained release or implantation may comprise pharmaceutically  
15 acceptable polymeric or hydrophobic materials such as an emulsion, an ion exchange resin, a sparingly soluble polymer, or a sparingly soluble salt.

A pharmaceutical composition of the invention may be prepared, packaged, or sold in a formulation suitable for pulmonary administration via the buccal cavity. Such a formulation may comprise dry particles which comprise the active  
20 ingredient and which have a diameter in the range from about 0.5 to about 7 nanometers, and preferably from about 1 to about 6 nanometers. Such compositions are conveniently in the form of dry powders for administration using a device comprising a dry powder reservoir to which a stream of propellant may be directed to disperse the powder or using a self-propelling solvent/powder-dispensing container such as a device comprising the  
25 active ingredient dissolved or suspended in a low-boiling propellant in a sealed container. Preferably, such powders comprise particles wherein at least 98% of the particles by weight have a diameter greater than 0.5 nanometers and at least 95% of the particles by number have a diameter less than 7 nanometers. More preferably, at least 95% of the particles by weight have a diameter greater than 1 nanometer and at least 90% of the  
30 particles by number have a diameter less than 6 nanometers. Dry powder compositions

preferably include a solid fine powder diluent such as sugar and are conveniently provided in a unit dose form.

Low boiling propellants generally include liquid propellants having a boiling point of below 65°F at atmospheric pressure. Generally the propellant may constitute 50 to 99.9% (w/w) of the composition, and the active ingredient may constitute 0.1 to 20% (w/w) of the composition. The propellant may further comprise additional ingredients such as a liquid non-ionic or solid anionic surfactant or a solid diluent (preferably having a particle size of the same order as particles comprising the active ingredient).

Formulations of a pharmaceutical composition suitable for parenteral administration comprise the active ingredient combined with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline. Such formulations may be prepared, packaged, or sold in a form suitable for bolus administration or for continuous administration. Injectable formulations may be prepared, packaged, or sold in unit dosage form, such as in ampules or in multi-dose containers containing a preservative. Formulations for parenteral administration include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations. Such formulations may further comprise one or more additional ingredients including, but not limited to, suspending, stabilizing, or dispersing agents. In one embodiment of a formulation for parenteral administration, the active ingredient is provided in dry (i.e., powder or granular) form for reconstitution with a suitable vehicle (e.g., sterile pyrogen-free water) prior to parenteral administration of the reconstituted composition.

The pharmaceutical compositions may be prepared, packaged, or sold in the form of a sterile injectable aqueous or oily suspension or solution. This suspension or solution may be formulated according to the known art, and may comprise, in addition to the active ingredient, additional ingredients such as the dispersing agents, wetting agents, or suspending agents described herein. Such sterile injectable formulations may be prepared using a non-toxic parenterally-acceptable diluent or solvent, such as water or 1,3-butane diol, for example. Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as

synthetic mono- or di-glycerides. Other parentally-administrable formulations that are useful include those that comprise the active ingredient in microcrystalline form, in a liposomal preparation, or as a component of a biodegradable polymer system.

5 Compositions for sustained release or implantation may comprise pharmaceutically acceptable polymeric or hydrophobic materials such as an emulsion, an ion exchange resin, a sparingly soluble polymer, or a sparingly soluble salt.

As used herein, "additional ingredients" include, but are not limited to, one or more of the following: excipients; surface active agents; dispersing agents; inert diluents; granulating and disintegrating agents; binding agents; lubricating agents; 10 sweetening agents; flavoring agents; coloring agents; preservatives; physiologically degradable compositions such as gelatin; aqueous vehicles and solvents; oily vehicles and solvents; suspending agents; dispersing or wetting agents; emulsifying agents, demulcents; buffers; salts; thickening agents; fillers; emulsifying agents; antioxidants; antibiotics; antifungal agents; stabilizing agents; and pharmaceutically acceptable 15 polymeric or hydrophobic materials. Other "additional ingredients" which may be included in the pharmaceutical compositions of the invention are known in the art and described, for example in Remington's Pharmaceutical Sciences (1985, Genaro, ed., Mack Publishing Co., Easton, PA), which is incorporated herein by reference.

## 20 EXPERIMENTAL EXAMPLES

The invention is further described in detail by reference to the following experimental examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Thus, the invention should in no way be construed as being limited to the following examples, but rather should be 25 construed to encompass any and all variations which become evident as a result of the teaching provided herein.

Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the present invention and practice the claimed methods. The following working 30 examples therefore are not to be construed as limiting in any way the remainder of the disclosure.

Example 1: Eliminating off-target effects of lipid-based carriers using a novel peptide-based double post-insertion technique to boost tissue-specific delivery and safety

Lipid nanoparticles (LNPs) have been used for the delivery of nucleoside-  
5 modified mRNA in small and large animal models. With systemic delivery, LNPs target  
the liver, which must be reduced or avoided when targeting mRNA delivery to other cells  
or tissues. The data presented herein demonstrate the development of methods to target  
specific cell types and tissues by linking antibodies, antibody fragments, and ligands to  
LNPs. In naive mice, mRNA-LNP delivery does not result in the release of pro-  
10 inflammatory mediators. However, in existing inflammatory conditions, treatment of  
mice with LNP-mRNA exacerbated the existing inflammation to the point that lethality  
could be observed. It was determined that macrophage uptake was responsible for the  
exacerbation of inflammation by mRNA-LNPs. Therefore, a method to diminish the off-  
target delivery of LNPs specifically to macrophages has been developed, by both  
15 attaching targeting ligands and blocking LNP uptake by macrophages. CD47 was used to  
reduce inflammation exacerbation, which was observed when mRNA-LNP was  
administered in inflamed mice (Figure 8). LNPs are decorated not only with targeting  
moiety, but also with CD47 peptide-lipids. This novel custom designed CD47 peptide-  
lipid provides evasion of uptake by the phagocytic system, while the targeting moiety  
20 allows for cell-specific targeting. Any type of lipid can be used to make the CD47  
peptide-lipid as long as it anchors effectively on the surface of LNP. In addition, for the  
CD47 peptide, any sequence spanning the binding site of CD47 protein can be used.

CD47 peptide-lipid can be used in micelle form, followed by  
incorporation into the LNP surface, or as a structural component of LNP itself. Figure 1  
25 shows the procedure which includes using micelles to make CD47 modified-targeted  
LNP construct.

While inflammation in mice challenged with LPS is exacerbated by  
mRNA-LNP, using mRNA-LNP that contains CD47, the inflammation exacerbation was  
alleviated significantly. Targeting efficiency was also boosted. As an example, using  
30 PECAM delivery to endothelial cells, localization in the tissue of interest is doubled by

using CD47 peptide to block macrophage uptake. Moreover, the ratio of mRNA expression in tissues of interest, compared to liver as off-target, could be increased up to 100 fold by this technology. The data also shows the enhanced targeted delivery to T cells when combining anti-CD4 targeting ligand and CD47 moieties. Therefore, linking  
5 of CD47 peptides to the surface of LNPs both significantly increases targeting and reduces inflammation exacerbation.

Experiments were conducted to examine the effect of CD47 on uptake of LNP into macrophages, and to show improvement in delivery efficacy to specific cell types when CD47 modification is combined with specific cell targeting.

10 Figure 2 shows that CD47 modification on LNP significantly decreases the non-specific uptake/mRNA translation. Figure 3 shows that CD47/mRNA-LNP recruits significantly less PBMC when compared to mRNA-LNP.

Figure 4 shows that the targeting efficiency increases when combined with CD47. Shown are data for endothelial targeting.

15 Figure 5 shows that the targeting efficiency increases when combined with CD47. Shown are data for T cell targeting.

Figure 6 shows that pro-inflammatory cytokines are elevated after IV treatment of LNP-mRNA in systemic mouse model of inflammation (IV-LPS).

20 Figure 7 shows enhanced LNP uptake by monocytes/macrophages in LPS-treated mice.

Figure 8 shows that removal of macrophages using Clodronate reduces systemic pro-inflammatory markers.

25 Figure 9 shows that decreasing macrophage uptake by CD47-modified LNPs alleviates systemic pro-inflammatory markers in LPS model of systemic inflammation.

Figure 10 shows that optimized D47/mRNA-LNP minimizes hepatic acute phase response by RNA-Seq analysis.

Figure 11 shows that protein corona formed around CD47-modified LNP in murine serum is completely different from the one on non-modified LNP.

The unique design and combination of targeting ligands along with CD47 moieties results in a significant expansion of therapeutic possibilities for mRNA-LNPs along with increased efficacy and reduction in adverse events.

5 This invention both allows improved delivery of nucleic acid therapeutics to target tissues *in vivo* using the LNP targeting technology, and reduces inflammation exacerbation when LNPs are given to mice with underlying inflammation. This technology could revolutionize both the targeted delivery of carriers and minimize their side effects by decreasing the chance of delivery to off-targets. With this invention, the dose of lipid-based carriers can be decreased and the LNPs directed to the tissue of  
10 interest with the least possible side effects. Many therapeutics could be developed with a broad range of targeted CD47-modified carriers including lipids, polymers, peptides, etc. By minimizing the off-target effects, the targeted therapeutics will have a chance to access hard to reach and rare targets, including stem cells.

15 SEQUENCES:

CD47 Peptide Sequences that were used for the experiments disclosed here are:

Murine: Lys(N3)-GGGNYTCEVTELSREGKTVELK (SEQ ID NO:1)

Human: Lys(N3)-GGGNYTCEVTELTREGETIIEK (SEQ ID NO:2)

20 The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety. While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention.  
25 The appended claims are intended to be construed to include all such embodiments and equivalent variations.

## CLAIMS

What is claimed is:

1. A composition for delivering a therapeutic agent to a subject in need thereof, the composition comprising a therapeutic agent and a delivery vehicle, wherein the delivery vehicle comprises a moiety to inhibit uptake of the composition by a macrophage.
2. The composition of claim 1, wherein the moiety to inhibit uptake of the composition by a macrophage is selected from the group consisting of a CD47 polypeptide, an active CD47 polypeptide fragment, an activator of SIRP $\alpha$  activity, a PD-L1 polypeptide, an active PD-L1 polypeptide fragment, an activator of PD-1 activity, a CD24 polypeptide, an active CD24 polypeptide fragment, an activator of Siglec-10 activity, a poly glutamic acid peptide, a  $\beta$ 2M polypeptide, an active  $\beta$ 2M polypeptide fragment, and an activator of LILRB1 activity.
3. The composition of claim 2, wherein the moiety to inhibit uptake of the composition by a macrophage comprises a CD47 polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, or a fragment or variant thereof.
4. The composition of claim 1, wherein the delivery vehicle further comprises a targeting moiety specific for binding to a target cell.
5. The composition of claim 4, wherein the target cell is selected from the group consisting of an endothelial cell, an immune cell and a stem cell.
6. The composition of claim 1, wherein the therapeutic agent comprises at least one isolated nucleoside-modified RNA molecule.

7. The composition of claim 6, wherein the at least one isolated nucleoside-modified RNA comprises at least one selected from the group consisting of pseudouridine and 1-methyl-pseudouridine.

8. The composition of claim 6, wherein the at least one isolated nucleoside-modified RNA is a purified nucleoside-modified RNA.

9. The composition of claim 1, wherein the composition further comprises an adjuvant.

10. The composition of claim 1, wherein the delivery vehicle comprises a lipid nanoparticle (LNP).

11. The composition of claim 10, wherein the at least one nucleoside-modified RNA is encapsulated within the LNP.

12. A method of treating a disease or disorder in a subject in need thereof, the method comprising administering a composition of claim 1 to the subject.

13. The method of claim 12, wherein the moiety to inhibit uptake of the composition by a macrophage is selected from the group consisting of a CD47 polypeptide, an active CD47 polypeptide fragment, an activator of SIRP $\alpha$  activity, a PD-L1 polypeptide, an active PD-L1 polypeptide fragment, an activator of PD-1 activity, a CD24 polypeptide, an active CD24 polypeptide fragment, an activator of Siglec-10 activity, a poly glutamic acid peptide, a  $\beta$ 2M polypeptide, an active  $\beta$ 2M polypeptide fragment, and an activator of LILRB1 activity.

14. The method of claim 13, wherein the moiety to inhibit uptake of the composition by a macrophage comprises a CD47 polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, or a fragment or variant thereof.

15. The method of claim 12, wherein the subject has an inflammatory or autoimmune disease or disorder.

16. The method of claim 15, wherein the therapeutic agent is an agent for the treatment of an inflammatory or autoimmune disease or disorder.

17. The method of claim 12, wherein the composition is administered by a delivery route selected from the group consisting of intradermal, subcutaneous, inhalation, intranasal, and intramuscular.

18. A method of delivering a therapeutic agent to a target cell, the method comprising administering a composition of claim 3 to the subject.

19. The method of claim 18, wherein the moiety to inhibit uptake of the composition by a macrophage is selected from the group consisting of a CD47 polypeptide, an active CD47 polypeptide fragment, an activator of SIRP $\alpha$  activity, a PD-L1 polypeptide, an active PD-L1 polypeptide fragment, an activator of PD-1 activity, a CD24 polypeptide, an active CD24 polypeptide fragment, an activator of Siglec-10 activity, a poly glutamic acid peptide, a  $\beta$ 2M polypeptide, an active  $\beta$ 2M polypeptide fragment, and an activator of LILRB1 activity.

20. The method of claim 19, wherein the moiety to inhibit uptake of the composition by a macrophage comprises a CD47 polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, or a fragment or variant thereof.

21. The method of claim 18, wherein the target cell is selected from the group consisting of an endothelial cell, an immune cell and a stem cell.

22. The method of claim 18, wherein the therapeutic agent is an agent for the treatment of an inflammatory or autoimmune disease or disorder.

23. The method of claim 18, wherein the composition is administered by a delivery route selected from the group consisting of intradermal, subcutaneous, inhalation, intranasal, and intramuscular.

24. A pharmaceutical composition for in vivo delivery of a lipid nanoparticle (LNP) to a non-hepatic cell of a subject while avoiding delivery to hepatic cells, wherein the LNP comprises a pegylated lipid conjugated to an active CD47 polypeptide, and a therapeutic agent.

25. The pharmaceutical composition of claim 24, wherein the LNP further comprises a pegylated lipid conjugated to a binding moiety.

26. The pharmaceutical composition of claim 24, wherein the binding moiety is a whole antibody or an antigen binding fragment thereof.

27. The pharmaceutical composition of any one of claims 24-26, wherein the LNP further comprises unconjugated pegylated lipid.

28. The pharmaceutical composition of any one of claims 24-27, wherein the active CD47 polypeptide comprises SEQ ID NO:1 or SEQ ID NO:2.

29. A method of delivering a LNP to a non-hepatic cell of a subject in vivo while avoiding delivery to hepatic cells comprising administering the pharmaceutical composition of any one of claims 24-28.

30. The method of claim 29, wherein administering comprises intravenous administration.

31. The method of any one of claims 29-30, wherein an inflammatory response is reduced, or not exacerbated as compared to an LNP lacking an active CD47 polypeptide and or PEG shielding. In some embodiments, a toxicity is reduced, or not exacerbated as compared to an LNP lacking an active CD47 polypeptide, PEG shielding, or a combination thereof.

32. The method of any one of claims 29-30, wherein a proportion of administered therapeutic agent reaching a targeted cell or tissue is increased as compared to an LNP lacking an active CD47 polypeptide, PEG shielding, or a combination thereof.

33. The method of any one of claims 29-30, wherein a physiologically effective dosage is reduced as compared to an LNP lacking an active CD47 polypeptide, PEG shielding, or a combination thereof.




Fig. 1




Fig. 2A – 2D





Fig. 3




Fig. 4A – 4C




Fig. 5A – 5C




Fig. 6




Fig. 7A – 7B




Fig. 8A – 8B




Fig. 9




Fig. 10A – 10B




Fig. 11

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US22/26998

A. CLASSIFICATION OF SUBJECT MATTER

IPC - INV. A61K 47/69; A61K 51/12; C12N 15/00 (2022.01)

ADD. A61K 48/00; A61P 29/00 (2022.01)

CPC - INV. A61K 47/6929; A61K 51/1234; A61K 51/1244; C12N 15/00

ADD. A61K 48/00; A61P 29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2017/106380 A1 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 22 June 2017; Page 9, lines 25-29; Claim: 1	1-23
Y	US 2020/0093936 A1 (THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA) 26 March 2020; Paragraphs: [0043], [0058], [0062], [0066], [0399], [0402], [0406]; claims: 1 and 6	1-23
Y	A. FOLKES ET AL. "Targeting CD47 as a cancer therapeutic strategy – the cutaneous T cell lymphoma experience" 1-11. HHS Public Access. Web. 01 September 2019; Title; abstract; page 2, second paragraph; page 6, last paragraph; DOI: 10.1097/CCO.0000000000000468.	2, 3, 9, 13, 14, 18-23
Y	WO 2020/048494 A1 (XI ZHIJIAN) 12 March 2020; Claims 1 and 4; page 3, third paragraph; page 6, third paragraph	3, 14, 18-23
A	US 2019/0046446 A1 (ERIOCHEM USA, LLC) 14 February 2019; Title; abstract; paragraph [0041]	1

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"D" document cited by the applicant in the international application

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

10 August 2022 (10.08.2022)

Date of mailing of the international search report

OCT 07 2022

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents  
P.O. Box 1450, Alexandria, Virginia 22313-1450  
Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

Telephone No. PCT Helpdesk: 571-272-4300

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US22/26998

## Box No. 1 Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
  - a.  forming part of the international application as filed:
    - in the form of an Annex C/ST.25 text file.
    - on paper or in the form of an image file.
  - b.  furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
  - c.  furnished subsequent to the international filing date for the purposes of international search only:
    - in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
    - on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2.  In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US22/26998

**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claims Nos.: 28-33  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:  
-\*\*\*-Please See Supplemental Page-\*\*\*-

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:  
1-23, SEQ ID NO:1 (insertion sequence);
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

-\*\*\*-Continued From Box No. III: Observations where unity of invention is lacking-\*\*\*-

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Groups I+, claims 1 -23, SEQ ID NO:1 (insertion sequence) is directed to a composition for delivering a therapeutic agent comprising a therapeutic agent and a delivery vehicle, wherein the delivery vehicle comprises a moiety to inhibit uptake of the composition by a macrophage and methods of treating a disease or disorder by administering such composition to a subject in need thereof.

Group II, claims 24-27, is a pharmaceutical composition for in vivo delivery of a lipid nanoparticle (LNP) to a non-hepatic cell of a subject while avoiding delivery to hepatic cells, wherein the LNP comprises a pegylated lipid conjugated to an active CD47 polypeptide, and a therapeutic agent.

The viruses and methods of Claims 1-2, 3 (in-part), 4-13,14 (in-part), and 15-23 are believed to encompass the first named invention of Groups I+ and are the claims that will be searched to the extent that they comprise an insertion sequence encompassing SEQ ID NO: 1 (first exemplary insertion sequence).

Applicant is invited to elect additional insertion sequences, with specified SEQ ID NO: for each, to be searched. Additional sequence(s) will be searched upon the payment of additional fees. Applicants must specify the searchable claims that encompass any additionally elected sequence(s). Applicants must further indicate, if applicable, the claims which encompass the first named invention, if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the "+" group(s) will result in only the first claimed invention to be searched/examined. An exemplary election would be SEQ ID NO: 2 (insertion sequence).

The inventions listed as Groups I+ do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

No technical features are shared between the insertion sequences of Groups I+, accordingly, these groups lack unity a priori.

Furthermore, the inventions listed as Group I+ and Group II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical features of Group I+ include a composition for delivering a therapeutic agent to a subject in need thereof, wherein the delivery vehicle comprises a moiety to inhibit uptake of the composition by a macrophage, not present in Group II; and the special technical features of Group II include a composition for in vivo delivery of a lipid nanoparticle (LNP) to a non-hepatic cell of a subject while avoiding delivery to hepatic cells, not present in Group I. Group I and Group II are considered to share the technical features including: compositions involving lipid nanoparticle (LNP) as drug delivery vehicles and comprising a CD 47 polypeptide and a therapeutic agent. These shared technical features are previously disclosed by Patent Publication number US 2019/0046446 A1 to Nunez, et al. (hereinafter "Nunez").

Nunez discloses lipid nanoparticles and methods of making and using the same, including pharmaceutical compositions, and the targeted delivery of drugs in various treatment methods (Abstract). The nanoparticle formulation includes, amongst other things, a therapeutic agent (Abstract). Nunez also discloses the use of antibody peptides to selective delivery of drugs to cells as well mAbs attached to liposomes and direct conjugation of a carrier to a drug (paragraphs [0003] – [0005]). Since Nunez discloses compositions involving lipid nanoparticle (LNP) as drug delivery vehicles and comprising an antibody polypeptide and a therapeutic agent, it anticipates the shared technical features of compositions involving lipid nanoparticle (LNP) as drug delivery vehicles and comprising a CD 47 polypeptide and a therapeutic agent in the instant application.

Since no special technical feature of the Group I+ and Group II Inventions is found in more than one of the inventions, and since all of the shared technical features are previously disclosed by the Nunez reference, unity of invention is lacking.